
<html lang="en"     class="pb-page"  data-request-id="ebc5a312-8a5c-4ebb-b677-df800c252f38"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2014.57.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm4017762;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity" /></meta><meta name="dc.Creator" content="Xitao  Li" /></meta><meta name="dc.Creator" content="Yingying  Zuo" /></meta><meta name="dc.Creator" content="Guanghui  Tang" /></meta><meta name="dc.Creator" content="Yan  Wang" /></meta><meta name="dc.Creator" content="Yiqing  Zhou" /></meta><meta name="dc.Creator" content="Xueying  Wang" /></meta><meta name="dc.Creator" content="Tianlin  Guo" /></meta><meta name="dc.Creator" content="Mengying  Xia" /></meta><meta name="dc.Creator" content="Ning  Ding" /></meta><meta name="dc.Creator" content="Zhengying  Pan" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impre..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impre..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 10, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4017762" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4017762" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4017762" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4017762" /></link>
        
    
    

<title>Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4017762" /></meta><meta property="og:title" content="Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0020.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clinical trials. Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk. Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a negative regulation loop for Btk. Two compounds from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells. In addition, compound 31 significantly prevented tumor growth in a mouse xenograft model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4017762"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4017762">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4017762&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4017762&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4017762&amp;href=/doi/10.1021/jm4017762" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5112-5128</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401733v" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401986p" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xitao++Li">Xitao Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yingying++Zuo">Yingying Zuo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guanghui++Tang">Guanghui Tang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yan++Wang">Yan Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yiqing++Zhou">Yiqing Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xueying++Wang">Xueying Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tianlin++Guo">Tianlin Guo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mengying++Xia">Mengying Xia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Ding">Ning Ding</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengying++Pan">Zhengying Pan</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Key Laboratory of Chemical Genomics, Key Laboratory of Structural Biology, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian District, Beijing, 100142, China</span></div><div class="corresp-info"><strong>*</strong>Phone: 86-755-26033072. E-mail: <a href="/cdn-cgi/l/email-protection#b5c5d4dbcfccf5c5dec0c6cf9bd0d1c09bd6db"><span class="__cf_email__" data-cfemail="8afaebe4f0f3cafae1fff9f0a4efeeffa4e9e4">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4017762&amp;href=/doi/10.1021%2Fjm4017762" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5112–5128</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 10, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 November 2013</li><li><span class="item_label"><b>Published</b> online</span>10 June 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 26 June 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4017762" title="DOI URL">https://doi.org/10.1021/jm4017762</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5112%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXitao%2BLi%252C%2BYingying%2BZuo%252C%2BGuanghui%2BTang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D12%26contentID%3Djm4017762%26title%3DDiscovery%2Bof%2Ba%2BSeries%2Bof%2B2%252C5-Diaminopyrimidine%2BCovalent%2BIrreversible%2BInhibitors%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2Bwith%2Bin%2BVivo%2BAntitumor%2BActivity%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5128%26publicationDate%3DJune%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4017762"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4219</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">44</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4017762" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xitao&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yingying&quot;,&quot;last_name&quot;:&quot;Zuo&quot;},{&quot;first_name&quot;:&quot;Guanghui&quot;,&quot;last_name&quot;:&quot;Tang&quot;},{&quot;first_name&quot;:&quot;Yan&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yiqing&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Xueying&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tianlin&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Mengying&quot;,&quot;last_name&quot;:&quot;Xia&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Zhengying&quot;,&quot;last_name&quot;:&quot;Pan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;10&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;5112-5128&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4017762&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clinical trials. Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk. Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a negative regulation loop for Btk. Two compounds from this series, 31 and 38, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells. In addition, compound 31 significantly prevented tumor growth in a mouse xenograft model.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4017762&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4017762" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4017762&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4017762" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4017762&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4017762" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4017762&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4017762&amp;href=/doi/10.1021/jm4017762" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4017762" /></input><a href="/doi/pdf/10.1021/jm4017762" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4017762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4017762%26sid%3Dliteratum%253Aachs%26pmid%3D24915291%26genre%3Darticle%26aulast%3DLi%26date%3D2014%26atitle%3DDiscovery%2Bof%2Ba%2BSeries%2Bof%2B2%252C5-Diaminopyrimidine%2BCovalent%2BIrreversible%2BInhibitors%2Bof%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2Bwith%2Bin%2BVivo%2BAntitumor%2BActivity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D12%26spage%3D5112%26epage%3D5128%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290682" title="Post-translational modification">Post-translational modification</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jmcmar.2014.57.issue-12/production/jmcmar.2014.57.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (Btk) is an attractive drug target for treating several B-cell lineage cancers. Ibrutinib is a first-in-class covalent irreversible Btk inhibitor and has demonstrated impressive effects in multiple clinical trials. Herein, we present a series of novel 2,5-diaminopyrimidine covalent irreversible inhibitors of Btk. Compared with ibrutinib, these inhibitors exhibited a different selectivity profile for the analyzed kinases as well as a dual-action mode of inhibition of both Btk activation and catalytic activity, which counteracts a negative regulation loop for Btk. Two compounds from this series, <b>31</b> and <b>38</b>, showed potent antiproliferative activities toward multiple B-cell lymphoma cell lines, including germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cells. In addition, compound <b>31</b> significantly prevented tumor growth in a mouse xenograft model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The B-cell receptor (BCR) signaling pathway plays an important role in B-cell development and differentiation.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Bruton’s tyrosine kinase (Btk) is a crucial component of the BCR pathway and is expressed only in hematopoietic cells except natural killer or T cells.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Patients with X-linked agammaglobulinemia, which is a rare genetic disease resulting from mutations in Btk, exhibit a reduced number of mature B-cells.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> Btk has also been linked to chronic BCR activation in activated B-cell-like diffuse large B cell lymphoma (ABC-DLBCL), which is a critical factor in the promotion of lymphoma cell survival.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6, 7)</a></div><div class="NLM_p">Since Btk was discovered in the 1990s, multiple Btk inhibitors have been developed.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> These inhibitors can be divided into two major classes, reversible and covalent irreversible ones (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). LFM-A13,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> dasatinib,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a><b>1</b> (CGI-1746),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a><b>2</b> (GDC-0834),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and RN-486<a onclick="showRef(event, 'ref9 ref14'); return false;" href="javascript:void(0);" class="ref ref9 ref14">(9, 14)</a> are reversible Btk inhibitors. These inhibitors have shown potent effects for immune disorders in multiple animal models, and <b>2</b> has been advanced into a phase I clinical trial. Ibrutinib<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> from Celera/Pharmacyclics/Janssen and <b>3</b> (CC-292)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> from Celgene and the imidazoquinoxaline compounds<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> from Pfizer are the primary examples of covalent irreversible Btk inhibitors. Ibrutinib and <b>3</b> are currently in multiple clinical trials, and ibrutinib was just approved to treat patients with mantle cell lymphoma in November 2013. Both compounds interact with a cysteine residue (Cys481) located at the rim of the ATP-binding pocket in Btk. These types of irreversible Btk inhibitors have unique characteristics compared with traditional reversible ones, such as a long drug–target residence time and the decoupling of pharmacokinetic and pharmacodynamic properties.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Btk inhibitors have been shown to be highly efficacious in animal models of rheumatoid arthritis, lupus, and lymphoma;<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> multiple clinical trials of ibrutinib and <b>3</b> have also shown encouraging results in patients.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> Therefore, developing Btk inhibitors is a promising strategy to treat overactive B-cell diseases such as autoimmune disorders and lymphoma.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of Btk inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Targeted covalent drugs have recently garnered significant interest, particularly for kinase inhibitors.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23-25)</a> Since the pioneering work on EGFR/HER2 inhibitors,<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26-28)</a> in addition to Btk, selective covalent inhibitors have been developed for Bmx,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> FGFR,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> GSK3β,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Itk,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> JNK,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Kit/PDGFR,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Nek2,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> PI3kα,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> RSK,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> and Src family kinases.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38, 39)</a> This field has also been discussed in several excellent reviews.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> Covalent bond formation between the inhibitors and nonconserved cysteine residues proximal to the ATP binding pockets of the kinase catalytic domain enhances the potency and selectivity of this type of inhibitor. We use a two-step procedure to develop such inhibitors. In the first step, we optimize the template without covalent reactive groups. In the second step, structural information is used to guide the placement of a reactive group at a suitable position on the parent template to enable an interaction with the sulfhydryl group of the targeted cysteine. After the first step, we select compounds reaching low nanomolar potency, which often suggest that the template substantially interacts with the target kinase, thus facilitating the selection of reactive groups in the second step. In the second step, a mild reactive group is typically preferred to limit the off-target effects that would result from indiscriminate reactions with other cellular nucleophiles.</div><div class="NLM_p">In cells, Btk is first activated by its upstream kinases through phosphorylation of a key tyrosine residue (Tyr551), which increases the catalytic activity of Btk by 10-fold.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Following autophosphorylation of another tyrosine residue (Tyr223), Btk becomes fully activated and phosphorylates its substrates, such as PLC-γ2 in the BCR pathway.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Btk is an efficient enzyme; only a small fraction of existing Btk is activated, and approximately 30 min of Btk activity is required for full signal transduction along the BCR pathway.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In vivo studies also indicate that more than 60% of Btk activity must be inhibited to achieve observable efficacy in animal models.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Thus, an irreversible inhibitor with a long drug–target residence time would be preferable for sustained Btk inhibition. In addition, Btk is also influenced by a negative feedback loop in the BCR pathway. The kinase PKCβ is downstream of Btk in the BCR pathway, and it has been suggested that PKCβ directly and negatively regulates Btk activity by impeding Btk’s engagement with the signaling complex.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Treating Namalwa cells with ibrutinib increases Tyr551 phosphorylation, the first step in Btk activation, suggesting the existence of Btk-mediated negative feedback loop.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> It has been suggested that enhanced kinase activation is a potential resistance mechanism that cells adopt to overcome the effects of inhibitors.<a onclick="showRef(event, 'ref48 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50">(48-50)</a> Multiple p38 kinase inhibitors have shown only transient activity in clinical trials.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> However, a dual-action p38 kinase inhibitor that prevents both the activation and kinase activity of p38 in cells, 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), has shown clinical efficacy in a phase IIa rheumatoid arthritis trial without tachyphylaxis.<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52, 53)</a> Inspired by this observation, we sought scaffolds with a dual-action mode that could prevent Btk Tyr551 from being phosphorylated and also inhibit Btk’s own catalytic ability. Developing such a dual-action mode Btk inhibitor that inhibits both Btk activation and catalysis could be a concise and effective strategy to further down-regulate BCR and other signal transduction pathways in which Btk plays an important role and to overcome potential resistance mechanisms due to increased Btk activation.</div><div class="NLM_p last">Herein, we present the first series of dual-action mode Btk covalent irreversible inhibitors based on a type II scaffold. These compounds are potent Btk inhibitors with high selectivity and have demonstrated significant antiproliferation activities in a mouse xenograft model of human B-cell lymphoma (DoHH2).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Structure-Based Design of Covalent Btk Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Kinase inhibitors can be categorized based on the kinase conformation that they recognize.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Type I kinase inhibitors (e.g., erlotinib and dasatinib) bind their target kinases in the active conformation, whereas type II inhibitors (e.g., imatinib and sorafenib) bind kinases in the inactive conformation. Because one of our goals is to prevent Btk activation, type I inhibitors that bind kinases in the active conformation may not be suitable; thus, we focused our efforts on type II inhibitors. Btk shares high sequence similarity with the Src family kinase Lck. We identified only one single amino acid difference between Btk (Cys481) and Lck (Ser323) within the direct contact range for analogues of ibrutinib.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In addition, the literature has suggested the existence of cross-reactivity for many Btk and Lck inhibitors.<a onclick="showRef(event, 'ref11 ref15 ref55'); return false;" href="javascript:void(0);" class="ref ref11 ref15 ref55">(11, 15, 55)</a> Thus, we hypothesized that known type II Lck inhibitors would provide useful insights regarding the design of novel Btk inhibitors; therefore, we used the 2,5-diaminopyrimidine compounds developed by scientists at Amgen as a starting point.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Structure of compound <b>4</b> and the “head”, “center”, and “tail” regions in the structure–activity relationship (SAR) study. (b) Compound <b>4</b> (carbon atoms in yellow) was docked in a structure of Btk (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PJ3">3PJ3</a>). The red dots indicate potential hydrogen bonds between compound <b>4</b> and Btk. Cys481 (carbon atoms in cyan) is highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">A Btk crystal structure that adopts a DFG-out conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PJ3">3PJ3</a>)<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> was used as a template for our design. The 2,5-diaminopyrimidine compound <b>4</b> was easily docked into this structure without obvious steric conflicts. As indicated in the model, compound <b>4</b> could form several important hydrogen bonds with Btk, including with Met477 at the hinge region and the gatekeeper residue Thr474, as well as hydrogen bonds with Glu445 and Ser538. Compared to the conformation of its parent compound in Lck (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BYU">3BYU</a>), compound <b>4</b> adopts an almost identical conformation and forms similar interactions with the protein. This model suggests that 2,5-diaminopyrimidine compounds have potential as inhibitors against Btk, but the selectivity between Btk and Lck might be difficult to achieve for this scaffold. However, because ibrutinib has demonstrated remarkable efficacy and safety in clinical studies even though it is a potent inhibitor of Lck, Lyn, and other Src family kinases, the selectivity between Btk and Lck was not a critical factor in our program.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00818" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00818" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure–Activity Relationship</h3><div class="NLM_p">On the basis of our docking model, we divided the 2,5-diaminopyrimidine scaffold into head, center, and tail regions (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>), which were then explored sequentially.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Head Region SAR<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates. ND, not determined.</p></div></div><div></div></div><div class="NLM_p">The head area is proximal to the hinge region in Btk, and the amino acid composition of this region is very similar between Btk and Lck; thus, the IC<sub>50</sub> values for the first set of compounds were surprising (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). Compound <b>4</b> yielded an IC<sub>50</sub> of 149 nM against Lck but only 3.42 μM for Btk, a 23-fold difference. Attaching an ethyl or cyclopropyl group at the R position (<b>5</b> and <b>6</b>) did not substantially improve the potency. A phenyl group (<b>7</b>) at this position improved the IC<sub>50</sub> values for Btk and Lck to 133 and 7 nM, respectively. Our model suggested that Btk’s Tyr476 would form π–π interactions with the newly added phenyl group in inhibitor <b>7</b>. Thus, we hypothesized that tuning the electron density of the phenyl group might impact inhibitor potency. Decorating the phenyl group with an <i>m</i>-CF<sub>3</sub> group yielded a less potent inhibitor (<b>8</b>). Substitution with the electron-donating group MeO (<b>9</b>) improved potency for Btk. However, substitution with electron-withdrawing F (<b>10</b>) yielded an inhibitor with a potency equal to that of <b>9</b>. Fortunately, substituting an amino group at either the meta or para positions of the phenyl ring produced inhibitors with comparable nanomolar potencies against both Btk and Lck. In the absence of crystal structures for the inhibitor–kinase complexes, it is difficult to identify the exact basis for the 10-fold improvement (compounds <b>7</b>–<b>12</b>) in potency toward Btk but the largely flat SAR for Lck. This difference may be not only due to the identities of the amino acid residues that directly contact the inhibitors but also due to the overall plasticity of the kinases in this region. Since the selectivity between Btk and Lck was not considered critical for our program, we did not explore this aspect of the inhibitors further.</div><div class="NLM_p">The docking structure of compound <b>7</b> in the Btk cocrystal structure with a DFG-out conformation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PJ3">3PJ3</a>) indicated that Cys481 is approximately 6–7 Å away from the phenyl ring at the head region of the inhibitors (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information Figure 1">Supporting Information Figure 1</a>). We anticipated that the addition of a linker group extending from the meta position of this phenyl ring would yield substituents that could directly interact with the Cys481 sulfhydryl group. Acylating the <i>m</i>-amino group with simple acids (<b>13</b> and <b>14</b>) largely maintained the potency even though the bis-acylated compound <b>15</b> exhibited significantly reduced potency. These results indicate that it is possible to accommodate a substitution at the meta position.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Center Region SAR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0016.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as mean values of duplicates.</p></div></div><div></div></div><div class="NLM_p">Next, we probed the SAR at the central region (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). The angular methyl group at the R position might fit snugly into in a small hydrophobic pocket formed with the gatekeeper residue Thr474. Replacing this methyl group with a common bioisostere (Cl) yielded the equally potent compound <b>16</b>. Decreasing the sizes of substitution to F (<b>17</b>) and H (<b>18</b>) decreased the potency by 3- and 16-fold, respectively. The amide at the L position was expected to form hydrogen bonds with Glu445 and Ser538, which may be important for type II inhibitors. Reversing the amide group orientation (<b>19</b>) reduced the potency 3-fold for Btk, while a urea linkage (<b>20</b>) reduced the potency 5-fold; thus, an amide linkage was selected in the next SAR studies.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Tail Region SAR<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0017.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">Btk IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">3-CF<sub>3</sub>-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">8563</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">cyclopropyl</td><td class="colsep0 rowsep0" align="char" char=".">4946</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">3-Cl-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">3-NMe<sub>2</sub>-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">3-F-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">166</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">3-Cl-5-CF<sub>3</sub>-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-CF<sub>3</sub>-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub>-phenyl</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">styryl</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">2-naphthyl</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are reported as means of duplicates.</p></div></div></div><div class="NLM_p">For type II inhibitors, we anticipated that tail region substitutions would occupy the hydrophobic pocket vacated by the movement of the phenyl group of the phenylalanine residue in the “DFG” sequence. As expected, an aromatic group was required at the R position (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) because compounds with either ethyl (<b>21</b>) or cyclopropyl (<b>22</b>) groups exhibited significantly reduced potency, likely due to a significant decrease in hydrophobic interactions with the protein. However, various aromatic ring substitutions were generally tolerated. By use of the <i>m</i>-CF<sub>3</sub>-substituted compound <b>12</b> as a benchmark, a chlorine substitution yielded an inhibitor (<b>23</b>) with comparable potency, a dimethylamino group (<b>24</b>) increased the IC<sub>50</sub> value by approximately 3-fold, and a fluorine atom (<b>25</b>) reduced the potency by more than 10-fold. A secondary chlorine substitution either meta or para to the amide did not significantly change the IC<sub>50</sub> values (<b>26</b> and <b>27</b>). Moving the CF<sub>3</sub> group to the para position (<b>28</b>) was well-tolerated, and compound <b>29</b>, which contained a styryl group, also had comparable potency. Introducing a naphthyl group at the R position (<b>30</b>) maintained the IC<sub>50</sub> at 39 nM. Collectively, these data suggest that Btk has a relatively large and plastic pocket in the tail region.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Reactive Group SAR<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0018.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0019.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">IC<sub>50</sub> values are reported as mean values of duplicates.</p></div></div><div></div></div><div class="NLM_p">The above SAR studies (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) indicated that compound <b>12</b> was highly potent against Btk, and our model indicated that the meta position (R<sup>1</sup>) is the preferred site for anchoring reactive groups (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Thus, <b>12</b> was used as the template to probe the interaction between the inhibitors and Cys481. A panel of potential covalent reactive groups was attached to the free amino group at the R<sup>1</sup> position. Because the apparent potency of irreversible inhibitors varies with the length of the preincubation time between the enzyme and inhibitors, the preincubation time in our kinase activity assays was kept constant at 10 min. Compound <b>31</b>, which includes the classic acrylamide group, yielded an IC<sub>50</sub> of 5 nM for Btk. Adding a methyl group to the terminal carbon of the acrylamide (<b>32</b>) reduced inhibitor potency, which was partially recovered through further substitution with a dimethylamino group at the allylic position (<b>33</b>), consistent with the trend observed for other covalent inhibitors of Btk and EGFR.<a onclick="showRef(event, 'ref15 ref58'); return false;" href="javascript:void(0);" class="ref ref15 ref58">(15, 58)</a> The methyl group reduced the electrophilicity and increased the steric hindrance of the Michael acceptor, which reduced the potency of compound <b>32</b> by 7-fold, while the dimethylamino group in compound <b>33</b> was proposed to form a hydrogen bond with the cysteine residue thiol group, thus enhancing its nucleophilicity.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The vinyl sulfonamide <b>34</b> and two additional compounds with good leaving groups (<b>35</b> and <b>36</b>) were also potent, but the potency of the bis-acylated compound (<b>37</b>) was reduced by more than 40-fold compared with compound <b>31</b>. Interestingly, compound <b>38</b>, which includes a glycyl spacer, exhibited excellent potency that was below the detection limit of our Btk enzyme assay. With acrylamide as the reactive group, variations at the R<sup>2</sup> position yielded compounds <b>39</b>–<b>41</b>, which were all potent inhibitors of Btk.</div><div class="NLM_p">One concern regarding covalent kinase inhibitors is that they may react nonselectively with thiols other than the intended target in a physiological environment. We used glutathione (GSH), which is a tripeptide that is naturally abundant in cells, as a surrogate to investigate acrylamide reactivity toward free thiols. When compound <b>31</b> (100 μM) was incubated with 5 mM GSH in PBS buffer at pH 7.4 at 37 °C, no adducts between compound <b>31</b> and GSH were detected after 2 h, suggesting that the acrylamide group does not react indiscriminately with thiols.</div><div class="NLM_p last">On the basis of their exceptional potency toward Btk, compounds <b>31</b> and <b>38</b> were selected for further biological evaluations.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Compounds <b>31</b> and <b>38</b> Are Selective Covalent Inhibitors of Btk</h3><div class="NLM_p">The selectivity of compound <b>31</b> was first profiled against a panel of kinases that included representatives of major classes of kinases and those kinases that directly participate in the BCR pathway (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). At 0.5 μM, compound <b>31</b> was inactive against the majority of the kinases tested and weakly active against Jak2. Compound <b>31</b> was moderately active against CSK but potently inhibited ABL, HER4, Lck, p38α, and VEGFR. Type II inhibitors for ABL, p38α, and VEGFR kinases have been well-documented in the literature.<a onclick="showRef(event, 'ref59 ref60 ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref59 ref60 ref61 ref62 ref63">(59-63)</a> Notably, the kinase selectivity of compound <b>31</b> was similar to that of ibrutinib for kinases that are directly involved in the BCR pathway, i.e., potent activity against Btk and Lck, which are representative Tec and Src family kinases, with no activity against Syk or PKC.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Selectivity of compound <b>31</b> against 18 kinases. The values are the mean of duplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Reversible and irreversible inhibitors have different requirements for sustained inhibitory effects in cells.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Reversible inhibitors are in equilibrium with the biological target, whereas irreversible inhibitors bind continuously to the targeted protein until the protein is degraded through biological processes. Thus, reversible inhibitors must be maintained at a high enough concentration to suppress the target activity. However, irreversible inhibitors require only a high-concentration pulse to occupy the target binding sites and exert a sustained effect. In fact, irreversible inhibitors with short half-lives may be preferred to mitigate potential off-target effects. Thus, for covalent irreversible inhibitors, special attention should be paid to kinases that share a cysteine residue at the structurally identical position. Btk is among a group of 11 kinases out of more than 500 in the human kinome with a cysteine at the identical position (Cys481 in Btk). These kinases include Blk, Jak3, MAP2K7, Tec family (Bmx, Btk, Itk, Rlk, and Tec), and EGFR family (EGFR, HER2, and HER4) kinases. We measured the inhibitory effects of compounds <b>31</b> and <b>38</b> against 10 of these kinases (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). They are quite potent against Blk, Bmx, Btk, Rlk, Tec, EGFR, HER2, and HER4. Notably, both compounds had weak activity against Jak3 in the micromolar range and no activity against Itk up to 30 μM. However, they were almost as potent as ibrutinib (5 nM) against EGFR. It is unclear whether this affinity for EGFR would produce major side effects in clinical studies. Also, caution should be taken when interpreting the selectivity of covalent inhibitors solely based on IC<sub>50</sub> values, as a recent study indicated that both reversible binding affinity and the chemical reactivity of these compounds can contribute separately to the overall biochemical potency.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Selectivity against Kinases with a Cysteine Structurally Identical to Cys481 in Btk<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="10" align="center" char=".">IC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">Blk</th><th class="colsep0 rowsep0" align="center" char=".">Btk</th><th class="colsep0 rowsep0" align="center" char=".">Bmx</th><th class="colsep0 rowsep0" align="center" char=".">EGFR</th><th class="colsep0 rowsep0" align="center" char=".">HER2</th><th class="colsep0 rowsep0" align="center" char=".">HER4</th><th class="colsep0 rowsep0" align="center" char=".">Itk</th><th class="colsep0 rowsep0" align="center" char=".">Jak3</th><th class="colsep0 rowsep0" align="center" char=".">Rlk</th><th class="colsep0 rowsep0" align="center" char=".">Tec</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">2.7</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="char" char=".">>30 000</td><td class="colsep0 rowsep0" align="char" char=".">2680</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char="."><4.4</td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">>30 000</td><td class="colsep0 rowsep0" align="char" char=".">6370</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">IC<sub>50</sub> values are reported as mean values of duplicates.</p></div></div></div><div class="NLM_p">Mass spectrometry was employed to determine whether compounds <b>31</b> and <b>38</b> formed covalent adducts with Btk. Incubating the Btk kinase domain with 3 equiv of each compound caused a complete mass peak shift, and the mass numbers for the new peaks were consistent with 1-to-1 complexes between the compounds and protein (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The adduct between compound <b>31</b> and Btk was digested with trypsin. Mass spectrometric analysis of the digested peptide fragments indicated that the modification site was, as expected, Cys481 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mass spectra of the Btk kinase domain indicating that 1-to-1 adducts were formed between <b>31</b> or <b>38</b> and Btk. The molecular weight of apo Btk (387–659) is 32136. After incubation with <b>31</b> (exact mass, 560.5) or <b>38</b> (exact mass, 617.6) at 4 °C for 1 h, the peaks were fully shifted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Compounds <b>31</b> and <b>38</b> Irreversibly Inhibit Btk Phosphorylation in Live Cells</h3><div class="NLM_p">In cells, BCR signaling is a graded process that is influenced by the convergence of both activating and negative regulatory events.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Upon BCR pathway activation, Btk moves to the cell membrane and is first phosphorylated at Tyr551 by upstream kinases. After an additional autophosphorylation step, Btk is fully activated and phosphorylates its physiological substrate, PLC-γ2. Approximately 30 min later, Btk activity returns to the basal level through a negative feedback loop. PKCβ, which is activated downstream of Btk, directly and negatively regulates Btk through Ser180 phosphorylation, which impairs Btk migration to the membrane and its overall phosphorylation/activation level.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Inhibiting Btk activity would interrupt downstream events in the BCR pathway, including the negative feedback loop, thus maintaining high Btk phosphorylation levels. Ibrutinib has been shown to augment Btk Tyr551 phosphorylation levels in Namalwa cells.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Among known Btk inhibitors, <b>1</b> binds the inactive conformation of Btk, in which Tyr551 is not phosphorylated. The crystal structure of Btk with <b>1</b> (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OCS">3OCS</a>) indicates that this compound extends into a deep pocket formed by Phe413, Leu542, Val546, and Tyr551, resulting in the movement of Tyr551 away from the solvent accessible area such that it may be unavailable for phosphorylation by upstream kinases.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">To test the inhibition mode of action of compounds <b>31</b> and <b>38</b>, we measured their abilities to inhibit the BCR pathway by monitoring the phosphorylation levels of Tyr551 in Btk and Tyr1217 in the Btk substrate PLC-γ2. Both compounds strongly inhibited both phosphorylation events in live Ramos cells. Compounds <b>31</b> and <b>38</b> exhibited IC<sub>50</sub> values of 14 and 13 nM, respectively, for Btk Tyr551 phosphorylation and IC<sub>50</sub> values of 8.5 and 13 nM, respectively, for PLC-γ2 Tyr1217 phosphorylation. In comparison, racemic version of ibrutinib (compound <b>4</b> in ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">15</a>) inhibited PLC-γ2 phosphorylation only, with an IC<sub>50</sub> of 14 nM, and showed virtually no inhibition (>7.5 μM) of Btk Tyr551 phosphorylation. Thus, compounds <b>31</b> and <b>38</b> clearly exhibit a dual-action mode of inhibition in live cells.</div><div class="NLM_p">Next, washout experiments were performed to confirm irreversible bond formation between Btk and the inhibitors in live cells (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). The acrylamide-containing compounds <b>31</b> and <b>38</b> maintained their inhibitory effects in cells even after a 2 h washout with fresh media, whereas Btk phosphorylation levels were largely restored in cells treated with the reversible analogue <b>13</b>, which contains a simple propylamide group, after removal of the compound. These data showed that both compounds <b>31</b> and <b>38</b> are irreversible inhibitors.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Washout experiments with the reversible inhibitor <b>13</b> and irreversible inhibitors <b>31</b> and <b>38</b>. In Ramos cells, Btk Tyr551 phosphorylation was measured after the cells were treated with compound for 1 h in a normal experiment or after treatment for 1 h followed by washout with fresh media for 2 h in the washout experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Antiproliferative Activities</h3><div class="NLM_p">Initial testing of compound <b>31</b> at two concentrations (1 and 10 μM) against multiple non-Hodgkin’s lymphoma and leukemia cell lines indicated that this compound was active in preventing the growth of these cancer cells (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Cell viability assays further confirmed the initial results. Both compounds <b>31</b> and <b>38</b> displayed single-digit nanomolar potency in Pfeiffer cells and better efficacy than ibrutinib in DoHH2 cells with GI<sub>50</sub> values of 73 nM (<b>31</b>) and 40 nM (<b>38</b>), respectively (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). SU-DHL-6 and WSU-NHL are two germinal center B-cell-like diffuse large B cell lymphoma (GCB-DLBCL) cell lines. It has been suggested that their survival does not solely rely on the BCR pathway; thus, they were not successfully targeted by ibrutinib in clinical studies. However, compared with ibrutinib, the antiproliferative potency of compounds <b>31</b> and <b>38</b> was approximately 13-fold stronger against SU-DHL-6 cells and 35-fold stronger against WSU-NHL cells (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). We are actively investigating the biological basis for these results and will report our findings in due course. One direction is to examine the changes of proteins directly involved in the BCR pathway, and the other one is to investigate potential involvements of additional pathways because of the fact that these compounds are also potent against quite a few of kinases with important functions. Overall, these results are certainly encouraging for potentially expanded applications of Btk inhibitors in clinical studies.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>31</b> is a potent inhibitor of proliferation in multiple malignant B cell lines. The values shown are the averages of triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Tumor cell proliferation assays. Representative dose–response curves of <b>31</b>, <b>38</b>, and ibrutinib treating DoHH2, Pfeiffer, SU-DHL-6, and WSU-NHL cells. Cells were seeded in 96-well plates, incubated for 24 h, then treated with compounds for 72 h, and measured with a luminescent cell viability assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Antiproliferation Activity against Several Cancer Cell Lines<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">GI<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">DoHH2</th><th class="colsep0 rowsep0" align="center" char=".">Pfeiffer</th><th class="colsep0 rowsep0" align="center" char=".">SU-DHL-6</th><th class="colsep0 rowsep0" align="center" char=".">WSU-NHL</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ibrutinib</td><td class="colsep0 rowsep0" align="char" char=".">0.41</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">1.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">0.073</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">0.040</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="char" char=".">0.029</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">GI<sub>50</sub> values are reported as mean values of two or three independent experiments in triplicate.</p></div></div></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Pharmacokinetic Properties of Compounds <b>31</b> and <b>38</b></h3><div class="NLM_p">Both compounds <b>31</b> and <b>38</b> displayed fair solubility and excellent stability in fasted state simulated intestinal fluid (FaSSIF) (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>),<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> which mimics the human intestinal environment. We estimated that these compounds would have a moderate hepatic clearance rate in mice based on a mouse microsome stability study. However, in vivo pharmacokinetic studies in mice showed that compound <b>31</b> had a fair half-life of 2.8 h, whereas compound <b>38</b> had a much shorter half-life of 0.6 h. Both compounds had small distribution volumes, and they were expected to primarily remain in the circulatory system.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Select PK Parameters for Compounds <b>31</b> and <b>38</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">compound</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center"><b>31</b></th><th class="colsep0 rowsep0" align="center"><b>38</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="center">FaSSIF</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">solubility (μM)</td><td class="colsep0 rowsep0" align="left">7.02</td><td class="colsep0 rowsep0" align="left">2.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stability (% remaining at 24 h)</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="center">Mouse Liver Microsome</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.64</td><td class="colsep0 rowsep0" align="left">0.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (μL min<sup>–1</sup> mg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">25.7</td><td class="colsep0 rowsep0" align="left">28.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL<sup>hep</sup> (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">47.8</td><td class="colsep0 rowsep0" align="left">49.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="center">In Vivo (iv)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">6.85</td><td class="colsep0 rowsep0" align="left">11.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.20</td><td class="colsep0 rowsep0" align="left">0.13</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">The in vivo pharmacokinetics of compounds <b>31</b> and <b>38</b> were evaluated in ICR mice (<i>n</i> = 3) following intravenous (iv) injection at 1 mg/kg dose level. At various time points, blood samples were collected and analyzed by LC–MS method.</p></div></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> In Vivo Efficacy of Compound <b>31</b></h3><div class="NLM_p">On the basis of its potency and PK properties, compound <b>31</b> was further examined in a mouse xenograft model inoculated with the human lymphoma DoHH2 cells. This study comprised four groups, with a vehicle control group and three treatment groups that included one dose of ibrutinib (10 mg/kg) and two doses of compound <b>31</b> (10 and 20 mg/kg). Ibrutinib was used as a positive control because its in vivo antiproliferative effects in a xenograft model of DoHH2 have been reported in the literature.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> The compounds were administered through the tail vein once a day for 14 consecutive days, and the tumor sizes were measured periodically. Plasma concentrations of compounds were determined at 2 and 24 h after the last drug administration. While all treatment groups achieved nice exposure of compounds at 2 h, neither the 10 mg/kg ibrutinib nor the 10 mg/kg compound <b>31</b> treatment groups had any detectable levels of compounds at 24 h and the 20 mg/kg compound <b>31</b> treatment group showed a dramatically reduced drug concentration (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>, at the end of the study, tumor sizes of the ibrutinib-treated group were reduced by 32% (<i>P</i> = 0.145), and both compound <b>31</b> dosage groups displayed more potent antiproliferative effects. Compared with the vehicle control group, the tumor size was reduced by 60% (<i>P</i> = 0.016) in the 10 mg/kg compound <b>31</b> treatment group, whereas the tumor size was reduced by 66% (<i>P</i> = 0.004) in the 20 mg/kg group. In every group, the mice slightly gained weight after the 14-day treatment, and no significant weight fluctuations were observed during the treatment. Thus, compound <b>31</b> was well-tolerated and exhibited a clear antiproliferative effect in this mouse xenograft model.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Btk inhibitor <b>31</b> in vivo efficacy study. (a) Compound <b>31</b> significantly prevented tumor growth in a xenograft mouse model. DoHH2 cells were implanted subcutaneously in female CB17/SCID mice. When tumors reached ∼167 mm<sup>3</sup> on average, mice were randomized into four groups (<i>n</i> = 6/group). Compounds were administered via tail vein as a clear solution in polyoxyl 15 hydroxystearate/ethanol (1:1). Tumor size and weight were monitored periodically for 14 days. Statistical analysis was conducted by one-way ANOVA. The Dunnett test was used to analyze the statistical significance between each treatment group and the vehicle group. (∗) <i>P</i> < 0.05 and (∗∗) <i>P</i> < 0.01 indicate statistical significance of tumor growth inhibition. (b) The body weights of the mice changed over time, and the mice in every group slightly gained weight at the end of the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The syntheses of this novel series of compounds were outlined in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, and <a class="ref internalNav" href="#sch3" aria-label="3">3</a> where the core structure was prepared using a method previously reported by Amgen scientists.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In general, reactions proceeded smoothly and provided desired products in good yields. Compound <b>42</b> was coupled with various amines, followed by a reduction step to form intermediates <b>43</b>, which underwent amide condensation to yield compounds <b>4</b>–<b>10</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>4</b>–<b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ammonium hydroxide, THF, rt, 1 h (96%); (b) R-NH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O, rt, 3 h (81–96%); (c) 5% Pd/C, H<sub>2</sub>, methanol, rt, overnight (88–93%); (d) 2-methyl-5-(3-(trifluoromethyl)benzamido)benzoic acid, HATU, DIEA, DMF, rt, 8 h (71–98%).</p></p></figure><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, aniline <b>44</b> was prepared from compound <b>42</b> via S<sub>N</sub>Ar reaction followed by catalytic reduction. Condensation reactions with aromatic acids with variations at the R position, followed by deprotection of the Boc group, afforded compounds <b>12</b> and <b>16</b>–<b>18</b>. <b>12</b> was further acylated with different reactive groups or other acids to yield compounds <b>13</b>–<b>15</b>, <b>31</b>–<b>38</b>. Compound <b>11</b> with an amino group at the para position was prepared in a manner similar to that for <b>12</b> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Reverse amide and urea compounds (<b>19</b> and <b>20</b>) were prepared using similar methods based on Amgen’s procedures, which were also described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>12</b>–<b>18</b>, <b>31</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-(<i>tert</i>-butoxycarbonylamino)aniline or 4-(<i>tert</i>-butoxycarbonylamino)aniline, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O, rt, 3 h (89%); (b) 5% Pd/C, H<sub>2</sub>, methanol, rt, overnight (88%); (c) various aromatic acids, HATU, DIEA, DMF, rt, 6 h (72–80%); (d) TFA, DCM, rt, 2 h (71–98%); (e) various acyl chlorides, THF–H<sub>2</sub>O, rt, 1 h (<b>13</b>, 91%; <b>31</b>, 90%; <b>35</b>, 87%); or various carboxylic acids, HATU, DIEA, DMF, rt, 5 h (<b>14</b>, 73%; <b>32</b>, 90%; <b>33</b>, 83%; <b>36</b>, 81%; <b>38</b>, 88%); or various acyl chlorides, THF, rt, 1 h (<b>15</b>, 91%; <b>37</b>, 93%); or 2-chloroethanesulfonyl chloride, DIEA, DMAP, THF, rt, 7 h (<b>34</b>, 84%).</p></p></figure><div class="NLM_p">An alternative synthetic route is outlined in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. Cbz-protected compound <b>45</b> was coupled with <b>44</b> followed by removal of the Cbz group to afford intermediate <b>46</b>. Compounds <b>21</b>–<b>30</b> were prepared by amide coupling with various carboxylic acids and the removal of Boc protection group. Finally, compounds <b>39</b>–<b>41</b> were obtained by acylating amine precursors with acryloyl chloride.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Alternative Route to 2,5-Diaminopyrimidines <b>21</b>–<b>30</b>, <b>39</b>–<b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>44</b>, HATU, DIEA, DMF, 5 h (71%); (b) 5% Pd/C, H<sub>2</sub>, methanol, 60 °C, 10 h (53%); (c) R-COOH, HATU, DMF, rt, 5 h (82–93%); (d) TFA, DCM, rt, 3 h (88–91%); (e) acryloyl chloride, THF, H<sub>2</sub>O, rt, 1 h (84–98%).</p></p></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36766" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36766" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We developed novel covalent irreversible inhibitors of Btk based on a type II scaffold. These compounds exhibited potent inhibitory activity in biochemical and cellular assays, presented a dual-action mode of inhibition that counteracted the negative regulation loop for Btk, and have a different selectivity profile from ibrutinib. These inhibitors were up to 35-fold more potent than the leading clinical drug, ibrutinib, in lymphoma cell viability assays. In a mouse xenograft model, compound <b>31</b> effectively prevented lymphoma tumor growth in a dose-dependent manner. Because of the emerging importance of Btk in a wide range of B-cell lineage hematological cancers, our results support a new direction for the development of novel Btk inhibitors. Further optimization of this series of compounds will be reported in due course.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45762" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45762" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div class="NLM_p last">All materials were obtained from commercial suppliers and used without further purification unless otherwise noted. Yields refer to chromatographic yields unless otherwise stated. Anhydrous THF was distilled from sodium. DCM and toluene were distilled from calcium hydride. Reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm Yantai silica gel plates (HSGF 254) using UV light as visualizing agents or an ethanolic solution of phosphomolybdic acid or ninhydrin as developing agents. Yantai silica gel (ZCX-II, particle size 0.048–0.075 mm) was used for flash column chromatography. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance 300 (<sup>1</sup>H, 300 MHz; <sup>13</sup>C, 75 MHz) or Bruker Advance 400 (<sup>1</sup>H, 400 MHz; <sup>13</sup>C, 100 MHz) or Bruker Advance 500 (<sup>1</sup>H, 500 MHz; <sup>13</sup>C, 125 MHz) spectrometer at ambient temperature. Chemical shifts are reported in ppm from the solvent resonance. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constants, and number of protons. Mass spectrometric data were obtained using an AB Q-Star mass spectrometer. All final compounds (<b>4</b>–<b>41</b>) were purified to >95% purity as determined by high performance liquid chromatography (HPLC) with UV detection at 254 nm. HPLC experiments were performed on an Agilent 1200 series LC system equipped with a quaternary pump (G1311A), a vacuum degasser (G1322A), a diode array detector (G1315D), and an autosampler (G1329A) using an Agilent Eclipse Plus C18 (5 μm, 4.6 mm × 250 mm) column. The mobile phase was constituted of H<sub>2</sub>O and CH<sub>3</sub>CN (eluent A, 30–100% CH<sub>3</sub>CN, 15 min; 100% CH<sub>3</sub>CN, 5 min; 1.00 mL/min flow rate; eluent B, 30–100% 0.1% TFA in CH<sub>3</sub>CN/0.1% TFA in H<sub>2</sub>O, 15 min; 100% 0.1% TFA in CH<sub>3</sub>CN, 5 min; 1.00 mL/min flow rate).</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Synthesis of <i>tert</i>-Butyl 3-(5-Aminopyrimidin-2-ylamino)phenylcarbamate (<b>44</b>)</h3><div class="NLM_p"><i>Step 1.</i> Potassium carbonate (0.702 g, 5.08 mmol) was added to a stirred solution of 2-chloro-5-nitropyrimidine (<b>42</b>) (0.352 g, 1.69 mmol) and <i>tert</i>-butyl 3-aminophenylcarbamate (0.270 g, 1.69 mmol) in acetonitrile (12 mL), and the mixture was stirred for 3 h at room temperature. The solution was diluted with water and extracted twice with ethyl acetate. The combined organic layers were dried, concentrated under vacuum, and purified via column chromatography (gradient, 20–75% EtOAc in hexanes) to yield <i>tert</i>-butyl 3-(5-nitropyrimidin-2-ylamino)phenylcarbamate (0.500 g, 89%) as yellow solids.</div><div class="NLM_p last"><i>Step 2. tert</i>-Butyl 3-(5-nitropyrimidin-2-ylamino)phenylcarbamate (0.500 g, 1.51 mmol) and 5% Pd/C (0.16 g) were dissolved in 10 mL of methanol, and then the mixture was stirred under hydrogen atmosphere at room temperature for 5 h. Once the reaction was completed, the mixture was filtered through Celite and the filtrate was concentrated and purified by column chromatography (gradient, 50–85% EtOAc in hexanes) to give the title compound (0.40 g, 88%) as yellow solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.13 (s, 1H), 8.86 (s, 1H), 7.95 (s, 2H), 7.77 (s, 1H), 7.25 (d, 1H, <i>J</i> = 8.1 Hz), 7.05 (t, 1H, <i>J</i> = 8.1 Hz), 6.92 (d, 1H, <i>J</i> = 7.8 Hz), 4.77 (s, 2H), 1.47 (s, 9H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 152.8, 152.7, 143.6, 141.9, 139.4, 135.5, 128.0, 111.7, 110.5, 107.9, 78.5, 28.0. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>15</sub>H<sub>20</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 302.1617. Found: 302.1602.</div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis of <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>12</b>)</h3><div class="NLM_p"><i>Step 1.</i><b>44</b> (0.100 g, 0.230 mmol), 3-(trifluoromethyl)benzoic acid (0.048 g, 0.25 mmol), and HATU (0.131 g, 0.345 mmol) were dissolved in DMF (2 mL), followed by the addition of DIEA (0.075 mL, 0.46 mmol). The mixture was stirred at room temperature for 7 h. Then the solution was concentrated under vacuum and the residue was diluted with saturated aqueous sodium bicarbonate and ethyl acetate. The aqueous phase was separated and extracted twice with ethyl acetate. The combined organic phases were washed with brine, dried over anhydrous magnesium sulfate, concentrated, and purified by column chromatography (gradient, 30–100% EtOAc in hexanes) to yield <i>tert</i>-butyl 3-(5-(2-methyl-5-(3-(trifluoromethyl)benzamido)benzamido)pyrimidin-2-ylamino)phenylcarbamate (0.12 g) as yellow solids.</div><div class="NLM_p last"><i>Step 2.</i> 3-(5-(2-Methyl-5-(3-(trifluoromethyl)benzamido)benzamido)pyrimidin-2-ylamino)phenylcarbamate (0.120 g, 0.198 mmol) was treated with TFA (2 mL) and DCM (2 mL). The mixture was stirred at room temperature for 2 h and concentrated under vacuum. The residue was diluted with saturated aqueous sodium bicarbonate and ethyl acetate. The organic phase was separated and washed with brine, dried over anhydrous magnesium sulfate, concentrated, and purified by column chromatography (gradient, 50–80% EtOAc in hexanes) to give the title compound (0.096 g, 82% for two steps) as white solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.56 (s, 1H), 10.36 (s, 1H), 9.30 (s, 1H), 8.76 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 7.98 (d, 1H, <i>J</i> = 7.8 Hz), 7.93 (d, 1H, <i>J</i> = 2.0 Hz), 7.85 (dd, 1H, <i>J</i> = 2.0 Hz, <i>J</i> = 8.3 Hz), 7.80 (t, 1H, <i>J</i> = 7.9 Hz), 7.33 (d, 1H, <i>J</i> = 8.4 Hz), 7.07 (s, 1H), 6.89 (t, 1H, <i>J</i> = 7.8 Hz), 6.84 (d, 1H, <i>J</i> = 8.1 Hz), 6.17 (d, 1H, <i>J</i> = 7.6 Hz), 4.94 (s, 2H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 163.9, 156.8, 149.8, 148.8, 141.1, 136.5, 136.4, 135.5, 131.8, 130.9, 130.8, 129.8, 129.3, 129.0, 128.6, 128.2, 125.8, 124.1, 121.7, 119.2, 107.7, 107.0, 104.2, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 505.1600. Found: 505.1591.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Synthesis of <i>N</i>-(2-(3-Acrylamidophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>31</b>)</h3><div class="NLM_p last">To a stirred suspension of <b>12</b> (0.080 g, 0.16 mmol) and DIEA (0.027 mL, 0.16 mmol) in 1 mL of THF and 1 mL of H<sub>2</sub>O was added acryloyl chloride (0.013 mL, 0.16 mmol). Then the mixture was kept stirring at room temperature for 1 h, then concentrated and diluted with ethyl acetate and 10% aqueous citric acid. The organic phase was separated, washed with brine, dried over anhydrous magnesium sulfate, and purified by column chromatography (gradient, 50–70% EtOAc in hexanes) to yield the title compound (0.080 g, 90%) as a white powder. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.44 (s, 1H), 10.10 (s, 1H), 9.69 (s, 1H), 8.82 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 8.0 Hz), 8.07 (s, 1H), 7.99 (d, 1H, <i>J</i> = 7.8 Hz), 7.94 (d, 1H, 2.0 Hz), 7.87–7.78 (m, 2H), 7.39–7.32 (m, 3H), 7.23–7.17 (m, 1H), 6.48 (dd, 1H, <i>J</i> = 10.0 Hz, <i>J</i> = 17.0 Hz), 6.25 (dd, 1H, <i>J</i> = 2.0 Hz, <i>J</i> = 17.0 Hz), 5.73 (dd, 1H, <i>J</i> = 1.9 Hz, <i>J</i> = 10.0 Hz), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, MeOD): δ 177.0, 173.4, 172.5, 166.0, 159.3, 150.4, 148.6, 146.0, 145.0, 141.5, 141.3, 140.4, 140.3, 139.3, 138.8, 138.5, 138.1, 137.7, 136.0, 135.8, 134.8, 133.6, 131.2, 128.7, 123.5, 122.2, 119.0, 28.3. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 561.1862. Found: 561.1859.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(2-Aminopyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>4</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.57 (s, 1H), 10.17 (s, 1H), 8.51 (s, 2H), 8.32 (s, 1H), 8.27 (d, 1H, <i>J</i> = 7.7 Hz), 7.98 (d, 1H, <i>J</i> = 7.4 Hz), 7.89 (d, 1H, <i>J</i> = 2.2 Hz), 7.84–7.77 (m, 2H), 7.30 (d, 1H, <i>J</i> = 8.4 Hz), 6.55 (s, 2H), 2.36 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.3, 163.8, 160.5, 150.7, 136.7, 136.3, 135.4, 131.6, 130.7, 130.6, 129.6, 128.04, 128.01, 124.2, 124.0, 123.9, 121.5, 119.1, 18.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>20</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 416.1334. Found: 416.1338.</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(2-(Ethylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>5</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.56 (s, 1H), 10.15 (s, 1H), 8.55 (s, 1H), 8.32 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 7.98 (d, 1H, <i>J</i> = 7.8 Hz), 7.89 (d, 1H, <i>J</i> = 2.2 Hz), 7.85–7.78 (m, 2H), 7.30 (d, 1H, <i>J</i> = 8.4 Hz), 7.07 (t, 1H, <i>J</i> = 5.6 Hz), 3.30–3.26 (m, 2H), 2.37 (s, 3H), 1.12 (t, 3H, <i>J</i> = 7.1 Hz). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.9, 165.4, 160.9, 152.3, 138.2, 137.9, 137.0, 133.3, 132.7, 132.4, 132.2, 131.3, 130.8, 129.7, 125.6, 125.4, 123.1, 120.7, 37.1, 20.3, 16.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>19</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 442.1491. Found: 442.1496.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(2-(Cyclopropylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>6</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.55 (s, 1H), 10.17 (s, 1H), 8.58 (s, 1H), 8.32–8.27 (m, 3H), 7.97 (d, 1H, <i>J</i> = 7.6 Hz), 7.89 (d, 1H, <i>J</i> = 2.0 Hz), 7.84–7.78 (m, 2H), 7.32–7.29 (m, 2H), 2.68–2.66 (m, 1H), 2.36 (s, 3H), 0.67–0.63 (m, 2H), 0.47–0.43 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.4, 163.9, 160.3, 150.6, 136.7, 136.4, 135.4, 131.8, 130.8, 130.7, 129.8, 128.2, 124.5, 124.1, 123.6, 122.2, 121.6, 119.2, 23.9, 18.8, 6.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>23</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 456.1647. Found: 456.1642.</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 2-Methyl-<i>N</i>-(2-(phenylamino)pyrimidin-5-yl)-5-(3-(trifluoromethyl)benzamido)benzamide (<b>7</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.57 (s, 1H), 10.41 (s, 1H), 9.63 (s, 1H), 8.80 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 8.0 Hz), 7.98 (d, 1H, <i>J</i> = 7.6 Hz), 7.93 (d, 1H, <i>J</i> = 2.0 Hz), 7.84 (dd, 1H, <i>J</i> = 2.1 Hz, <i>J</i> = 8.3 Hz), 7.80 (t, 1H, <i>J</i> = 7.8 Hz), 7.74 (d, 2H, <i>J</i> = 7.8 Hz), 7.33 (d, 1H, <i>J</i> = 8.4 Hz), 7.27 (t, 2H, <i>J</i> = 8.1 Hz), 6.93 (t, 1H, <i>J</i> = 7.3 Hz), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 163.9, 156.5, 149.9, 140.6, 136.5, 135.4, 131.8, 130.9, 130.8, 129.8, 129.3, 129.0, 128.4, 128.2, 126.2, 124.1, 121.7, 121.0, 119.2, 118.4, 118.3, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 492.1647. Found: 492.1650.</div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-Methyl-5-(3-(trifluoromethyl)benzamido)-<i>N</i>-(2-(3-(trifluoromethyl)phenylamino)pyrimidin-5-yl)benzamide (<b>8</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.50 (s, 1H), 10.03 (s, 1H), 8.87 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 8.22 (s, 1H), 7.99 (t, 2H, <i>J</i> = 9.6 Hz), 7.94 (d, 1H, <i>J</i> = 2.2 Hz), 7.86–7.78 (m, 2H), 7.51 (t, 1H, <i>J</i> = 8.0 Hz), 7.33 (d, 1H, <i>J</i> = 8.5 Hz), 7.25 (d, 1H, <i>J</i> = 7.7 Hz), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.5, 165.8, 158.0, 151.7, 143.3, 138.4, 138.3, 137.3, 133.7, 132.9, 132.8, 131.7, 131.5, 130.2, 128.8, 127.6, 127.2, 126.0, 124.9, 124.5, 123.7, 123.5, 121.5, 118.9, 115.7, 20.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>27</sub>H<sub>18</sub>F<sub>6</sub>N<sub>5</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 558.1365. Found: 558.1370.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(2-(3-Methoxyphenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>9</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.44 (s, 1H), 9.63 (s, 1H), 8.81 (d, 2H, <i>J</i> = 2.2 Hz), 8.32 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.8 Hz), 7.98 (d, 1H, <i>J</i> = 7.4 Hz), 7.94 (s, 1H), 7.85–7.78 (m, 2H), 7.48 (d, 1H, <i>J</i> = 1.8 Hz), 7.32 (t, 2H, <i>J</i> = 8.8 Hz), 7.19–7.14 (m, 1H), 6.50 (d, 1H, <i>J</i> = 8.0 Hz), 3.73 (d, 3H, <i>J</i> = 2.2 Hz), 2.38 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 163.8, 159.5, 156.4, 149.8, 141.7, 136.4, 135.4, 131.6, 130.8, 130.7, 129.6, 129.0, 128.1, 126.2, 124.0, 121.7, 119.2, 110.8, 106.2, 104.3, 54.8, 18.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>27</sub>H<sub>21</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub><sup>–</sup> [M – H]<sup>−</sup>: 520.1596. Found: 520.1600.</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(2-(3-Fluorophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>10</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.49 (s, 1H), 9.92 (s, 1H), 8.86 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.8 Hz), 7.98 (d, 1H, <i>J</i> = 7.5 Hz), 7.95 (s, 1H), 7.86–7.78 (m, 3H), 7.47 (d, 1H, <i>J</i> = 8.0 Hz), 7.35–7.26 (m, 2H), 6.72 (td, 1H, <i>J</i> = 2.1 Hz, <i>J</i> = 8.4 Hz), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.5, 165.8, 165.4, 163.1, 158.0, 151.7, 144.3, 138.4, 137.3, 133.7, 132.9, 131.9, 131.7, 131.2, 130.1, 128.7, 127.2, 126.0, 124.5, 123.7, 121.1, 115.9, 109.1, 106.5, 20.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>18</sub>F<sub>4</sub>N<sub>5</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 508.1397. Found: 508.1402.</div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(2-(4-Aminophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>11</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, MeOD): δ 8.64 (s, 2H), 8.27 (s, 1H), 8.20 (d, 1H, <i>J</i> = 8.1 Hz), 7.93–7.88 (m, 2H), 7.74 (d, 1H, <i>J</i> = 7.9 Hz), 7.67 (dd, 1H, <i>J</i> = 2.2 Hz, <i>J</i> = 8.2 Hz), 7.34–7.31 (m, 3H), 6.74 (d, 2H, <i>J</i> = 8.7 Hz), 4.63 (s, 3H), 2.45 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.4, 163.9, 157.5, 157.3, 151.3, 150.2, 143.6, 143.4, 136.6, 136.4, 135.4, 134.9, 131.8, 130.9, 129.8, 128.2, 125.0, 124.1, 121.1, 120.9, 119.2, 114.0, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 507.1756. Found: 507.1741.</div></div><div id="sec6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-Methyl-<i>N</i>-(2-(3-propionamidophenylamino)pyrimidin-5-yl)-5-(3-(trifluoromethyl)benzamido)benzamide (<b>13</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.43 (s, 1H), 9.81 (s, 1H), 9.63 (s, 1H), 8.80 (s, 2H), 8.32 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.8 Hz), 7.98–7.93 (m, 3H), 7.86–7.77 (m, 2H), 7.33 (d, 2H, <i>J</i> = 8.3 Hz), 7.28 (d, 1H, <i>J</i> = 7.7 Hz), 7.15 (t, 1H, <i>J</i> = 8.1 Hz), 2.38 (s, 3H), 2.30 (q, 2H, <i>J</i> = 7.5 Hz), 1.07 (t, 3H, <i>J</i> = 7.5 Hz). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.7, 169.4, 165.8, 158.5, 151.7, 142.7, 141.4, 138.4, 138.3, 137.4, 133.7, 132.9, 132.7, 131.7, 131.2, 130.9, 130.3, 130.1, 128.2, 126.0, 123.7, 121.1, 115.5, 114.4, 111.3, 31.3, 20.7, 11.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 563.2018. Found: 563.2012.</div></div><div id="sec6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(2-(3-(3-(Dimethylamino)propanamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>14</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.43 (s, 1H), 10.13 (s, 1H), 9.67 (s, 1H), 8.81 (s, 2H), 8.32 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 8.03 (s, 1H), 7.99–7.96 (m, 2H), 7.84–7.78 (m, 2H), 7.36–7.28 (m, 3H), 7.21–7.17 (m, 1H), 3.28–3.06 (m, 4H), 2.94–2.90 (m, 1H), 2.79 (t, 1H, <i>J</i> = 7.0 Hz), 2.74 (s, 4H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.0, 167.5, 163.9, 156.4, 149.8, 140.9, 139.0, 136.5, 136.4, 135.4, 131.8, 130.9, 130.8, 129.8, 128.6, 128.2, 126.3, 125.3, 124.1, 122.6, 121.8, 119.3, 113.9, 112.4, 109.4, 52.9, 42.6, 31.2, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>31</sub>H<sub>31</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 606.2440. Found: 606.2433.</div></div><div id="sec6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 2-Methyl-<i>N</i>-(2-(3-(<i>N</i>-propionylpropionamido)phenylamino)pyrimidin-5-yl)-5-(3-(trifluoromethyl)benzamido)benzamide (<b>15</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.88 (s, 1H), 10.59 (s, 1H), 9.93 (s, 1H), 9.11 (s, 2H), 8.31 (s, 1H), 8.27 (d, 1H, <i>J</i> = 7.8 Hz), 7.98–7.97 (m, 2H), 7.83 (dd, 1H, <i>J</i> = 2.1 Hz, <i>J</i> = 8.3 Hz), 7.78 (d, 1H, <i>J</i> = 7.8 Hz), 7.53 (s, 1H), 7.49 (d, 1H, <i>J</i> = 8.2 Hz), 7.34 (d, 1H, <i>J</i> = 8.4 Hz), 7.30 (t, 1H, <i>J</i> = 8.0 Hz), 6.89 (d, 1H, <i>J</i> = 8.8 Hz), 2.44 (q, 2H, <i>J</i> = 7.4 Hz), 2.38 (s, 3H), 2.29 (q, 2H, <i>J</i> = 7.6 Hz), 1.07–1.04 (m, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 173.7, 172.1, 168.1, 164.0, 155.9, 149.3, 141.5, 140.0, 136.5, 135.8, 135.4, 132.0, 131.8, 131.1, 131.0, 129.8, 129.1, 128.2, 124.1, 122.2, 119.3, 118.1, 117.4, 29.5, 28.5, 18.8, 9.5, 9.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>30</sub>F<sub>3</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>: 619.2281. Found: 619.2274.</div></div><div id="sec6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-2-chloro-5-(3-(trifluoromethyl)benzamido)benzamide (<b>16</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.74 (s, 1H), 10.62 (s, 1H), 9.38 (s, 1H), 8.76 (s, 2H), 8.34 (s, 1H), 8.29 (d, 1H, <i>J</i> = 7.9 Hz), 8.06 (d, 1H, <i>J</i> = 2.4 Hz), 8.00 (d, 1H, <i>J</i> = 7.7 Hz), 7.97 (dd, 1H, <i>J</i> = 2.5 Hz, <i>J</i> = 8.8 Hz), 7.82 (t, 1H, <i>J</i> = 7.6 Hz), 7.61 (d, 1H, <i>J</i> = 8.8 Hz), 7.09 (s, 1H), 6.91 (t, 1H, <i>J</i> = 7.7 Hz), 6.86 (d, 1H, <i>J</i> = 8.1 Hz), 6.20 (d, 1H, <i>J</i> = 7.5 Hz), 5.08 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 164.5, 164.1, 156.9, 150.9, 149.7, 148.6, 140.9, 137.8, 136.2, 135.1, 131.7, 131.6, 130.0, 129.7, 128.5, 128.3, 125.4, 124.3, 124.1, 122.8, 120.4, 107.8, 107.1, 104.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 527.1210. Found: 527.1209.</div></div><div id="sec6_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-2-fluoro-5-(3-(trifluoromethyl)benzamido)benzamide (<b>17</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, MeOD): δ 8.70 (s, 2H), 8.27 (s, 1H), 8.20 (d, 1H, <i>J</i> = 7.9 Hz), 8.13 (dd, 1H, <i>J</i> = 2.7 Hz, <i>J</i> = 6.3 Hz), 7.94–7.91 (m, 1H), 7.88 (d, 1H, <i>J</i> = 7.8 Hz), 7.72 (t, 1H, <i>J</i> = 7.9 Hz), 7.27 (t, 1H, <i>J</i> = 9.3 Hz), 7.20 (t, 1H, <i>J</i> = 2.0 Hz), 7.02 (t, 1H, <i>J</i> = 7.9 Hz), 6.92 (dd, 1H, <i>J</i> = 1.0 Hz, <i>J</i> = 8.1 Hz), 6.40 (dd, 1H, <i>J</i> = 1.3 Hz, <i>J</i> = 7.8 Hz), 4.56 (s, 1H). <sup>13</sup>C NMR (125 MHz, MeOD): δ 167.1, 165.0, 164.9, 159.0, 158.9, 156.5, 152.4, 149.1, 142.1, 136.8, 136.4, 136.3, 132.4, 130.7, 130.3, 129.5, 127.1, 126.5, 125.6, 124.4, 123.9, 117.8, 110.9, 107.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>17</sub>F<sub>4</sub>N<sub>6</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 509.1349. Found: 509.1355.</div></div><div id="sec6_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-3-(3-(trifluoromethyl)benzamido)benzamide (<b>18</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.70 (s, 1H), 10.36 (s, 1H), 9.32 (s, 1H), 8.78 (s, 2H), 8.36 (s, 2H), 8.31 (d, 1H, <i>J</i> = 8.0 Hz), 8.06 (d, 1H, <i>J</i> = 8.2 Hz), 8.00 (d, 1H, <i>J</i> = 7.8 Hz), 7.82 (t, 1H, <i>J</i> = 7.8 Hz), 7.77 (d, 1H, <i>J</i> = 7.9 Hz), 7.57 (t, 1H, <i>J</i> = 7.8 Hz), 7.09 (s, 1H), 6.91 (t, 1H, <i>J</i> = 7.7 Hz), 6.86 (d, 1H, <i>J</i> = 8.0 Hz), 6.19 (d, 1H, <i>J</i> = 7.5 Hz), 4.98 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 165.2, 164.0, 156.8, 150.7, 148.6, 141.0, 138.9, 135.4, 134.7, 131.7, 129.6, 129.0, 128.6, 128.5, 128.1, 125.6, 124.9, 124.1, 123.6, 122.7, 120.0, 107.7, 107.1, 104.3. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>20</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 493.1600. Found: 493.1648.</div></div><div id="sec6_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i><sup>3</sup>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-4-methyl-<i>N</i><sup>1</sup>-(3-(trifluoromethyl)phenyl)isophthalamide (<b>19</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, MeOD): δ 8.73 (s, 2H), 8.18 (s, 1H), 8.15 (d, 1H, <i>J</i> = 1.8 Hz), 8.00 (dd, 1H, <i>J</i> = 1.9 Hz, <i>J</i> = 8.0 Hz), 7.94 (d, 1H, <i>J</i> = 8.4 Hz), 7.58–7.42 (m, 3H), 7.21 (t, 1H, <i>J</i> = 2.0 Hz), 7.06–6.92 (m, 2H), 6.40 (dt, 1H, <i>J</i> = 1.1 Hz, <i>J</i> = 7.8 Hz), 2.56 (s, 3H). <sup>13</sup>C NMR (75 MHz, MeOD): δ 168.8, 166.3, 157.4, 150.7, 147.6, 140.8, 140.6, 139.4, 136.2, 132.0, 131.0, 130.9, 130.5, 129.3, 129.0, 128.8, 126.3, 125.4, 123.7, 120.4, 117.0, 109.7, 109.5, 106.4, 18.5. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 507.1756. Found: 507.1743.</div></div><div id="sec6_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(3-(trifluoromethyl)phenyl)ureido)benzamide (<b>20</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.31 (s, 1H), 9.29 (s, 1H), 9.10 (s, 1H), 8.90 (s, 1H), 8.75 (s, 2H), 8.03 (s, 1H), 7.65 (s, 1H), 7.57 (d, 1H, <i>J</i> = 8.0 Hz), 7.51 (t, 1H, <i>J</i> = 7.9 Hz), 7.45 (d, 1H, <i>J</i> = 8.4 Hz), 7.31 (d, 1H, <i>J</i> = 7.4 Hz), 7.23 (d, 1H, <i>J</i> = 8.2 Hz), 7.07 (s, 1H), 6.89 (t, 1H, <i>J</i> = 7.8 Hz), 6.84 (d, 1H, <i>J</i> = 8.0 Hz), 6.17 (d, 1H, <i>J</i> = 7.5 Hz), 4.96 (br s, 2H), 2.34 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 156.7, 152.4, 149.8, 148.2, 141.1, 140.4, 136.9, 136.6, 130.8, 129.7, 129.3, 128.7, 128.5, 125.8, 125.2, 121.8, 119.8, 118.0, 117.2, 114.1, 107.8, 107.3, 104.5, 18.5. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>23</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 522.1865. Found: 522.1852.</div></div><div id="sec6_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-2-methyl-5-propionamidobenzamide (<b>21</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.29 (s, 1H), 9.95 (s, 1H), 9.26 (s, 1H), 8.74 (s, 2H), 7.76 (d, 1H, <i>J</i> = 1.6 Hz), 7.59 (dd, 1H, <i>J</i> = 1.8 Hz, <i>J</i> = 8.2 Hz), 7.22 (d, 1H, <i>J</i> = 8.4 Hz), 7.07 (s, 1H), 6.89 (t, 1H, <i>J</i> = 7.8 Hz), 6.84 (d, 1H, <i>J</i> = 8.2 Hz), 6.18 (d, 1H, <i>J</i> = 1.9 Hz), 4.92 (s, 2H), 2.35–2.30 (m, 5H), 1.09 (t, 3H, <i>J</i> = 7.6 Hz). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 172.0, 167.6, 156.7, 149.8, 148.6, 141.0, 136.9, 136.4, 130.7, 129.5, 128.5, 125.8, 120.3, 117.8, 107.7, 107.1, 104.3, 29.4, 18.5, 9.5. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>21</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 391.1882. Found: 391.1913.</div></div><div id="sec6_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-(cyclopropanecarboxamido)-2-methylbenzamide (<b>22</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.32 (d, 2H, <i>J</i> = 5.4 Hz), 9.33 (s, 1H), 8.76 (s, 2H), 7.78 (s, 1H), 7.60 (d, 1H, <i>J</i> = 8.2 Hz), 7.23 (d, 1H, <i>J</i> = 8.3 Hz), 7.08 (s, 1H), 6.90 (t, 1H, <i>J</i> = 7.7 Hz), 6.85 (d, 1H, <i>J</i> = 8.1 Hz), 6.18 (d, 1H, <i>J</i> = 7.6 Hz), 4.97 (s, 2H), 2.34 (s, 3H), 1.81–1.76 (m, 1H), 0.82–0.80 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.7, 167.6, 156.8, 149.8, 148.8, 141.1, 137.1, 136.5, 130.9, 129.6, 128.7, 125.9, 120.2, 117.7, 107.7, 106.9, 104.2, 18.7, 14.5, 7.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>22</sub>H<sub>23</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 403.1882. Found: 403.2030.</div></div><div id="sec6_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-(3-chlorobenzamido)-2-methylbenzamide (<b>23</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.43 (s, 1H), 10.34 (s, 1H), 9.27 (s, 1H), 8.77 (s, 2H), 8.04 (s, 1H), 7.95–7.94 (m, 2H), 7.82 (d, 1H, <i>J</i> = 8.3 Hz), 7.67 (d, 1H, <i>J</i> = 8.0 Hz), 7.58 (t, 1H, <i>J</i> = 7.9 Hz), 7.31 (d, 1H, <i>J</i> = 8.4 Hz), 7.08 (s, 1H), 6.90 (t, 1H, <i>J</i> = 7.8 Hz), 6.86 (d, 1H, <i>J</i> = 8.1 Hz), 6.19 (d, 1H, <i>J</i> = 7.6 Hz), 4.92 (s, 2H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 164.0, 156.8, 149.9, 148.8, 141.1, 136.60, 136.57, 136.54, 133.3, 131.5, 130.9, 130.8, 130.5, 128.7, 127.3, 126.5, 125.9, 121.7, 119.2, 107.7, 107.0, 104.2, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>22</sub>ClN<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 473.1493. Found: 473.1519.</div></div><div id="sec6_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-(3-(dimethylamino)benzamido)-2-methylbenzamide (<b>24</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.53 (s, 1H), 10.38 (s, 1H), 9.33 (s, 1H), 8.80 (s, 2H), 8.00 (s, 1H), 7.86 (d, 1H, <i>J</i> = 6.7 Hz), 7.34–7.26 (m, 4H), 7.09 (s, 1H), 6.94–6.84 (m, 3H), 6.18 (d, 1H, <i>J</i> = 7.5 Hz), 4.97 (br s, 2H), 2.98 (s, 6H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.5, 168.0, 158.6, 152.2, 151.7, 150.7, 143.0, 138.9, 138.1, 137.3, 132.7, 132.3, 130.8, 130.6, 127.9, 123.6, 121.2, 117.2, 117.1, 113.0, 109.5, 108.8, 106.0, 26.9, 20.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>27</sub>H<sub>28</sub>N<sub>7</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 482.2304. Found: 482.2508.</div></div><div id="sec6_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-(3-fluorobenzamido)-2-methylbenzamide (<b>25</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.44 (s, 1H), 10.38 (s, 1H), 9.32 (s, 1H), 8.77 (s, 2H), 7.95 (d, 1H, <i>J</i> = 2.1 Hz), 7.85–7.78 (m, 3H), 7.64–7.58 (m, 1H), 7.46 (td, 1H, <i>J</i> = 2.5 Hz, <i>J</i> = 8.8 Hz), 7.32 (d, 1H, <i>J</i> = 8.4 Hz), 7.08 (s, 1H), 6.90 (t, 1H, <i>J</i> = 7.9 Hz), 6.85 (d, 1H, <i>J</i> = 8.2 Hz), 6.18 (d, 1H, <i>J</i> = 7.6 Hz), 4.96 (s, 2H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.6, 164.1, 163.2, 160.8, 156.8, 149.9, 148.8, 141.2, 137.0, 136.6, 131.0, 130.7, 130.6, 128.7, 125.9, 123.9, 121.7, 119.2, 118.6, 114.4, 107.8, 107.0, 104.3, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>22</sub>FN<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 457.1788. Found: 457.1844.</div></div><div id="sec6_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-(3-chloro-5-(trifluoromethyl)benzamido)-2-methylbenzamide (<b>26</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, MeOD): δ 8.73 (s, 2H), 8.24 (d, 2H, <i>J</i> = 11.4 Hz), 7.95 (d, 2H, <i>J</i> = 2.3 Hz), 7.69 (dd, 1H, <i>J</i> = 2.3 Hz, <i>J</i> = 8.3 Hz), 7.33 (d, 1H, <i>J</i> = 8.4 Hz), 7.23 (t, 1H, <i>J</i> = 2.0 Hz), 7.05 (t, 1H, <i>J</i> = 7.9 Hz), 6.94 (d, 1H, <i>J</i> = 8.1 Hz), 6.43 (d, 1H, <i>J</i> = 9.0 Hz), 4.63 (s, 3H), 2.47 (s, 3H). <sup>13</sup>C NMR (75 MHz, MeOD): δ 170.8, 165.6, 158.8, 152.0, 148.9, 142.2, 139.0, 137.6, 137.3, 136.7, 133.9, 133.7, 133.4, 132.6, 132.5, 130.3, 126.9, 124.1, 124.0, 121.0, 111.1, 111.0, 107.9, 19.3. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 539.1210. Found: 539.1218.</div></div><div id="sec6_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-(4-chloro-3-(trifluoromethyl)benzamido)-2-methylbenzamide (<b>27</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.63 (s, 1H), 10.37 (s, 1H), 9.31 (s, 1H), 8.75 (s, 2H), 8.41 (d, 1H, <i>J</i> = 1.5 Hz), 8.28 (dd, 1H, <i>J</i> = 1.7 Hz, <i>J</i> = 8.4 Hz), 7.94 (d, 1H, <i>J</i> = 8.4 Hz), 7.90 (d, 1H, <i>J</i> = 2.0 Hz), 7.82 (dd, 1H, <i>J</i> = 2.0 Hz, <i>J</i> = 8.3 Hz), 7.33 (d, 1H, <i>J</i> = 8.4 Hz), 7.07 (s, 1H), 6.89 (t, 1H, <i>J</i> = 7.9 Hz), 6.84 (d, 1H, <i>J</i> = 8.2 Hz), 6.17 (d, 1H, <i>J</i> = 7.6 Hz), 4.96 (s, 2H), 2.38 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.4, 162.9, 156.8, 149.8, 148.6, 141.0, 136.5, 136.2, 133.9, 133.8, 133.2, 131.9, 130.8, 128.5, 126.8, 126.5, 125.7, 123.6, 121.7, 121.4, 119.2, 107.7, 107.0, 104.3, 18.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>–</sup> [M – H]<sup>−</sup>: 539.1210. Found: 539.1212.</div></div><div id="sec6_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-2-methyl-5-(4-(trifluoromethyl)benzamido)benzamide (<b>28</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.60 (s, 1H), 10.39 (s, 1H), 9.36 (s, 1H), 8.78 (s, 2H), 8.18 (d, 2H, <i>J</i> = 8.2 Hz), 7.97 (d, 1H, <i>J</i> = 1.8 Hz), 7.94 (d, 2H, <i>J</i> = 8.3 Hz), 7.83 (dd, 1H, <i>J</i> = 1.8 Hz, <i>J</i> = 8.3 Hz), 7.33 (d, 1H, <i>J</i> = 8.4 Hz), 7.12 (s, 1H), 6.94–6.87 (m, 2H), 6.21 (d, 1H, <i>J</i> = 7.3 Hz), 5.22 (br s, 2H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.4, 166.2, 158.7, 151.7, 150.1, 143.0, 140.3, 138.4, 138.3, 132.8, 132.7, 130.6, 130.4, 127.8, 127.3, 127.2, 124.4, 123.6, 121.1, 109.8, 109.2, 106.4, 20.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 507.1756. Found: 507.1754.</div></div><div id="sec6_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-(2-(3-Aminophenylamino)pyrimidin-5-yl)-5-cinnamamido-2-methylbenzamide (<b>29</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.37 (d, 2H, <i>J</i> = 3.0 Hz), 9.41 (s, 1H), 8.77 (s, 2H), 7.87 (d, 1H, <i>J</i> = 2.2 Hz), 7.70 (dd, 1H, <i>J</i> = 2.1 Hz, <i>J</i> = 8.3 Hz), 7.65–7.56 (m, 3H), 7.47–7.40 (m, 3H), 7.27 (d, 1H, <i>J</i> = 8.7 Hz), 7.20 (s, 1H), 6.96 (d, 2H, <i>J</i> = 5.0 Hz), 6.81 (d, 1H, <i>J</i> = 15.8 Hz), 6.28 (s, 1H), 2.35 (s, 3H). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.0, 164.0, 157.1, 153.8, 150.4, 150.1, 146.0, 141.7, 140.8, 137.4, 137.0, 135.0, 131.5, 130.6, 130.3, 129.5, 129.3, 128.2, 127.8, 126.5, 122.5, 121.0, 118.4, 19.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>27</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 465.2039. Found: 465.2037.</div></div><div id="sec6_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(3-(2-(3-Aminophenylamino)pyrimidin-5-ylcarbamoyl)-4-methylphenyl)-2-naphthamide (<b>30</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.56 (s, 1H), 10.40 (s, 1H), 9.34 (s, 1H), 8.79 (s, 1H), 8.62 (s, 1H), 8.11–7.89 (m, 6H), 7.88 (d, 1H, <i>J</i> = 7.83 Hz), 7.65 (s, 2H), 7.33 (d, 1H, <i>J</i> = 8.4 Hz), 7.11 (s, 1H), 6.92–6.88 (m, 2H), 6.20 (d, 1H, <i>J</i> = 7.4 Hz), 5.16 (br s, 2H), 2.40 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.5, 167.4, 158.7, 151.7, 150.5, 143.0, 138.8, 138.4, 136.2, 133.9, 133.8, 132.8, 132.3, 130.8, 130.6, 129.9, 129.8, 129.7, 129.6, 128.8, 127.8, 126.2, 123.5, 120.9, 109.7, 109.0, 106.2, 20.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup>: 489.2039. Found: 489.2048.</div></div><div id="sec6_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> (<i>E</i>)-<i>N</i>-(2-(3-But-2-enamidophenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>32</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.76 (s, 2H), 8.27 (s, 1H), 8.21 (d, 1H, <i>J</i> = 7.7 Hz), 8.11 (s, 1H), 7.94 (s, 1H), 7.89 (d, 1H, <i>J</i> = 7.7 Hz), 7.73 (t, 1H, <i>J</i> = 7.8 Hz), 7.68 (dd, 1H, <i>J</i> = 1.9 Hz, <i>J</i> = 8.3 Hz), 7.35–7.32 (m, 2H), 7.27 (d, 1H, <i>J</i> = 7.8 Hz), 7.22 (t, 1H, <i>J</i> = 8.0 Hz), 6.91 (dt, 1H, <i>J</i> = 7.0 Hz, <i>J</i> = 15.2 Hz), 6.15 (dd, 1H, <i>J</i> = 1.3 Hz, <i>J</i> = 15.2 Hz), 2.46 (s, 3H), 1.91 (d, 3H, <i>J</i> = 6.8 Hz). <sup>13</sup>C NMR (100 MHz, MeOD): δ 170.8, 167.1, 166.7, 158.6, 152.0, 142.1, 140.3, 137.6, 137.5, 137.1, 133.6, 132.5, 132.3, 131.9, 130.7, 129.9, 129.5, 129.4, 127.3, 126.7, 125.6, 125.5, 124.1, 121.1, 116.2, 115.2, 112.2, 19.3, 17.9. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 575.2018. Found: 575.2015.</div></div><div id="sec6_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> (<i>E</i>)-<i>N</i>-(2-(3-(4-(Dimethylamino)but-2-enamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>33</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.57 (s, 1H), 10.41 (s, 1H), 10.02 (s, 1H), 9.62 (s, 1H), 8.81 (s, 2H), 8.32 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 8.06 (s, 1H), 7.98 (d, 1H, <i>J</i> = 7.8 Hz), 7.93 (d, 1H, <i>J</i> = 1.9 Hz), 7.83 (dd, 1H, <i>J</i> = 2.0 Hz, <i>J</i> = 8.3 Hz), 7.80 (t, 1H, <i>J</i> = 7.8 Hz), 7.38–7.33 (m, 3H), 7.19 (t, 1H, <i>J</i> = 8.1 Hz), 6.73 (dt, 1H, <i>J</i> = 6.1 Hz, <i>J</i> = 15.4 Hz), 6.33 (d, 1H, <i>J</i> = 15.4 Hz), 3.17 (s, 2H), 2.39 (s, 3H), 2.26 (s, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.4, 163.8, 162.8, 156.4, 149.7, 140.8, 139.1, 136.4, 135.3, 131.7, 130.8, 130.7, 129.7, 129.2, 128.9, 128.4, 128.1, 127.0, 126.2, 125.2, 124.0, 122.5, 121.7, 119.1, 113.9, 112.5, 109.5, 59.2, 44.5, 18.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>31</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 618.2440. Found: 618.2432.</div></div><div id="sec6_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 2-Methyl-5-(3-(trifluoromethyl)benzamido)-<i>N</i>-(2-(3-(vinylsulfonamido)phenylmino)pyrimidin-5-yl)benzamide (<b>34</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.57 (s, 1H), 10.42 (s, 1H), 9.92 (s, 1H), 9.68 (s, 1H), 8.81 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.8 Hz), 7.98 (d, 1H, <i>J</i> = 7.9 Hz), 7.94 (d, 1H, <i>J</i> = 1.7 Hz), 7.84 (dd, 1H, <i>J</i> = 1.7 Hz, <i>J</i> = 8.2 Hz), 7.80 (t, 1H, <i>J</i> = 7.7 Hz), 7.76 (s, 1H), 7.39 (d, 1H, <i>J</i> = 8.4 Hz), 7.34 (d, 1H, <i>J</i> = 8.4 Hz), 7.17 (t, 1H, <i>J</i> = 8.2 Hz), 6.77 (dd, 1H, <i>J</i> = 9.9 Hz, <i>J</i> = 16.4 Hz), 6.71 (d, 1H, <i>J</i> = 7.9 Hz), 6.18 (d, 1H, <i>J</i> = 16.4 Hz), 6.06 (d, 1H, <i>J</i> = 9.9 Hz), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 163.9, 156.4, 149.8, 141.3, 138.0, 136.5, 136.3, 135.5, 131.8, 131.0, 130.9, 129.8, 129.4, 129.0, 128.9, 128.2, 127.6, 126.4, 124.1, 122.6, 121.8, 119.3, 113.9, 112.5, 109.6, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>24</sub>F<sub>3</sub>N<sub>6</sub>O<sub>4</sub>S<sup>+</sup> [M + H]<sup>+</sup>: 597.1532. Found: 597.1516.</div></div><div id="sec6_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-(2-(3-(2-Chloroacetamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>35</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.58 (s, 1H), 10.43 (s, 1H), 10.25 (s, 1H), 9.70 (s, 1H), 8.82 (s, 2H), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 8.01–7.94 (m, 3H), 7.86–7.78 (m, 2H), 7.41 (d, 1H, <i>J</i> = 8.1 Hz), 7.35–7.28 (m, 2H), 7.21 (t, 1H, <i>J</i> = 8.1 Hz), 4.26 (s, 2H), 2.39 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 164.5, 163.9, 156.5, 149.8, 141.0, 138.6, 136.5, 135.5, 131.8, 130.9, 130.8, 129.8, 129.4, 129.0, 128.7, 128.2, 126.4, 124.2, 124.1, 121.8, 119.3, 114.3, 112.5, 109.5, 43.6, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>21</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>3</sub><sup>–</sup> [M – H]<sup>−</sup>: 581.1316. Found: 581.1323.</div></div><div id="sec6_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 2-Methyl-<i>N</i>-(2-(3-(2-(3-oxobenzo[<i>d</i>]isothiazol-2(3<i>H</i>)-yl)acetamido)phenylamino)pyrimidin-5-yl)-5-(3-(trifluoromethyl)benzamido)benzamide (<b>36</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.59 (s, 1H), 10.44 (s, 1H), 10.32 (s, 1H), 9.70 (s, 1H), 8.83 (s, 2H), 8.34 (s, 1H), 8.29 (d, 1H, <i>J</i> = 7.8 Hz), 8.05 (s, 1H), 8.01–7.98 (m, 2H), 7.94 (d, 1H, <i>J</i> = 1.8 Hz), 7.91 (d, 1H, <i>J</i> = 7.8 Hz), 7.86 (dd, 1H, <i>J</i> = 4.0 Hz, <i>J</i> = 8.4 Hz), 7.81 (t, 1H, <i>J</i> = 7.8 Hz), 7.72 (t, 1H, <i>J</i> = 7.2 Hz), 7.46 (t, 1H, <i>J</i> = 7.3 Hz), 7.39 (d, 1H, <i>J</i> = 8.2 Hz), 7.34 (d, 1H, <i>J</i> = 8.4 Hz), 7.29 (d, 1H, <i>J</i> = 8.2 Hz), 7.21 (t, 1H, <i>J</i> = 8.0 Hz), 4.71 (s, 2H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 165.2, 164.9, 163.9, 156.5, 149.7, 141.4, 140.9, 138.7, 136.5, 135.4, 131.9, 131.8, 130.9, 130.8, 129.8, 129.3, 129.0, 128.7, 128.2, 126.4, 125.6, 125.3, 124.2, 124.1, 123.4, 122.6, 121.7, 119.2, 114.0, 112.3, 109.3, 46.1, 18.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>35</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O<sub>4</sub>S<sup>+</sup> [M + H]<sup>+</sup>: 698.1797. Found: 698.1786.</div></div><div id="sec6_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>N</i>-(2-(3-(<i>N</i>-Acryloylacrylamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>37</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.89 (s, 1H), 10.60 (s, 1H), 10.24 (s, 1H), 9.13 (s, 2H), 8.32 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.9 Hz), 7.98 (d, 2H, <i>J</i> = 7.0 Hz), 7.86–7.79 (m, 2H), 7.61–7.59 (d, 2H, <i>J</i> = 8.6 Hz), 7.39–7.35 (m, 2H), 6.92 (d, 1H, <i>J</i> = 8.4 Hz), 6.44–6.24 (m, 4H), 5.78–5.75 (m, 2H), 2.40 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.0, 165.6, 163.9, 163.2, 155.6, 149.3, 141.1, 139.7, 136.5, 135.8, 135.4, 132.1, 131.8, 131.6, 131.0, 130.9, 130.3, 129.7, 129.3, 128.2, 127.1, 125.2, 124.1, 124.0, 122.5, 122.1, 119.3, 18.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>26</sub>F<sub>3</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>: 615.1968. Found: 615.2026.</div></div><div id="sec6_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-(2-(3-(2-Acrylamidoacetamido)phenylamino)pyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)benzamido)benzamide (<b>38</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.57 (s, 1H), 10.41 (s, 1H), 9.99 (s, 1H), 9.64 (s, 1H), 8.81 (s, 2H), 8.43 (t, 1H, <i>J</i> = 5.7 Hz), 8.33 (s, 1H), 8.28 (d, 1H, <i>J</i> = 7.8 Hz), 8.03 (s, 1H), 7.98 (d, 1H, <i>J</i> = 7.8 Hz), 7.93 (s, 1H), 7.85 (d, 1H, <i>J</i> = 8.5 Hz), 7.81 (t, 1H, <i>J</i> = 7.8 Hz), 7.37–7.33 (m, 2H), 7.27 (d, 1H, <i>J</i> = 8.0 Hz), 7.19 (t, 1H, <i>J</i> = 8.1 Hz), 6.36 (dd, 1H, <i>J</i> = 10.3 Hz, <i>J</i> = 17.1 Hz), 6.12 (d, 1H, <i>J</i> = 17.0 Hz), 5.63 (d, 1H, 10.4 Hz), 4.00 (d, 2H, <i>J</i> = 5.8 Hz), 2.39 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 167.3, 164.9, 163.9, 156.5, 149.8, 140.8, 138.9, 136.4, 136.3, 135.4, 131.6, 131.4, 130.8, 130.7, 129.6, 128.4, 128.1, 126.2, 125.3, 124.9, 124.0, 122.7, 121.7, 119.2, 113.8, 112.5, 109.5, 42.6, 18.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>31</sub>H<sub>27</sub>F<sub>3</sub>N<sub>7</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup>: 618.2077. Found: 618.2086.</div></div><div id="sec6_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> <i>N</i>-(2-(3-Acrylamidophenylamino)pyrimidin-5-yl)-5-(3-fluorobenzamido)-2-methylbenzamide (<b>39</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.45 (s, 2H), 10.12 (s, 1H), 9.69 (s, 1H), 8.82 (s, 2H), 8.08 (s, 1H), 7.96 (s, 1H), 7.85–7.77 (m, 3H), 7.60 (dd, 1H, <i>J</i> = 7.7 Hz, <i>J</i> = 13.6 Hz), 7.49–7.31 (m, 4H), 7.21 (t, 1H, <i>J</i> = 7.9 Hz), 6.48 (dd, 1H, <i>J</i> = 10.0 Hz, <i>J</i> = 16.9 Hz), 6.25 (d, 1H, <i>J</i> = 17.3 Hz), 5.74 (d, 1H, <i>J</i> = 10.8 Hz), 2.38 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.5, 164.0, 163.0, 162.8, 160.9, 156.5, 149.8, 140.8, 139.0, 136.8, 136.5, 132.0, 130.8, 130.6, 130.5, 128.5, 126.3, 123.7, 121.7, 119.1, 118.5, 118.3, 114.4, 114.2, 112.8, 109.7, 18.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>23</sub>FN<sub>6</sub>O<sub>3</sub>Na<sup>+</sup> [M + Na]<sup>+</sup>: 533.1713. Found: 533.1705.</div></div><div id="sec6_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N</i>-(2-(3-Acrylamidophenylamino)pyrimidin-5-yl)-5-(4-chloro-3-(trifluoromethyl)benzamido)-2-methylbenzamide (<b>40</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.62 (s, 1H), 10.41 (s, 1H), 10.08 (s, 1H), 9.65 (s, 1H), 8.82 (s, 2H), 8.43 (s, 1H), 8.29 (d, 1H, <i>J</i> = 8.4 Hz), 8.08 (s, 1H), 7.94 (d, 1H, <i>J</i> = 8.4 Hz), 7.92 (s, 1H), 7.84 (d, 1H, <i>J</i> = 8.3 Hz), 7.39 (t, 2H, <i>J</i> = 6.9 Hz), 7.34 (d, 1H, <i>J</i> = 8.3 Hz), 7.21 (t, 1H, <i>J</i> = 8.1 Hz), 6.48 (dd, 1H, <i>J</i> = 10.2 Hz, <i>J</i> = 16.9 Hz), 6.26 (d, 1H, <i>J</i> = 17.0 Hz), 5.74 (d, 1H, <i>J</i> = 10.2 Hz), 2.40 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): δ 168.0, 165.5, 163.9, 163.1, 155.5, 149.2, 141.1, 139.7, 136.4, 135.8, 135.4, 132.0, 131.6, 131.5, 130.9, 130.8, 130.2, 129.6, 129.2, 128.1, 126.9, 124.0, 122.5, 122.1, 119.3, 118.2, 117.8, 18.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>21</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>3</sub><sup>–</sup> [M – H]<sup>−</sup>: 593.1316. Found: 593.1338.</div></div><div id="sec6_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N</i>-(3-(2-(3-Acrylamidophenylamino)pyrimidin-5-ylcarbamoyl)-4-methylphenyl)-2-naphthamide (<b>41</b>)</h3><div class="NLM_p last">White solids. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.56 (s, 1H), 10.45 (s, 1H), 10.11 (s, 1H), 9.68 (s, 1H), 8.85 (s, 2H), 8.62 (s, 1H), 8.11–8.02 (m, 6H), 7.88 (dd, 1H, <i>J</i> = 1.9 Hz, <i>J</i> = 8.3 Hz), 7.66–7.64 (m, 2H), 7.39 (d, 2H, <i>J</i> = 8.0 Hz), 7.34 (d, 1H, <i>J</i> = 8.4 Hz), 7.22 (t, 1H, <i>J</i> = 8.0 Hz), 6.50 (dd, 1H, <i>J</i> = 10.1 Hz, <i>J</i> = 16.9 Hz), 6.25 (dd, 1H, <i>J</i> = 1.7 Hz, <i>J</i> = 17.0 Hz), 5.75 (dd, 1H, <i>J</i> = 1.8 Hz, <i>J</i> = 10.2 Hz), 2.41 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 169.5, 167.4, 164.9, 158.4, 151.7, 142.8, 141.0, 138.8, 138.4, 136.2, 133.9, 133.8, 133.7, 132.8, 132.4, 130.8, 130.5, 129.9, 129.8, 129.7, 129.5, 128.8, 128.5, 128.3, 126.2, 123.5, 121.0, 116.0, 114.6, 111.4, 20.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>27</sub>N<sub>6</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup>: 543.2145. Found: 543.2126.</div></div><div id="sec6_41_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Biological Assays. Kinase Enzymology Assays</h3><div class="NLM_p last">Kinases were purchased from Carna Biosciences. Kinase enzymology assays were performed according to the protocols specified in HTRF KinEase assays sold by Cisbio Bioassays.</div></div><div id="sec6_41_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Cellular Phosphorylation Assays</h3><div class="NLM_p last">The assays were performed using a similar procedure as described in literature.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> 5 × 10<sup>5</sup> Ramos cells were seeded in a 12-well plate overnight. After being treated with compounds for 1 h, cells were stimulated with goat anti-human IgM antibody for 3–5 min. After centrifugation, cells were lysed by boiling in SDS buffer. Proteins were analyzed by Western blot. Data were analyzed with ImageJ and Excel.</div></div><div id="sec6_41_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Cell Viability Assay</h3><div class="NLM_p last">Lymphoma cells were seeded in 96-well plates (5000 cells/well), incubated for 24 h, then treated with compounds for 72 h, and measured with CellTiter-Glo luminescent cell viability assay by Promega. Data analysis was performed with GraphPad Prism 5.0.</div></div><div id="sec6_41_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Stability Test in FaSSIF</h3><div class="NLM_p last">FaSSIF solutions of compounds in a 96-well plate were incubated on a minishaker at 350 rpm at 37 °C. At each defined time point (2, 6, 10, and 24 h), samples were collected and measured with LC–MS method.</div></div><div id="sec6_41_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Mouse Liver Microsome Stability Study</h3><div class="NLM_p last">Compounds were incubated with liver microsomes and NADPH at 37 °C. Samples were collected at different time points and centrifuged, and the supernatants were analyzed with LC–MS/MS. First-order kinetics was used to calculate <i>t</i><sub>1/2</sub> and CL. CL<sup>hep</sup> was derived from the equation CL<sup>hep</sup> = (CL)(<i>Q</i>)/(CL + <i>Q</i>), where <i>Q</i> is the estimated liver blood flow of mice at 90 mL min<sup>–1</sup> kg<sup>–1</sup>. Testosterone, propranolol, and clozapine were used as positive controls.</div></div><div id="sec6_41_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> In Vivo Pharmacokinetic Study</h3><div class="NLM_p last">The pharmacokinetics of compounds <b>31</b> and <b>38</b> were evaluated in ICR mice (<i>n</i> = 3) following intravenous (iv) injection at the 1 mg/kg dose level. At various time points, blood samples were taken and analyzed by the LC–MS method.</div></div><div id="sec6_41_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> In Vivo Pharmacodynamic Study</h3><div class="NLM_p last">Female CB17/SCID mice were injected subcutaneously with 5 × 10<sup>6</sup> DoHH2 cells. When tumors reached ∼167 mm<sup>3</sup> on average, mice were randomized into four groups (<i>n</i> = 6/group) and daily dosing began. Compounds were administered via tail vein as a clear solution in polyoxyl 15 hydroxystearate (Solutol)/ethanol (1:1). Tumor size and body weight were monitored periodically for 14 days. Statistical analysis was conducted using one-way ANOVA. The Dunnett test was used to analyze the statistical significance between each treatment group and the vehicle group. <i>P</i> < 0.05 is considered statistically significant. All animal studies were conducted under approved animal care protocols and AAALAC standards.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70"><a href="/doi/suppl/10.1021/jm4017762">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30805" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30805" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Syntheses of compounds <b>11</b>, <b>19</b>, and <b>20</b>, modeling study, and detailed procedures and data for biological assays. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4017762/suppl_file/jm4017762_si_001.pdf">jm4017762_si_001.pdf (747.13 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm4017762" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengying Pan</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0272636c787b4272697771782c6766772c616c"><span class="__cf_email__" data-cfemail="0b7b6a6571724b7b607e7871256e6f7e256865">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xitao Li</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingying Zuo</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guanghui Tang</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yan Wang</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yiqing Zhou</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xueying Wang</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tianlin Guo</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mengying Xia</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of
Chemical Genomics, Key Laboratory of Structural Biology, School of
Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University, Shenzhen, 518055, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Ding</span> - <span class="hlFld-Affiliation affiliation">Key Laboratory of Carcinogenesis and Translational Research (Ministry
of Education), Department of Lymphoma, Peking
University Cancer Hospital and Institute, No. 52 Fucheng Road, Haidian
District, Beijing, 100142, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d128e5059-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i71">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Authors thank the scientists at Crown Biosciences at Beijing and Taicang, China, for their great efforts in biological assays, and Professor Junmin Quan at Peking University, China, for helpful discussions. The following financial support is gratefully acknowledged: to Z.P., Grants 2013CB910700 (973 Program), 81373270 and 21142005 (National Natural Science Foundation of China), KQTD201103, CXB201005260059A and JC201005270281A (Shenzhen Municipal Science and Technology Innovation Council), and 20100001120030 (Ministry of Education); to N.D., Grants 81201873 (National Natural Science Foundation of China) and 7132050 (Beijing Natural Science Foundation).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i72" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i72"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i73" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i73"> Abbreviations Used</h2><tr><td class="NLM_term">ABL</td><td class="NLM_def"><p class="first last">asbelson murine leukemia viral oncogene</p></td></tr><tr><td class="NLM_term">Bmx</td><td class="NLM_def"><p class="first last">bone marrow tyrosine kinase gene in chromosome X protein</p></td></tr><tr><td class="NLM_term">Blk</td><td class="NLM_def"><p class="first last">B lymphoid tyrosine kinase</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">ethyldiisopropylamine</p></td></tr><tr><td class="NLM_term">GI<sub>50</sub></td><td class="NLM_def"><p class="first last">the concentration for 50% of maximal inhibition of cell proliferation</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">(<i>O</i>-(7-azabenzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium hexafluorophosphate)</p></td></tr><tr><td class="NLM_term">HER</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">Itk</td><td class="NLM_def"><p class="first last">IL2-inducible T-cell kinase</p></td></tr><tr><td class="NLM_term">Jak</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term">JNK</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">Lck</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">MAP2K7</td><td class="NLM_def"><p class="first last">dual specificity mitogen-activated protein kinase kinase 7</p></td></tr><tr><td class="NLM_term">Nek2</td><td class="NLM_def"><p class="first last">“never in mitosis gene a”-related kinase 2</p></td></tr><tr><td class="NLM_term">NIMA</td><td class="NLM_def"><p class="first last">never in mitosis gene a</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor</p></td></tr><tr><td class="NLM_term">PLC-γ2</td><td class="NLM_def"><p class="first last">1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase γ2</p></td></tr><tr><td class="NLM_term">Rlk</td><td class="NLM_def"><p class="first last">resting lymphocyte kinase</p></td></tr><tr><td class="NLM_term">RSK</td><td class="NLM_def"><p class="first last">ribosomal s6 kinase</p></td></tr><tr><td class="NLM_term">Syk</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46431" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46431" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 67 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Küppers, R.</span><span> </span><span class="NLM_article-title">Mechanisms of B-cell lymphoma pathogenesis</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnrc1589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=251-262&author=R.+K%C3%BCppers&title=Mechanisms+of+B-cell+lymphoma+pathogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of B-cell lymphoma pathogenesis</span></div><div class="casAuthors">Kueppers, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosomal translocations involving the Ig loci are a hallmark of many types of B-cell lymphoma.  Other factors, however, also have important roles in the pathogenesis of B-cell malignancies.  Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signaling seems to be an important factor for lymphoma pathogenesis.  Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJru-Lq2OdbVg90H21EOLACvtfcHk0lhtmGGdWe16OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D&md5=c8451de36e49f59432a4cee00419f97d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1589%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCppers%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520B-cell%2520lymphoma%2520pathogenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Nakken, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munthe, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekanecz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szodoray, P.</span><span> </span><span class="NLM_article-title">B-cells and their targeting in rheumatoid arthritis—current concepts and future perspectives</span> <span class="citation_source-journal">Autoimmun. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2Fj.autrev.2011.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSksbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=28-34&author=B.+Nakkenauthor=L.+A.+Muntheauthor=Y.+T.+Konttinenauthor=A.+K.+Sandbergauthor=Z.+Szekaneczauthor=P.+Alexauthor=P.+Szodoray&title=B-cells+and+their+targeting+in+rheumatoid+arthritis%E2%80%94current+concepts+and+future+perspectives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">B-cells and their targeting in rheumatoid arthritis - Current concepts and future perspectives</span></div><div class="casAuthors">Nakken, Britt; Munthe, Ludvig A.; Konttinen, Yrjoe T.; Sandberg, Anna Klokk; Szekanecz, Zoltan; Alex, Philip; Szodoray, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Autoimmunity Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-34</span>CODEN:
                <span class="NLM_cas:coden">ARUEBU</span>;
        ISSN:<span class="NLM_cas:issn">1568-9972</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a chronic, autoimmune disease that affects primarily the joints and without proper treatment results in their progressive destruction.  In addn. to T-cells, B-cells play a central role in the pathogenesis of this disease.  The synovial tissue is an active site of B-cell accumulation, plasma cell differentiation and in situ antibody-prodn. in RA.  As part of the complex role of B-cells in the joints and synovial membrane of RA patients, B cells secrete chemokines and cytokines and may function as antigen presenting cells.  The multifaceted pathogenic function of B-cells identifies them as excellent targets for immunosuppressive therapy.  B-cell targeting involves a wide spectrum of mols., for example the B-cell antigen CD20 that allows specific and effective B-cell depletion.  Another target, CD79, expressed by B-cell and plasma cell precursors is an obvious candidate that induces apoptosis as well as inhibition of B-cell receptor (BCR) activation and possibly depletion of ectopic germinal centers (GC).  Inhibition of B-cell co-stimulatory mols. such as CD40, CD80/86 and ICOS, can lead to diminished B-cell activation.  Moreover, anti-chemokine and anti-cytokine therapies can be efficacious in RA by the disruption of B-cell activation and autoantibody prodn., B-cell synovial migration and ectopic GC formation.  Finally, targeting the signal transduction pathways required for proximal BCR signaling has also been found efficacious in early clin. trials in RA.  Even so, some B cells inhibit immune responses, these regulatory B cells may play a part in immune regulation in patients and it is unclear what effects B cell depletion strategies have in terms of such B cell subsets.  This review discusses current strategies of targeting B-cells as therapeutic candidates in the management of RA.  Better insights into the pathogenic role of B-cells provide efficacious opportunities to improve both therapy and prognosis of patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXuHEK_hHsLVg90H21EOLACvtfcHk0lhtmGGdWe16OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSksbvK&md5=a854c46ccb57e4b81179702a7028c66a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.autrev.2011.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.autrev.2011.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DNakken%26aufirst%3DB.%26aulast%3DMunthe%26aufirst%3DL.%2BA.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26aulast%3DSandberg%26aufirst%3DA.%2BK.%26aulast%3DSzekanecz%26aufirst%3DZ.%26aulast%3DAlex%26aufirst%3DP.%26aulast%3DSzodoray%26aufirst%3DP.%26atitle%3DB-cells%2520and%2520their%2520targeting%2520in%2520rheumatoid%2520arthritis%25E2%2580%2594current%2520concepts%2520and%2520future%2520perspectives%26jtitle%3DAutoimmun.%2520Rev.%26date%3D2011%26volume%3D11%26spage%3D28%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäckesjö, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglöf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.+M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Nore&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0lhtmGGdWe16OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.%2BM.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Smith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vořechovský, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olerup, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabbani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarström, L.</span><span> </span><span class="NLM_article-title">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fj.1600-065X.1994.tb00851.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=8070814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1994&pages=159-183&author=C.+Smithauthor=K.+B.+Islamauthor=I.+Vo%C5%99echovsk%C3%BDauthor=O.+Olerupauthor=E.+Wallinauthor=H.+Rabbaniauthor=B.+Baskinauthor=L.+Hammarstr%C3%B6m&title=X-linked+agammaglobulinemia+and+other+immunoglobulin+deficiencies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Khalid B.; Vorechovsky, Igor; Olerup, Olle; Wallin, Erik; Rabbani, Hodjattallah; Baskin, Berivan; Hammarstroem, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-83</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    </div><div class="casAbstract">A review with 123 refs. discussing Ig deficiencies, isolation of the XLA gene, structure and expression of Btk, mutation anal. in patients with XLA, the naturally occurring mouse mutant CBA/N, deletions in the IgH locus, IgA deficiency and common variable immunodeficiency, genetics of IgAD and CVID, the B-lymphocyte abnormality in IgAD, and IgG3 deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqcdUsf_XJ8LVg90H21EOLACvtfcHk0ljkzscg3ayQYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D&md5=90f59e592743c3baeb1531c8c0689946</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.1994.tb00851.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.1994.tb00851.x%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVo%25C5%2599echovsk%25C3%25BD%26aufirst%3DI.%26aulast%3DOlerup%26aufirst%3DO.%26aulast%3DWallin%26aufirst%3DE.%26aulast%3DRabbani%26aufirst%3DH.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26atitle%3DX-linked%2520agammaglobulinemia%2520and%2520other%2520immunoglobulin%2520deficiencies%26jtitle%3DImmunol.%2520Rev.%26date%3D1994%26volume%3D138%26spage%3D159%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sideras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span> </span><span class="NLM_article-title">Molecular and cellular aspects of X-linked agammaglobulinemia</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1995&pages=135-224&author=P.+Siderasauthor=C.+I.+Smith&title=Molecular+and+cellular+aspects+of+X-linked+agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DMolecular%2520and%2520cellular%2520aspects%2520of%2520X-linked%2520agammaglobulinemia%26jtitle%3DAdv.%2520Immunol.%26date%3D1995%26volume%3D59%26spage%3D135%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Rickert, R. C.</span><span> </span><span class="NLM_article-title">New insights into pre-BCR and BCR signalling with relevance to B cell malignancies</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">578</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnri3487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKnt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=578-591&author=R.+C.+Rickert&title=New+insights+into+pre-BCR+and+BCR+signalling+with+relevance+to+B+cell+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into pre-BCR and BCR signalling with relevance to B cell malignancies</span></div><div class="casAuthors">Rickert, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">578-591</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The B cell receptor (BCR) and its precursor (pre-BCR) control B cell homeostasis, differentiation and function.  Moreover, aberrant pre-BCR and BCR signalling have a central role in B cell neoplasia; for example, enhanced pos. signalling or disrupted neg. signalling downstream of the pre-BCR promotes B cell acute lymphocytic leukemia.  The emerging distinctions between tonic and chronic active BCR signalling have contributed to the identification of oncogenic targets downstream of BCR signalling in mature B cell neoplasms.  Indeed, the encouraging results of several ongoing clin. trials that target the activity of phosphoinositide 3-kinase δ-isoform (PI3Kδ), Bruton tyrosine kinase (BTK) or spleen tyrosine kinase (SYK) downstream of the BCR highlight the therapeutic potential of inhibiting BCR signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEVfPnHXGyE7Vg90H21EOLACvtfcHk0ljkzscg3ayQYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKnt7nK&md5=8ae8c95aff039852282e02f6353979ca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnri3487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3487%26sid%3Dliteratum%253Aachs%26aulast%3DRickert%26aufirst%3DR.%2BC.%26atitle%3DNew%2520insights%2520into%2520pre-BCR%2520and%2520BCR%2520signalling%2520with%2520relevance%2520to%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D578%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Chronic active B cell receptor signalling in diffuse large B cell lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B+cell+receptor+signalling+in+diffuse+large+B+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B%2520cell%2520receptor%2520signalling%2520in%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Pan, Z.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase as a drug discovery target</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1358%2Fdnp.2008.21.7.1255308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=19259548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=357&author=Z.+Pan&title=Bruton%E2%80%99s+tyrosine+kinase+as+a+drug+discovery+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase as a drug discovery target</span></div><div class="casAuthors">Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways.  Fifteen years of research have revealed a complex role for Btk in hematopoietic cells.  These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases.  Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases.  Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chem. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Pn8DtrLdQ7Vg90H21EOLACvtfcHk0lijf7B_NTnRug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP&md5=dbb3e077ce56474a93b83c3be3783334</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2008.21.7.1255308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2008.21.7.1255308%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2008%26volume%3D21%26spage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4539</span><span class="NLM_x">–</span> <span class="NLM_lpage">4350</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4350&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudbeck, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hupke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uckun, F. M.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-<i>N</i>-(2,5-dibromophenyl)propenamide]</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">9587</span><span class="NLM_x">–</span> <span class="NLM_lpage">9599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=9587-9599&author=S.+Mahajanauthor=S.+Ghoshauthor=E.+A.+Sudbeckauthor=Y.+Zhengauthor=S.+Downsauthor=M.+Hupkeauthor=F.+M.+Uckun&title=Rational+design+and+synthesis+of+a+novel+anti-leukemic+agent+targeting+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%2C+LFM-A13+%5B%CE%B1-cyano-%CE%B2-hydroxy-%CE%B2-methyl-N-%282%2C5-dibromophenyl%29propenamide%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DSudbeck%26aufirst%3DE.%2BA.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDowns%26aufirst%3DS.%26aulast%3DHupke%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520a%2520novel%2520anti-leukemic%2520agent%2520targeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%252C%2520LFM-A13%2520%255B%25CE%25B1-cyano-%25CE%25B2-hydroxy-%25CE%25B2-methyl-N-%25282%252C5-dibromophenyl%2529propenamide%255D%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D9587%26epage%3D9599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürckstümmer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">13283</span><span class="NLM_x">–</span> <span class="NLM_lpage">13288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13283-13288&author=O.+Hantschelauthor=U.+Rixauthor=U.+Schmidtauthor=T.+B%C3%BCrckst%C3%BCmmerauthor=M.+Kneidingerauthor=G.+Sch%C3%BCtzeauthor=J.+Colingeauthor=K.+L.+Bennettauthor=W.+Ellmeierauthor=P.+Valentauthor=G.+Superti-Furga&title=The+Btk+tyrosine+kinase+is+a+major+target+of+the+Bcr-Abl+inhibitor+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DB%25C3%25BCrckst%25C3%25BCmmer%26aufirst%3DT.%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSch%25C3%25BCtze%26aufirst%3DG.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520Btk%2520tyrosine%2520kinase%2520is%2520a%2520major%2520target%2520of%2520the%2520Bcr-Abl%2520inhibitor%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D13283%26epage%3D13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barck, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForge, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgjaNy60Ism6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coraggio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuebler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1840</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1840-1849&author=L.+Liuauthor=J.+S.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+C.+Davisauthor=X.+C.+Liaoauthor=J.+W.+Lubachauthor=A.+Deeseauthor=C.+G.+Sowellauthor=K.+S.+Currieauthor=W.+B.+Youngauthor=S.+C.+Khojastehauthor=C.+E.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%2BC.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1840%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postelnek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.+Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span></div><div class="casAuthors">Xu Daigen; Kim Yong; Postelnek Jennifer; Vu Minh Diem; Hu Dong-Qing; Liao Cheng; Bradshaw Mike; Hsu Jonathan; Zhang Jun; Pashine Achal; Srinivasan Dinesh; Woods John; Levin Anita; O'Mahony Alison; Owens Timothy D; Lou Yan; Hill Ronald J; Narula Satwant; Demartino Julie; Fine Jay S</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor cross-linking-induced degranulation in mast cells (IC(50) = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α production in monocytes (IC(50) = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC(50) = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-molecule disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqSnPYc5dDCNj_Vg2vObihfW6udTcc2eZcsTIb32DNcrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D&md5=a04c33939073dc33beda20c4b5e833d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.%2BQ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Evans, E.; Ponader, S.; Karp, R.; Tester, R.; Sheets, M.; Aslanian, S.; Zhu, Z.; Chaturvedi, P.; Mazdiyasni, H.; Nacht, M.; Burger, J.; Petter, R.; Westlin, W.; Singh, J.</span><span> </span><span class="NLM_article-title">AVL-292: a targeted therapy for Bruton’s tyrosine kinase in B cell malignancies</span>. Presented at the 16th Congress of the European Hematology Association, London, U.K., June 9–12,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=E.+Evans&author=S.+Ponader&author=R.+Karp&author=R.+Tester&author=M.+Sheets&author=S.+Aslanian&author=Z.+Zhu&author=P.+Chaturvedi&author=H.+Mazdiyasni&author=M.+Nacht&author=J.+Burger&author=R.+Petter&author=W.+Westlin&author=J.+Singh&title=AVL-292%3A+a+targeted+therapy+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DAVL-292%253A%2520a%2520targeted%2520therapy%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Kim, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H. C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.-H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+C.+N.+Soutterauthor=S.+K.+R.+Hanauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%2BC.%2BN.%26aulast%3DHan%26aufirst%3DS.%2BK.%2BR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhO3YHoEZ-tcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lhO3YHoEZ-tcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francesco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sokolove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magadala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">R115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=R115&author=B.+Y.+Changauthor=M.+M.+Huangauthor=M.+Francescoauthor=J.+Chenauthor=J.+Sokoloveauthor=P.+Magadalaauthor=W.+H.+Robinsonauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+ameliorates+autoimmune+arthritis+by+inhibition+of+multiple+effector+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DHuang%26aufirst%3DM.%2BM.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSokolove%26aufirst%3DJ.%26aulast%3DMagadala%26aufirst%3DP.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520ameliorates%2520autoimmune%2520arthritis%2520by%2520inhibition%2520of%2520multiple%2520effector%2520cells%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2011%26volume%3D13%26spage%3DR115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Aalipour, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, R. H.</span><span> </span><span class="NLM_article-title">Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fbjh.12573" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2013&pages=463-443&author=A.+Aalipourauthor=R.+H.+Advani&title=Bruton+tyrosine+kinase+inhibitors%3A+a+promising+novel+targeted+treatment+for+B+cell+lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12573%26sid%3Dliteratum%253Aachs%26aulast%3DAalipour%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DBruton%2520tyrosine%2520kinase%2520inhibitors%253A%2520a%2520promising%2520novel%2520targeted%2520treatment%2520for%2520B%2520cell%2520lymphomas%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D163%26spage%3D463%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamasy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fsji.12069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=23672610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOit77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2013&pages=130-139&author=L.+Vargasauthor=A.+Hamasyauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Inhibitors+of+BTK+and+ITK%3A+state+of+the+new+drugs+for+cancer%2C+autoimmunity+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases</span></div><div class="casAuthors">Vargas, L.; Hamasy, A.; Nore, B. F.; E. Smith, C. I.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-139</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  BTK and ITK are cytoplasmic tyrosine kinases of crucial importance for B and T cell development, with loss-of-function mutations causing X-linked agammaglobulinemia and susceptibility to severe, frequently lethal, Epstein-Barr virus infection, resp.  Over the last few years, considerable efforts have been made in order to develop small-mol. inhibitors for these kinases to treat lymphocyte malignancies, autoimmunity or allergy/hypersensitivity.  The rationale is that even if complete lack of BTK or ITK during development causes severe immunodeficiency, inactivation after birth may result in a less severe phenotype.  Moreover, therapy can be transient or only partially block the activity of BTK or ITK.  Furthermore, a drug-induced B cell deficiency is treatable by gamma globulin substitution therapy.  The newly developed BTK inhibitor PCI-32765, recently renamed Ibrutinib, has already entered several clin. trials for various forms of non-Hodgkin lymphoma as well as for multiple myeloma.  Exptl. animal studies have demonstrated highly promising treatment effects also in autoimmunity.  ITK inhibitors are still under the early developmental phase, but it can be expected that such drugs will also become very useful.  In this study, we present BTK and ITK with their signalling pathways and review the development of the corresponding inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP0_rsdqSDoLVg90H21EOLACvtfcHk0liMuu4qik3VJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOit77M&md5=f9ba77b041266d4746a7cef27604f11a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fsji.12069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fsji.12069%26sid%3Dliteratum%253Aachs%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DHamasy%26aufirst%3DA.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DInhibitors%2520of%2520BTK%2520and%2520ITK%253A%2520state%2520of%2520the%2520new%2520drugs%2520for%2520cancer%252C%2520autoimmunity%2520and%2520inflammatory%2520diseases%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D2013%26volume%3D78%26spage%3D130%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Sanderson, K.</span><span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0liMuu4qik3VJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lgJR4__YPEnng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lgJR4__YPEnng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2FS0163-7258%2802%2900194-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=12191617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=253-261&author=W.+A.+Denny&title=Irreversible+inhibitors+of+the+erbB+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The erbB family of transmembrane receptor tyrosine kinases initiates a large no. of cellular signaling pathways.  Their over-expression in human tumors correlates with poor prognosis, and they have become important targets for drug development.  The 4-anilinoquinazolines are potent and selective ATP site inhibitors of these enzymes, esp. erbB1 (epidermal growth factor receptor).  Structure-activity studies for binding at the ATP site are narrow, consistent with homol. and crystal structure-binding models.  Combinations of small lipophilic groups at the 3'-position of the aniline and electron-donating groups at the 6- or 7-positions of the quinazoline result in extremely potent (picomolar) reversible inhibitors, several of which are in clin. trial.  Observation that the erbB family of enzymes contains a unique Cys residue (Cys773) close to the ATP-binding site prompted the development of irreversible inhibitors, the most successful being 6-acrylamides and related butynamides, which show significantly improved in vivo antitumor activity compared with closely related reversibly binding compds.  Solubilizing side chains can be placed either at the terminus of the alkylating unit or at the quinazoline C-7, and examples of both types are in clin. trial.  Both reversible and irreversible inhibitors synergize with a variety of DNA-damaging anticancer drugs, and it is likely that the greatest impact of these agents will be in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwN71GFZA09rVg90H21EOLACvtfcHk0ljSzxdst54YFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D&md5=7937e2efbf606734ae781554e7c26d15</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900194-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900194-8%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a selective irreversible BMX inhibitor for prostate cancer</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb4000629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1423-1428&author=F.+Liuauthor=X.+Zhangauthor=E.+Weisbergauthor=S.+Chenauthor=W.+Hurauthor=H.+Wuauthor=Z.+Zhaoauthor=W.+Wangauthor=M.+Maoauthor=C.+Caiauthor=N.+I.+Simonauthor=T.+Sandaauthor=J.+Wangauthor=A.+T.+Lookauthor=J.+D.+Griffinauthor=S.+P.+Balkauthor=Q.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+selective+irreversible+BMX+inhibitor+for+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer</span></div><div class="casAuthors">Liu, Feiyang; Zhang, Xin; Weisberg, Ellen; Chen, Sen; Hur, Wooyoung; Wu, Hong; Zhao, Zheng; Wang, Wenchao; Mao, Mao; Cai, Changmeng; Simon, Nicholas I.; Sanda, Takaomi; Wang, Jinhua; Look, A. Thomas; Griffin, James D.; Balk, Steven P.; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1428</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BMX is a member of the TEC family of nonreceptor tyrosine kinases.  We have used structure-based drug design in conjunction with kinome profiling to develop a potent, selective, and irreversible BMX kinase inhibitor, BMX-IN-1, which covalently modifies Cys496.  BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concns. but requires single digit micromolar concns. to inhibit the proliferation of prostate cancer cell lines.  Using a combinatorial kinase inhibitor screening strategy, we discovered that the allosteric Akt inhibitor, MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2n6bH8dNlUrVg90H21EOLACvtfcHk0ljSzxdst54YFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D&md5=bf861dad7c1a1f227695e8049f82a4d9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fcb4000629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4000629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DN.%2BI.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520irreversible%2520BMX%2520inhibitor%2520for%2520prostate%2520cancer%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1423%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0liooCkbGRi1NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Perez, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palomo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dans, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span> </span><span class="NLM_article-title">Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4042</span><span class="NLM_x">–</span> <span class="NLM_lpage">4056</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1016279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4042-4056&author=D.+I.+Perezauthor=V.+Palomoauthor=C.+Perezauthor=C.+Gilauthor=P.+D.+Dansauthor=F.+J.+Luqueauthor=S.+Condeauthor=A.+Martinez&title=Switching+reversibility+to+irreversibility+in+glycogen+synthase+kinase+3+inhibitors%3A+clues+for+specific+design+of+new+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm1016279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1016279%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DDans%26aufirst%3DP.%2BD.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DConde%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DSwitching%2520reversibility%2520to%2520irreversibility%2520in%2520glycogen%2520synthase%2520kinase%25203%2520inhibitors%253A%2520clues%2520for%2520specific%2520design%2520of%2520new%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4042%26epage%3D4056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstenberger, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limburg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medley, Q. G.</span><span> </span><span class="NLM_article-title">Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10047</span><span class="NLM_x">–</span> <span class="NLM_lpage">10063</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+inhibitors+of+interleukin-2+inducible+T+cell+kinase+%28Itk%29+with+nanomolar+potency+in+a+whole-blood+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0liooCkbGRi1NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520inhibitors%2520of%2520interleukin-2%2520inducible%2520T%2520cell%2520kinase%2520%2528Itk%2529%2520with%2520nanomolar%2520potency%2520in%2520a%2520whole-blood%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inesta-Vaquera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niepel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoGrasso, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorger, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective covalent inhibitors of JNK</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2Fj.chembiol.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=22284361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=140-154&author=T.+Zhangauthor=F.+Inesta-Vaqueraauthor=M.+Niepelauthor=J.+Zhangauthor=S.+B.+Ficarroauthor=T.+Machleidtauthor=T.+Xieauthor=J.+A.+Martoauthor=N.+Kimauthor=T.+Simauthor=J.+D.+Laughlinauthor=H.+Parkauthor=P.+V.+LoGrassoauthor=M.+Patricelliauthor=T.+K.+Nomanbhoyauthor=P.+K.+Sorgerauthor=D.+R.+Alessiauthor=N.+S.+Gray&title=Discovery+of+potent+and+selective+covalent+inhibitors+of+JNK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Covalent Inhibitors of JNK</span></div><div class="casAuthors">Zhang, Tinghu; Inesta-Vaquera, Francisco; Niepel, Mario; Zhang, Jianming; Ficarro, Scott B.; Machleidt, Thomas; Xie, Ting; Marto, Jarrod A.; Kim, Nam Doo; Sim, Taebo; Laughlin, John D.; Park, Hajeung; LoGrasso, Philip V.; Patricelli, Matt; Nomanbhoy, Tyzoon K.; Sorger, Peter K.; Alessi, Dario R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-154</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response.  Here, we report the discovery of irreversible inhibitors of JNK1/2/3.  We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resoln. that show the compds. form covalent bonds with a conserved cysteine residue.  JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue.  Extensive biochem., cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compd. will be broadly useful as a pharmacol. probe of JNK-dependent signal transduction.  Potential lead compds. have also been identified for kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXs0FY7FSmt7Vg90H21EOLACvtfcHk0liooCkbGRi1NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D&md5=f7d9647fb2be162c637b1d31a778ceb4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DInesta-Vaquera%26aufirst%3DF.%26aulast%3DNiepel%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DLaughlin%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520covalent%2520inhibitors%2520of%2520JNK%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D140%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.+M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lhMQD8SrlPB0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Henise, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4133</span><span class="NLM_x">–</span> <span class="NLM_lpage">4146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lhMQD8SrlPB0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazdiyasni, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhavsar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3008745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=712-721&author=M.+Nachtauthor=L.+Qiaoauthor=M.+P.+Sheetsauthor=T.+St+Martinauthor=M.+Labenskiauthor=H.+Mazdiyasniauthor=R.+Karpauthor=Z.+Zhuauthor=P.+Chaturvediauthor=D.+Bhavsarauthor=D.+Niuauthor=W.+Westlinauthor=R.+C.+Petterauthor=A.+P.+Medikondaauthor=J.+Singh&title=Discovery+of+a+potent+and+isoform-selective+targeted+covalent+inhibitor+of+the+lipid+kinase+PI3K%CE%B1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα</span></div><div class="casAuthors">Nacht, Mariana; Qiao, Lixin; Sheets, Michael P.; St. Martin, Thia; Labenski, Matthew; Mazdiyasni, Hormoz; Karp, Russell; Zhu, Zhendong; Chaturvedi, Prasoon; Bhavsar, Deepa; Niu, Deqiang; Westlin, William; Petter, Russell C.; Medikonda, Aravind Prasad; Singh, Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-721</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kα has been identified as an oncogene in human tumors.  By use of rational drug design, a targeted covalent inhibitor 3 (CNX-1351) was created that potently and specifically inhibits PI3Kα.  We demonstrate, using mass spectrometry and X-ray crystallog., that the selective inhibitor covalently modifies PI3Kα on cysteine 862 (C862), an amino acid unique to the α isoform, and that PI3Kβ, -γ, and -δ are not covalently modified. 3 is able to potently (EC50 < 100 nM) and specifically inhibit signaling in PI3Kα-dependent cancer cell lines, and this leads to a potent antiproliferative effect (GI50 < 100 nM).  A covalent probe, 8 (CNX-1220), which selectively bonds to PI3Kα, was used to investigate the duration of occupancy of 3 with PI3Kα in vivo.  This is the first report of a PI3Kα-selective inhibitor, and these data demonstrate the biol. impact of selectively targeting PI3Kα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrGxtOJ4wQbVg90H21EOLACvtfcHk0lhMQD8SrlPB0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjsr4%253D&md5=42bf6d9221fdb9eafe010064807d22b9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm3008745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008745%26sid%3Dliteratum%253Aachs%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DSheets%26aufirst%3DM.%2BP.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DBhavsar%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DMedikonda%26aufirst%3DA.%2BP.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520isoform-selective%2520targeted%2520covalent%2520inhibitor%2520of%2520the%2520lipid%2520kinase%2520PI3K%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D712%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0liMWJy0O3dPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Kwarcinski, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffey, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soellner, M. B.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1910</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300337u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kms77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1910-1917&author=F.+E.+Kwarcinskiauthor=C.+C.+Foxauthor=M.+E.+Steffeyauthor=M.+B.+Soellner&title=Irreversible+inhibitors+of+c-Src+kinase+that+target+a+nonconserved+cysteine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine</span></div><div class="casAuthors">Kwarcinski, Frank E.; Fox, Christel C.; Steffey, Michael E.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1910-1917</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed the first irreversible inhibitors of wild-type c-Src kinase.  We demonstrate that our irreversible inhibitors display improved potency and selectivity relative to that of their reversible counterparts.  Our strategy involves modifying a promiscuous kinase inhibitor with an electrophile to generate covalent inhibitors of c-Src.  We applied this methodol. to two inhibitor scaffolds that exhibit increased cellular efficacy when rendered irreversible.  In addn., we have demonstrated the utility of irreversible inhibitors in studying the conformation of an important loop in kinases that can control inhibitor selectivity and cause drug resistance.  Together, we have developed a general and robust framework for generating selective irreversible inhibitors from reversible, promiscuous inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcojrr4XAxmLVg90H21EOLACvtfcHk0liMWJy0O3dPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kms77J&md5=db928e772f1ed18be2ac37ec930d743c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcb300337u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300337u%26sid%3Dliteratum%253Aachs%26aulast%3DKwarcinski%26aufirst%3DF.%2BE.%26aulast%3DFox%26aufirst%3DC.%2BC.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DIrreversible%2520inhibitors%2520of%2520c-Src%2520kinase%2520that%2520target%2520a%2520nonconserved%2520cysteine%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1910%26epage%3D1917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Gushwa, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Selective targeting of distinct active site nucleophiles by irreversible Src-family kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">20214</span><span class="NLM_x">–</span> <span class="NLM_lpage">20217</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja310659j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCgsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=20214-20217&author=N.+N.+Gushwaauthor=S.+Kangauthor=J.+Chenauthor=J.+Taunton&title=Selective+targeting+of+distinct+active+site+nucleophiles+by+irreversible+Src-family+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Targeting of Distinct Active Site Nucleophiles by Irreversible Src-Family Kinase Inhibitors</span></div><div class="casAuthors">Gushwa, Nathan N.; Kang, Sumin; Chen, Jing; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">20214-20217</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Src-family tyrosine kinases play pivotal roles in human physiol. and disease, and several drugs that target members of this family are in clin. use.  None of these drugs appear to discriminate among closely related kinases.  However, assessing their selectivity toward endogenous kinases in living cells remains a significant challenge.  Here, we report the design of two Src-directed chem. probes, each consisting of a nucleoside scaffold with a 5'-electrophile.  A 5'-fluorosulfonylbenzoate (1) reacts with the conserved catalytic lysine (Lys295) and shows little discrimination among related kinases.  By contrast, a 5'-vinylsulfonate (2) reacts with a poorly conserved, proximal cysteine (Cys277) found in three Src-family and six unrelated kinases.  Both 1 and 2 bear an alkyne tag and efficiently label their resp. endogenous kinase targets in intact cells.  Using 1 as a competitive probe, we detd. the extent to which ponatinib, a clin. Bcr-Abl inhibitor, targets Src-family kinases.  Remarkably, while ponatinib had little effect on endogenous Fyn or Src, it potently blocked the crit. T-cell kinase, Lck.  Probes 1 and 2 thus enable competitive profiling vs. distinct kinase subsets in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOvY8gbkN9P7Vg90H21EOLACvtfcHk0liMWJy0O3dPVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCgsLfN&md5=21e537d7111cb159caba17a1fec4ef59</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fja310659j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja310659j%26sid%3Dliteratum%253Aachs%26aulast%3DGushwa%26aufirst%3DN.%2BN.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DSelective%2520targeting%2520of%2520distinct%2520active%2520site%2520nucleophiles%2520by%2520irreversible%2520Src-family%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D20214%26epage%3D20217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lhzOq0wEIgStA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Garuti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2981</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.2174%2F092986711796391705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21651479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2981-2994&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Irreversible+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible protein kinase inhibitors</span></div><div class="casAuthors">Garuti, L.; Roberti, M.; Bottegoni, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2981-2994</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting cancer with small mol. irreversible inhibitors of kinases represents an emerging challenge in drug discovery.  Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket.  The most common mechanism is the Michael reaction, that refers to the addn. of a nucleophile, such as cysteine, to an α,β-unsatd. carbonyl.  The nucleophile reacts at the electrophilic β-position to form an adduct; as a result the inhibitor irreversibly blocks binding of ATP to the kinase, rendering the kinase inactive.  Different cysteine-reactive groups have been evaluated, an acrylamide or a substituted acrylamide moiety are the Michael acceptors of choice.  There are some advantages for the irreversible kinase inhibition.  These compds. are highly selective because they target a specific cysteine and only a limited no. of kinases has a cysteine at the corresponding position.  Another advantage is that covalent bond formation can overcome competition with the high endogenous concn. of ATP.  A further motivation for designing irreversible inhibitors is their longer duration of action respect to conventional inhibitors.  In fact, once bound to enzyme, these compds. do not readily dissoc. and the inhibition continues even after the inhibitor leaves the circulation.  Moreover, these inhibitors have the potential to overcome and prevent the emergence of acquired resistance conferred by mutations.  In this review examples of irreversible inhibitors are reported, focusing on chem. structures, SAR and biol. activities.  The great potential of these compds. could open new and promising perspectives for a broader application of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkLFECsvPg2LVg90H21EOLACvtfcHk0lhzOq0wEIgStA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D&md5=8c732cb9de810f9fac6484c245e41867</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F092986711796391705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391705%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2981%26epage%3D2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Dinh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunberger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span> </span><span class="NLM_article-title">Activation mechanism and steady state kinetics of Bruton’s tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">8768</span><span class="NLM_x">–</span> <span class="NLM_lpage">8776</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=8768-8776&author=M.+Dinhauthor=D.+Grunbergerauthor=H.+Hoauthor=S.+Y.+Tsingauthor=D.+Shawauthor=S.+Leeauthor=J.+Barnettauthor=R.+J.+Hillauthor=D.+C.+Swinneyauthor=J.+M.+Bradshaw&title=Activation+mechanism+and+steady+state+kinetics+of+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDinh%26aufirst%3DM.%26aulast%3DGrunberger%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DTsing%26aufirst%3DS.%2BY.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBarnett%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DActivation%2520mechanism%2520and%2520steady%2520state%2520kinetics%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D8768%26epage%3D8776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wahl, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fluckiger, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span> </span><span class="NLM_article-title">Phosphorylation of two regulatory tyrosine residues in the activation of Bruton’s tyrosine kinase via alternative receptors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">11526</span><span class="NLM_x">–</span> <span class="NLM_lpage">11533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=11526-11533&author=M.+I.+Wahlauthor=A.-C.+Fluckigerauthor=R.+M.+Katoauthor=H.+Parkauthor=O.+N.+Witteauthor=D.+J.+Rawlings&title=Phosphorylation+of+two+regulatory+tyrosine+residues+in+the+activation+of+Bruton%E2%80%99s+tyrosine+kinase+via+alternative+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWahl%26aufirst%3DM.%2BI.%26aulast%3DFluckiger%26aufirst%3DA.-C.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DPhosphorylation%2520of%2520two%2520regulatory%2520tyrosine%2520residues%2520in%2520the%2520activation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520via%2520alternative%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D11526%26epage%3D11533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Nisitani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, M. I.</span><span> </span><span class="NLM_article-title">In situ detection of activated Bruton’s tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">2221</span><span class="NLM_x">–</span> <span class="NLM_lpage">2226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=2221-2226&author=S.+Nisitaniauthor=R.+M.+Katoauthor=D.+J.+Rawlingsauthor=O.+N.+Witteauthor=M.+I.+Wahl&title=In+situ+detection+of+activated+Bruton%E2%80%99s+tyrosine+kinase+in+the+Ig+signaling+complex+by+phosphopeptide-specific+monoclonal+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNisitani%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DWahl%26aufirst%3DM.%2BI.%26atitle%3DIn%2520situ%2520detection%2520of%2520activated%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520the%2520Ig%2520signaling%2520complex%2520by%2520phosphopeptide-specific%2520monoclonal%2520antibodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D2221%26epage%3D2226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0lgJiz53ovRaQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kang, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitaura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabuchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarakhovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turck, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span> </span><span class="NLM_article-title">PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5692</span><span class="NLM_x">–</span> <span class="NLM_lpage">5702</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=5692-5702&author=S.+W.+Kangauthor=M.+I.+Wahlauthor=J.+Chuauthor=J.+Kitauraauthor=Y.+Kawakamiauthor=R.+M.+Katoauthor=R.+Tabuchiauthor=A.+Tarakhovskyauthor=T.+Kawakamiauthor=C.+W.+Turckauthor=O.+N.+Witteauthor=D.+J.+Rawlings&title=PKC%CE%B2+modulates+antigen+receptor+signaling+via+regulation+of+Btk+membrane+localization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BW.%26aulast%3DWahl%26aufirst%3DM.%2BI.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DKitaura%26aufirst%3DJ.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DTabuchi%26aufirst%3DR.%26aulast%3DTarakhovsky%26aufirst%3DA.%26aulast%3DKawakami%26aufirst%3DT.%26aulast%3DTurck%26aufirst%3DC.%2BW.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DPKC%25CE%25B2%2520modulates%2520antigen%2520receptor%2520signaling%2520via%2520regulation%2520of%2520Btk%2520membrane%2520localization%26jtitle%3DEMBO%2520J.%26date%3D2001%26volume%3D20%26spage%3D5692%26epage%3D5702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">de Rooij, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geest, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eldering, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pals, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaargaren, M.</span><span> </span><span class="NLM_article-title">The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">2590</span><span class="NLM_x">–</span> <span class="NLM_lpage">2594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2590-2594&author=M.+F.+de+Rooijauthor=A.+Kuilauthor=C.+R.+Geestauthor=E.+Elderingauthor=B.+Y.+Changauthor=J.+J.+Buggyauthor=S.+T.+Palsauthor=M.+Spaargaren&title=The+clinically+active+BTK+inhibitor+PCI-32765+targets+B-cell+receptor-+and+chemokine-controlled+adhesion+and+migration+in+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRooij%26aufirst%3DM.%2BF.%26aulast%3DKuil%26aufirst%3DA.%26aulast%3DGeest%26aufirst%3DC.%2BR.%26aulast%3DEldering%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DPals%26aufirst%3DS.%2BT.%26aulast%3DSpaargaren%26aufirst%3DM.%26atitle%3DThe%2520clinically%2520active%2520BTK%2520inhibitor%2520PCI-32765%2520targets%2520B-cell%2520receptor-%2520and%2520chemokine-controlled%2520adhesion%2520and%2520migration%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2590%26epage%3D2594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommolt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashkar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title"><i>PTEN</i> loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3256</span><span class="NLM_x">–</span> <span class="NLM_lpage">3261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3256-3261&author=M.+L.+Sosauthor=M.+Kokerauthor=B.+A.+Weirauthor=S.+Heynckauthor=R.+Rabinovskyauthor=T.+Zanderauthor=J.+M.+Seegerauthor=J.+Weissauthor=F.+Fischerauthor=P.+Frommoltauthor=K.+Michelauthor=M.+Peiferauthor=C.+Mermelauthor=L.+Girardauthor=M.+Peytonauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=L.+A.+Garrawayauthor=H.+Kashkarauthor=W.+Paoauthor=M.+Meyersonauthor=R.+K.+Thomas&title=PTEN+loss+contributes+to+erlotinib+resistance+in+EGFR-mutant+lung+cancer+by+activation+of+Akt+and+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DRabinovsky%26aufirst%3DR.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DSeeger%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DKashkar%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPTEN%2520loss%2520contributes%2520to%2520erlotinib%2520resistance%2520in%2520EGFR-mutant%2520lung%2520cancer%2520by%2520activation%2520of%2520Akt%2520and%2520EGFR%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3256%26epage%3D3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Versele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldrini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palaskas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulholland, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekaran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dikic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellinghoff, I. K.</span><span> </span><span class="NLM_article-title">The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">6459</span><span class="NLM_x">–</span> <span class="NLM_lpage">6464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=6459-6464&author=I.+Vivancoauthor=D.+Rohleauthor=M.+Verseleauthor=A.+Iwanamiauthor=D.+Kugaauthor=B.+Oldriniauthor=K.+Tanakaauthor=J.+Dangauthor=S.+Kubekauthor=N.+Palaskasauthor=T.+Hsuehauthor=M.+Evansauthor=D.+Mulhollandauthor=D.+Wolleauthor=S.+Rajasekaranauthor=A.+Rajasekaranauthor=L.+M.+Liauauthor=T.+F.+Cloughesyauthor=I.+Dikicauthor=C.+Brennanauthor=H.+Wuauthor=P.+S.+Mischelauthor=T.+Pereraauthor=I.+K.+Mellinghoff&title=The+phosphatase+and+tensin+homolog+regulates+epidermal+growth+factor+receptor+%28EGFR%29+inhibitor+response+by+targeting+EGFR+for+degradation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DRohle%26aufirst%3DD.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DIwanami%26aufirst%3DA.%26aulast%3DKuga%26aufirst%3DD.%26aulast%3DOldrini%26aufirst%3DB.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DDang%26aufirst%3DJ.%26aulast%3DKubek%26aufirst%3DS.%26aulast%3DPalaskas%26aufirst%3DN.%26aulast%3DHsueh%26aufirst%3DT.%26aulast%3DEvans%26aufirst%3DM.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DWolle%26aufirst%3DD.%26aulast%3DRajasekaran%26aufirst%3DS.%26aulast%3DRajasekaran%26aufirst%3DA.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DDikic%26aufirst%3DI.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26atitle%3DThe%2520phosphatase%2520and%2520tensin%2520homolog%2520regulates%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitor%2520response%2520by%2520targeting%2520EGFR%2520for%2520degradation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D6459%26epage%3D6464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Sierra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cepero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1186%2F1476-4598-9-75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20385023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A280%3ADC%252BC3czhtVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=75&author=J.+R.+Sierraauthor=V.+Ceperoauthor=S.+Giordano&title=Molecular+mechanisms+of+acquired+resistance+to+tyrosine+kinase+targeted+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy</span></div><div class="casAuthors">Sierra J Rafael; Cepero Virna; Giordano Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In recent years, tyrosine kinases (TKs) have been recognized as central players and regulators of cancer cell proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anti-cancer therapies.  Several strategies for targeting TKs have been developed, the most successful being monoclonal antibodies and small molecule tyrosine kinase inhibitors.  However, increasing evidence of acquired resistance to these drugs has been documented, and extensive preclinical studies are ongoing to try to understand the molecular mechanisms by which cancer cells are able to bypass their inhibitory activity.This review intends to present the most recently identified molecular mechanisms that mediate acquired resistance to tyrosine kinase inhibitors, identified through the use of in vitro models or the analysis of patient samples.  The knowledge obtained from these studies will help to design better therapies that prevent and overcome resistance to treatment in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmF8Wk15sVr2xpATR2EQURfW6udTcc2eYpeY6wCJq1XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czhtVelsQ%253D%253D&md5=89d75465d845f4bc04159d114fe57488</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-75%26sid%3Dliteratum%253Aachs%26aulast%3DSierra%26aufirst%3DJ.%2BR.%26aulast%3DCepero%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DMolecular%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520tyrosine%2520kinase%2520targeted%2520therapy%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M. J.</span><span> </span><span class="NLM_article-title">Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2345</span><span class="NLM_x">–</span> <span class="NLM_lpage">2353</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9012906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2345-2353&author=D.+M.+Goldsteinauthor=A.+Kuglstatterauthor=Y.+Louauthor=M.+J.+Soth&title=Selective+p38%CE%B1+inhibitors+clinically+evaluated+for+the+treatment+of+chronic+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm9012906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012906%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DSoth%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520p38%25CE%25B1%2520inhibitors%2520clinically%2520evaluated%2520for%2520the%2520treatment%2520of%2520chronic%2520inflammatory%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2345%26epage%3D2353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6639</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100540x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6629-6639&author=C.+Liuauthor=J.+Linauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=J.+Hynesauthor=H.+Wuauthor=A.+J.+Dyckmanauthor=T.+Liauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=D.+J.+Shusterauthor=H.+Zhangauthor=P.+H.+Maratheauthor=A.+M.+Doweykoauthor=J.+S.+Sackauthor=S.+E.+Kieferauthor=K.+F.+Kishauthor=J.+A.+Newittauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Discovery+of+4-%285-%28cyclopropylcarbamoyl%29-2-methylphenylamino%29-5-methyl-N-propylpyrrolo%5B1%2C2-f%5D%5B1%2C2%2C4%5Dtriazine-6-carboxamide+%28BMS-582949%29%2C+a+clinical+p38%CE%B1+MAP+kinase+inhibitor+for+the+treatment+of+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm100540x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100540x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204-%25285-%2528cyclopropylcarbamoyl%2529-2-methylphenylamino%2529-5-methyl-N-propylpyrrolo%255B1%252C2-f%255D%255B1%252C2%252C4%255Dtriazine-6-carboxamide%2520%2528BMS-582949%2529%252C%2520a%2520clinical%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6629%26epage%3D6639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Schieven, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petra, R.-M.</span><span> </span><span class="NLM_article-title">BMS-582949 is a dual action p38 kinase inhibitor well suited to avoid resistance mechanisms that increase p38 activation in cells</span> <span class="citation_source-journal">Arthitis Rheum</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">S629</span><span class="NLM_x">–</span> <span class="NLM_lpage">S630</span><div class="note"><p class="first last">(presented at the 2010 Congress American College of Rheumatology)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=S629-S630&issue=Suppl.+10&author=G.+Schievenauthor=R.+Zhangauthor=S.+Pittauthor=D.-R.+Shenauthor=J.+Caoauthor=J.+Sackauthor=D.+Arthurauthor=R.-M.+Petra&title=BMS-582949+is+a+dual+action+p38+kinase+inhibitor+well+suited+to+avoid+resistance+mechanisms+that+increase+p38+activation+in+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchieven%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.-R.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DArthur%26aufirst%3DD.%26aulast%3DPetra%26aufirst%3DR.-M.%26atitle%3DBMS-582949%2520is%2520a%2520dual%2520action%2520p38%2520kinase%2520inhibitor%2520well%2520suited%2520to%2520avoid%2520resistance%2520mechanisms%2520that%2520increase%2520p38%2520activation%2520in%2520cells%26jtitle%3DArthitis%2520Rheum%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3DS629%26epage%3DS630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lhyX3Ofkv8xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Goldberg, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapadia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morwick, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzenbeck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peet, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokopowicz, A. S.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschantz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">Optimization of 2-phenylaminoimidazo[4,5-<i>h</i>]isoquinolin-9-ones: orally active inhibitors of lck kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1337</span><span class="NLM_x">–</span> <span class="NLM_lpage">1349</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020446l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1337-1349&author=D.+R.+Goldbergauthor=T.+Butzauthor=M.+G.+Cardozoauthor=R.+J.+Ecknerauthor=A.+Hammachauthor=J.+Huangauthor=S.+Jakesauthor=S.+Kapadiaauthor=M.+Kashemauthor=S.+Lukasauthor=T.+M.+Morwickauthor=M.+Panzenbeckauthor=U.+Patelauthor=S.+Pavauthor=G.+W.+Peetauthor=J.+D.+Petersonauthor=A.+S.+Prokopowiczauthor=R.+J.+Snowauthor=R.+Sellatiauthor=H.+Takahashiauthor=J.+Tanauthor=M.+A.+Tschantzauthor=X.+J.+Wangauthor=Y.+Wangauthor=J.+Wolakauthor=P.+Xiongauthor=N.+Moss&title=Optimization+of+2-phenylaminoimidazo%5B4%2C5-h%5Disoquinolin-9-ones%3A+orally+active+inhibitors+of+lck+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm020446l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020446l%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DButz%26aufirst%3DT.%26aulast%3DCardozo%26aufirst%3DM.%2BG.%26aulast%3DEckner%26aufirst%3DR.%2BJ.%26aulast%3DHammach%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJakes%26aufirst%3DS.%26aulast%3DKapadia%26aufirst%3DS.%26aulast%3DKashem%26aufirst%3DM.%26aulast%3DLukas%26aufirst%3DS.%26aulast%3DMorwick%26aufirst%3DT.%2BM.%26aulast%3DPanzenbeck%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DU.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DPeet%26aufirst%3DG.%2BW.%26aulast%3DPeterson%26aufirst%3DJ.%2BD.%26aulast%3DProkopowicz%26aufirst%3DA.%2BS.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DSellati%26aufirst%3DR.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DTschantz%26aufirst%3DM.%2BA.%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWolak%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DOptimization%2520of%25202-phenylaminoimidazo%255B4%252C5-h%255Disoquinolin-9-ones%253A%2520orally%2520active%2520inhibitors%2520of%2520lck%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1337%26epage%3D1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">DiMauro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deak, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faust, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira-dos-Santos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turci, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welcher, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure–activity relationships, and inhibition of in vivo T cell activation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1681</span><span class="NLM_x">–</span> <span class="NLM_lpage">1694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7010996" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1681-1694&author=E.+F.+DiMauroauthor=J.+Newcombauthor=J.+J.+Nunesauthor=J.+E.+Bemisauthor=C.+Boucherauthor=L.+Chaiauthor=S.+C.+Chaffeeauthor=H.+L.+Deakauthor=L.+F.+Epsteinauthor=T.+Faustauthor=P.+Gallantauthor=A.+Goreauthor=Y.+Guauthor=B.+Henkleauthor=F.+Hsiehauthor=X.+Huangauthor=J.+L.+Kimauthor=J.+H.+Leeauthor=M.+W.+Martinauthor=D.+C.+McGowanauthor=D.+Metzauthor=D.+Mohnauthor=K.+A.+Morgensternauthor=A.+Oliveira-dos-Santosauthor=V.+F.+Patelauthor=D.+Powersauthor=P.+E.+Roseauthor=S.+Schneiderauthor=S.+A.+Tomlinsonauthor=Y.+Y.+Tudorauthor=S.+M.+Turciauthor=A.+A.+Welcherauthor=H.+Zhaoauthor=L.+Zhuauthor=X.+Zhu&title=Structure-guided+design+of+aminopyrimidine+amides+as+potent%2C+selective+inhibitors+of+lymphocyte+specific+kinase%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+inhibition+of+in+vivo+T+cell+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm7010996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010996%26sid%3Dliteratum%253Aachs%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DNunes%26aufirst%3DJ.%2BJ.%26aulast%3DBemis%26aufirst%3DJ.%2BE.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DChai%26aufirst%3DL.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DDeak%26aufirst%3DH.%2BL.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DFaust%26aufirst%3DT.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHenkle%26aufirst%3DB.%26aulast%3DHsieh%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DMcGowan%26aufirst%3DD.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DOliveira-dos-Santos%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%2BE.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DS.%2BA.%26aulast%3DTudor%26aufirst%3DY.%2BY.%26aulast%3DTurci%26aufirst%3DS.%2BM.%26aulast%3DWelcher%26aufirst%3DA.%2BA.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DStructure-guided%2520design%2520of%2520aminopyrimidine%2520amides%2520as%2520potent%252C%2520selective%2520inhibitors%2520of%2520lymphocyte%2520specific%2520kinase%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520inhibition%2520of%2520in%2520vivo%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1681%26epage%3D1694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villaseñor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span> </span><span class="NLM_article-title">Insights into the conformational flexibility of Bruton’s tyrosine kinase from multiple ligand complex structures</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1002%2Fpro.575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21280133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=428-436&author=A.+Kuglstatterauthor=A.+Wongauthor=S.+Tsingauthor=S.+W.+Leeauthor=Y.+Louauthor=A.+G.+Villase%C3%B1orauthor=J.+M.+Bradshawauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Browner&title=Insights+into+the+conformational+flexibility+of+Bruton%E2%80%99s+tyrosine+kinase+from+multiple+ligand+complex+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures</span></div><div class="casAuthors">Kuglstatter, Andreas; Wong, April; Tsing, Stan; Lee, Simon W.; Lou, Yan; Villasenor, Armando G.; Bradshaw, J. Michael; Shaw, David; Barnett, Jim W.; Browner, Michelle F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases.  We have detd. the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chem. classes.  Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop.  The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homol. 2-kinase domain linker.  Two novel activation loop conformations and an atypical DFG conformation are obsd. representing unique inactive states of BTK.  Two regions within the activation loop are shown to structurally transform between 310- and α-helixes, one of which collapses into the adenosine-5'-triphosphate binding pocket.  The first crystal structure of a Tec kinase family member in the pharmacol. important DFG-out conformation and bound to a type II kinase inhibitor is described.  The different protein conformations obsd. provide insights into the structural flexibility of BTK, the mol. basis of its regulation, and the structure-based design of specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbjgkMYHniALVg90H21EOLACvtfcHk0lixLLJoBxAUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D&md5=4e46f4d05ac3d7b90f1a3e89c0275516</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fpro.575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.575%26sid%3Dliteratum%253Aachs%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26atitle%3DInsights%2520into%2520the%2520conformational%2520flexibility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520from%2520multiple%2520ligand%2520complex%2520structures%26jtitle%3DProtein%2520Sci.%26date%3D2011%26volume%3D20%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2FS0960-894X%2896%2900601-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=187-192&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydon&title=Potent+and+selective+inhibitors+of+the+Abl-kinase%3A+phenylamino-pyrimidine+%28PAP%29+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives</span></div><div class="casAuthors">Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-192</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Due to its relatively clear etiol., chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase.  Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEGaTJgyxfUbVg90H21EOLACvtfcHk0lixLLJoBxAUVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D&md5=35962f1735e8d3a595fdb49d95cdc305</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2896%2900601-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252896%252900601-4%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520Abl-kinase%253A%2520phenylamino-pyrimidine%2520%2528PAP%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D187%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capolino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroe, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torcellini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">Structure–activity relationships of the p38α MAP kinase inhibitor 1-(5-<i>tert</i>-butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (BIRB 796)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4686</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030121k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4676-4686&author=J.+Reganauthor=A.+Capolinoauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=E.+Hickeyauthor=R.+R.+Kroeauthor=J.+Madwedauthor=M.+Moriakauthor=R.+Nelsonauthor=C.+A.+Pargellisauthor=A.+Swinamerauthor=C.+Torcelliniauthor=M.+Tsangauthor=N.+Moss&title=Structure%E2%80%93activity+relationships+of+the+p38%CE%B1+MAP+kinase+inhibitor+1-%285-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl%29-3-%5B4-%282-morpholin-4-yl-ethoxy%29naphthalen-1-yl%5D-urea+%28BIRB+796%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm030121k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030121k%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DCapolino%26aufirst%3DA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DKroe%26aufirst%3DR.%2BR.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DMoriak%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DR.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DTorcellini%26aufirst%3DC.%26aulast%3DTsang%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%2520the%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitor%25201-%25285-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl%2529-3-%255B4-%25282-morpholin-4-yl-ethoxy%2529naphthalen-1-yl%255D-urea%2520%2528BIRB%2520796%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4676%26epage%3D4686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1765</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fsj.bjc.6603170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=16721371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFequr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=1765-1769&author=E.+Weisbergauthor=P.+Manleyauthor=J.+Mestanauthor=S.+Cowan-Jacobauthor=A.+Rayauthor=J.+D.+Griffin&title=AMN107+%28nilotinib%29%3A+a+novel+and+selective+inhibitor+of+BCR-ABL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL</span></div><div class="casAuthors">Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1765-1769</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) and Philadelphia chromosome pos. (Ph+) acute lymphoblastic leukemia (ALL) are caused by the BCR-ABL oncogene.  Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML.  However, accelerated or blast-crisis phase CML patients and Ph+ ALL patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain.  This has stimulated the development of new kinase inhibitors that are able to over-ride resistance to imatinib.  The novel, selective BCR-ABL inhibitor, AMN107, was designed to fit into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib.  In addn. to being more potent than imatinib (IC50<30 nM) against wild-type BCR-ABL, AMN107 is also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.  In preclin. studies, AMN107 demonstrated activity in vitro and in vivo against wild-type and imatinib-resistant BCR-ABL-expressing cells.  In phase I/II clin. trials, AMN107 has produced haematol. and cytogenetic responses in CML patients, who either did not initially respond to imatinib or developed imatinib resistance.  Dasatinib (BMS-354825), which inhibits Abl and Src family kinases, is another promising new clin. candidate for CML that has shown good efficacy in CML patients.  In this review, the early characterization and development of AMN107 is discussed, as is the current status of AMN107 in clin. trials for imatinib-resistant CML and Ph+ ALL.  Future trends investigating prediction of mechanisms of resistance to AMN107, and how and where AMN107 is expected to fit into the overall picture for treatment of early-phase CML and imatinib-refractory and late-stage disease are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp04St4tlQLI7Vg90H21EOLACvtfcHk0lgPGZ1OjM8c6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFequr4%253D&md5=ed9c74a560ee222b98d8c465a5160a84</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603170%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DAMN107%2520%2528nilotinib%2529%253A%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520BCR-ABL%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D1765%26epage%3D1769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.-S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span> </span><span class="NLM_article-title">Development and strategies of VEGFR-2/KDR inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1839</span><span class="NLM_x">–</span> <span class="NLM_lpage">1852</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.4155%2Ffmc.12.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=23043480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOhsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1839-1852&author=L.+Huangauthor=Z.+Huangauthor=Z.+Baiauthor=R.+Xieauthor=L.+Sunauthor=K.+Lin&title=Development+and+strategies+of+VEGFR-2%2FKDR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Development and strategies of VEGFR-2/KDR inhibitors</span></div><div class="casAuthors">Huang, Lingyi; Huang, Zhengui; Bai, Zhiqiang; Xie, Rui; Sun, Liping; Lin, Kejiang</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1839-1852</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  VEGF is an important signaling protein involved in both vasculogenesis and angiogenesis.  As an essential receptor protein tyrosine kinase propagating cellular signal transduction processes, VEGFR-2 is a central target for drug discovery against tumor-assocd. angiogenesis.  Since the autophosphorylation of VEGFR-2 represents a key step in this signal pathway that contributes to angiogenesis, the discovery of small mol. inhibitors that block this reaction has attracted great interest for novel drugs research and development.  Advances in the understanding of catalytic cleft and the conformational changes of DFG motif have resulted in the development of small mol. inhibitors known as type I and type II.  High-resoln. crystal structures of various inhibitors in complex with the receptor offer an insight into the relationship among binding modes, inhibition mechanisms, activity, selectivity and resistance.  To control selectivity, improve activity and introduce intellectual property novelty, the strategies for the further development are discussed through structural and conformational anal. in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMgCdblpbQc7Vg90H21EOLACvtfcHk0lgPGZ1OjM8c6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOhsb3O&md5=96cc54622cc92d45a8549eb88d551a7f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.121%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DK.%26atitle%3DDevelopment%2520and%2520strategies%2520of%2520VEGFR-2%252FKDR%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1839%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0liN73E5rVxN8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact ≤ 2.1 × 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0liN73E5rVxN8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Kostwicz, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauns, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span> </span><span class="NLM_article-title">Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=345-349&author=E.+S.+Kostwiczauthor=U.+Braunsauthor=R.+Beckerauthor=J.+B.+Dressman&title=Forecasting+the+oral+absorption+behavior+of+poorly+soluble+weak+bases+using+solubility+and+dissolution+studies+in+biorelevant+media"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKostwicz%26aufirst%3DE.%2BS.%26aulast%3DBrauns%26aufirst%3DU.%26aulast%3DBecker%26aufirst%3DR.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26atitle%3DForecasting%2520the%2520oral%2520absorption%2520behavior%2520of%2520poorly%2520soluble%2520weak%2520bases%2520using%2520solubility%2520and%2520dissolution%2520studies%2520in%2520biorelevant%2520media%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26spage%3D345%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Honigberg, L. A.; Smith, A. M.; Chen, J.; Thiemann, P.; Vernet, E.</span><span> </span><span class="NLM_article-title">Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo</span>.  <span class="citation_source-book">Blood</span>, ASH Annual Meeting Abstracts, Nov 2007; <span class="NLM_publisher-name">American Society of Hematology</span>: <span class="NLM_publisher-loc">Washington, DC</span>, 2007; Vol.  <span class="NLM_volume">110</span>, p  <span class="NLM_fpage">1592</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Honigberg%2C+L.+A.%3B+Smith%2C+A.+M.%3B+Chen%2C+J.%3B+Thiemann%2C+P.%3B+Vernet%2C+E.+Targeting+Btk+in+lymphoma%3A+PCI-32765+inhibits+tumor+growth+in+mouse+lymphoma+models+and+a+fluorescent+analog+of+PCI-32765+is+an+active-site+probe+that+enables+assessment+of+Btk+inhibition+in+vivo.+Blood%2C+ASH+Annual+Meeting+Abstracts%2C+Nov+2007%3B+American+Society+of+Hematology%3A+Washington%2C+DC%2C+2007%3B+Vol.+110%2C+p+1592."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26atitle%3DTargeting%2520Btk%2520in%2520lymphoma%253A%2520PCI-32765%2520inhibits%2520tumor%2520growth%2520in%2520mouse%2520lymphoma%2520models%2520and%2520a%2520fluorescent%2520analog%2520of%2520PCI-32765%2520is%2520an%2520active-site%2520probe%2520that%2520enables%2520assessment%2520of%2520Btk%2520inhibition%2520in%2520vivo%26btitle%3DBlood%26pub%3DAmerican%2520Society%2520of%2520Hematology%26volume%3D110%26spage%3D1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 44 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Gregory B. Craven, Edward L. Briggs, Charlotte M. Zammit, Alexander McDermott, Stephanie Greed, Dominic P. Affron, Charlotte Leinfellner, Hannah R. Cudmore, Ruth R. Tweedy, Renzo Luisi, James A. Bull, <span class="NLM_string-name hlFld-ContribAuthor">Alan Armstrong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Configurational Assignment of Vinyl Sulfoximines and Sulfonimidamides. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>86 </em>
                                    (11)
                                     , 7403-7424. <a href="https://doi.org/10.1021/acs.joc.1c00373" title="DOI URL">https://doi.org/10.1021/acs.joc.1c00373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.1c00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.1c00373%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DSynthesis%252Band%252BConfigurational%252BAssignment%252Bof%252BVinyl%252BSulfoximines%252Band%252BSulfonimidamides%26aulast%3DCraven%26aufirst%3DGregory%2BB.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D15022021%26date%3D18052021%26volume%3D86%26issue%3D11%26spage%3D7403%26epage%3D7424" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sabrina Tassini, Emily Langron, Leen Delang, Carmen Mirabelli, Kristina Lanko, Emmanuele Crespan, Miroslava Kissova, Giulia Tagliavini, Greta Fontò, Simona Bertoni, Simone Palese, Carmine Giorgio, Francesca Ravanetti, Luisa Ragionieri, Claudio Zamperini, Arianna Mancini, Elena Dreassi, Giovanni Maga, Paola Vergani, Johan Neyts, <span class="NLM_string-name hlFld-ContribAuthor">Marco Radi</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10833-10847. <a href="https://doi.org/10.1021/acs.jmedchem.9b01416" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01416%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMultitarget%252BCFTR%252BModulators%252BEndowed%252Bwith%252BMultiple%252BBeneficial%252BSide%252BEffects%252Bfor%252BCystic%252BFibrosis%252BPatients%25253A%252BToward%252Ba%252BSimplified%252BTherapeutic%252BApproach%26aulast%3DTassini%26aufirst%3DSabrina%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27082019%26date%3D03122019%26date%3D15112019%26volume%3D62%26issue%3D23%26spage%3D10833%26epage%3D10847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu Xue, Peiran Song, Zilan Song, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu, Liping Sun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4608-4627. <a href="https://doi.org/10.1021/acs.jmedchem.8b00441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4%25252C7-Diamino-5-%2525284-phenoxyphenyl%252529-6-methylene-pyrimido%25255B5%25252C4-b%25255Dpyrrolizines%252Bas%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DXue%26aufirst%3DYu%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D09052018%26date%3D01052018%26volume%3D61%26issue%3D10%26spage%3D4608%26epage%3D4627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaofei  Liang</span>, <span class="hlFld-ContribAuthor ">Fengchao  Lv</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Weili  Miao</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Shanchuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zi  Ye</span>, <span class="hlFld-ContribAuthor ">Chu  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Yinsheng  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, and <span class="hlFld-ContribAuthor ">Jing  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1793-1816. <a href="https://doi.org/10.1021/acs.jmedchem.6b01413" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01413%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2-%252528%2525283-Acrylamido-4-methylphenyl%252529amino%252529-N-%2525282-methyl-5-%2525283%25252C4%25252C5-trimethoxybenzamido%252529phenyl%252529-4-%252528methylamino%252529pyrimidine-5-carboxamide%252B%252528CHMFL-BMX-078%252529%252Bas%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BType%252BII%252BIrreversible%252BBone%252BMarrow%252BKinase%252Bin%252Bthe%252BX%252BChromosome%252B%252528BMX%252529%252BKinase%252BInhibitor%26aulast%3DLiang%26aufirst%3DXiaofei%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D22092016%26date%3D14022017%26date%3D09032017%26date%3D31012017%26volume%3D60%26issue%3D5%26spage%3D1793%26epage%3D1816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>, <span class="hlFld-ContribAuthor ">Martin E.  Dowty</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Brian  Juba</span>, <span class="hlFld-ContribAuthor ">Jason  Jussif</span>, <span class="hlFld-ContribAuthor ">Tsung  Lin</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Robert M.  Czerwinski</span>, <span class="hlFld-ContribAuthor ">Agustin  Casimiro-Garcia</span>, <span class="hlFld-ContribAuthor ">Ray  Unwalla</span>, <span class="hlFld-ContribAuthor ">John I.  Trujillo</span>, <span class="hlFld-ContribAuthor ">Sidney  Liang</span>, <span class="hlFld-ContribAuthor ">Paul  Balbo</span>, <span class="hlFld-ContribAuthor ">Ye  Che</span>, <span class="hlFld-ContribAuthor ">Adam M.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Matthew  Hayward</span>, <span class="hlFld-ContribAuthor ">Justin  Montgomery</span>, <span class="hlFld-ContribAuthor ">Louis  Leung</span>, <span class="hlFld-ContribAuthor ">Xin  Yang</span>, <span class="hlFld-ContribAuthor ">Sarah  Soucy</span>, <span class="hlFld-ContribAuthor ">Martin  Hegen</span>, <span class="hlFld-ContribAuthor ">Jotham  Coe</span>, <span class="hlFld-ContribAuthor ">Jonathan  Langille</span>, <span class="hlFld-ContribAuthor ">Felix  Vajdos</span>, <span class="hlFld-ContribAuthor ">Jill  Chrencik</span>, and <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>  . </span><span class="cited-content_cbyCitation_article-title">Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (5)
                                     , 1971-1993. <a href="https://doi.org/10.1021/acs.jmedchem.6b01694" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01694%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Ba%252BJanus%252BKinase%252B3%252B%252528JAK3%252529%252BSpecific%252BInhibitor%252B1-%252528%2525282S%25252C5R%252529-5-%252528%2525287H-Pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%252529amino%252529-2-methylpiperidin-1-yl%252529prop-2-en-1-one%252B%252528PF-06651600%252529%252BAllowing%252Bfor%252Bthe%252BInterrogation%252Bof%252BJAK3%252BSignaling%252Bin%252BHumans%26aulast%3DThorarensen%26aufirst%3DAtli%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D23112016%26date%3D16022017%26date%3D09032017%26date%3D31012017%26volume%3D60%26issue%3D5%26spage%3D1971%26epage%3D1993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Balyn W.  Zaro</span>, <span class="hlFld-ContribAuthor ">Landon R.  Whitby</span>, <span class="hlFld-ContribAuthor ">Kenneth M.  Lum</span>, and <span class="hlFld-ContribAuthor ">Benjamin F.  Cravatt</span>  . </span><span class="cited-content_cbyCitation_article-title">Metabolically Labile Fumarate Esters Impart Kinetic Selectivity to Irreversible Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2016,</strong> <em>138 </em>
                                    (49)
                                     , 15841-15844. <a href="https://doi.org/10.1021/jacs.6b10589" title="DOI URL">https://doi.org/10.1021/jacs.6b10589</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.6b10589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.6b10589%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DMetabolically%252BLabile%252BFumarate%252BEsters%252BImpart%252BKinetic%252BSelectivity%252Bto%252BIrreversible%252BInhibitors%26aulast%3DZaro%26aufirst%3DBalyn%2BW.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D09102016%26date%3D05122016%26date%3D14122016%26volume%3D138%26issue%3D49%26spage%3D15841%26epage%3D15844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Yue  Jin</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Bruton’s Tyrosine Kinase (BTK) Inhibitors Bearing a N,9-Diphenyl-9H-purin-2-amine Scaffold. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (12)
                                     , 1050-1055. <a href="https://doi.org/10.1021/acsmedchemlett.6b00235" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00235%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitors%252BBearing%252Ba%252BN%25252C9-Diphenyl-9H-purin-2-amine%252BScaffold%26aulast%3DGe%26aufirst%3DYang%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D11062016%26date%3D21092016%26date%3D27092016%26date%3D08122016%26date%3D21092016%26volume%3D7%26issue%3D12%26spage%3D1050%26epage%3D1055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Danfeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Haozhong  Tian</span>, <span class="hlFld-ContribAuthor ">Yu  Jiao</span>, <span class="hlFld-ContribAuthor ">Zhihao  Shi</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Haichun  Liu</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Anyang  Xu</span>, <span class="hlFld-ContribAuthor ">Xin  Qiao</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Lingfeng  Yin</span>, <span class="hlFld-ContribAuthor ">Weineng  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, and <span class="hlFld-ContribAuthor ">Yadong  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pharmaceutics</span><span> <strong>2016,</strong> <em>13 </em>
                                    (9)
                                     , 3106-3118. <a href="https://doi.org/10.1021/acs.molpharmaceut.6b00302" title="DOI URL">https://doi.org/10.1021/acs.molpharmaceut.6b00302</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.molpharmaceut.6b00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.molpharmaceut.6b00302%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pharmaceutics%26atitle%3DIdentification%252Bof%252BCovalent%252BBinding%252BSites%252BTargeting%252BCysteines%252BBased%252Bon%252BComputational%252BApproaches%26aulast%3DZhang%26aufirst%3DYanmin%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D05042016%26date%3D02082016%26date%3D07072016%26date%3D10082016%26date%3D06092016%26date%3D02082016%26volume%3D13%26issue%3D9%26spage%3D3106%26epage%3D3118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Teng</span>, <span class="hlFld-ContribAuthor ">Xiang  Lu</span>, <span class="hlFld-ContribAuthor ">Maoxu  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhenbang  Li</span>, <span class="hlFld-ContribAuthor ">Yumei  Zou</span>, <span class="hlFld-ContribAuthor ">Shengnan  Ren</span>, <span class="hlFld-ContribAuthor ">Yu  Cheng</span>, <span class="hlFld-ContribAuthor ">Guoshun  Luo</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and highly selective covalent inhibitors of Bruton’s tyrosine kinase bearing triazine scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112339. <a href="https://doi.org/10.1016/j.ejmech.2020.112339" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112339</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112339%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bhighly%252Bselective%252Bcovalent%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Bbearing%252Btriazine%252Bscaffold%26aulast%3DTeng%26aufirst%3DYu%26date%3D2020%26volume%3D199%26spage%3D112339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yosuke  Taniguchi</span>, <span class="hlFld-ContribAuthor ">Yuya  Magata</span>, <span class="hlFld-ContribAuthor ">Takayuki  Osuki</span>, <span class="hlFld-ContribAuthor ">Ryotaro  Notomi</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Hidenori  Okamura</span>, <span class="hlFld-ContribAuthor ">Shigeki  Sasaki</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel C-nucleoside analogues for the formation of antiparallel-type triplex DNA with duplex DNA that includes TA and dUA base pairs. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (15)
                                     , 2845-2851. <a href="https://doi.org/10.1039/D0OB00420K" title="DOI URL">https://doi.org/10.1039/D0OB00420K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00420K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00420K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252BC-nucleoside%252Banalogues%252Bfor%252Bthe%252Bformation%252Bof%252Bantiparallel-type%252Btriplex%252BDNA%252Bwith%252Bduplex%252BDNA%252Bthat%252Bincludes%252BTA%252Band%252BdUA%252Bbase%252Bpairs%26aulast%3DTaniguchi%26aufirst%3DYosuke%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D15%26spage%3D2845%26epage%3D2851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Xue</span>, <span class="hlFld-ContribAuthor ">Jiahui  Chen</span>, <span class="hlFld-ContribAuthor ">Lihong  Liu</span>, <span class="hlFld-ContribAuthor ">Danli  Zhou</span>, <span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Tiancheng  Fu</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Protein degradation through covalent inhibitor-based PROTACs. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (10)
                                     , 1521-1524. <a href="https://doi.org/10.1039/C9CC08238G" title="DOI URL">https://doi.org/10.1039/C9CC08238G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC08238G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC08238G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DProtein%252Bdegradation%252Bthrough%252Bcovalent%252Binhibitor-based%252BPROTACs%26aulast%3DXue%26aufirst%3DGang%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D10%26spage%3D1521%26epage%3D1524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aditya  Sharma</span>, <span class="hlFld-ContribAuthor ">B. K.  Thelma</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore modeling and virtual screening in search of novel Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2019,</strong> <em>25 </em>
                                    (7)
                                     <a href="https://doi.org/10.1007/s00894-019-4047-y" title="DOI URL">https://doi.org/10.1007/s00894-019-4047-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-019-4047-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-019-4047-y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DPharmacophore%252Bmodeling%252Band%252Bvirtual%252Bscreening%252Bin%252Bsearch%252Bof%252Bnovel%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSharma%26aufirst%3DAditya%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Ming-Xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Xiao-Ling  Huang</span>, <span class="hlFld-ContribAuthor ">Hua-Hong  Zou</span>, <span class="hlFld-ContribAuthor ">Bi-Qun  Zou</span>, <span class="hlFld-ContribAuthor ">Bei-Bei  Shi</span>, <span class="hlFld-ContribAuthor ">Shu-Hua  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Complexes of lanthanides(
              iii
              ) with mixed 2,2′-bipyridyl and 5,7-dibromo-8-quinolinoline chelating ligands as a new class of promising anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Metallomics</span><span> <strong>2019,</strong> <em>11 </em>
                                    (5)
                                     , 1005-1015. <a href="https://doi.org/10.1039/C9MT00037B" title="DOI URL">https://doi.org/10.1039/C9MT00037B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9MT00037B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9MT00037B%26sid%3Dliteratum%253Aachs%26jtitle%3DMetallomics%26atitle%3DComplexes%252Bof%252Blanthanides%252528%252Biii%252B%252529%252Bwith%252Bmixed%252B2%25252C2%2525E2%252580%2525B2-bipyridyl%252Band%252B5%25252C7-dibromo-8-quinolinoline%252Bchelating%252Bligands%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Bpromising%252Banti-cancer%252Bagents%26aulast%3DQin%26aufirst%3DQi-Pin%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D5%26spage%3D1005%26epage%3D1015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Avick Kumar  Ghosh</span>, <span class="hlFld-ContribAuthor ">Indranil  Samanta</span>, <span class="hlFld-ContribAuthor ">Anushree  Mondal</span>, <span class="hlFld-ContribAuthor ">Wenshe Ray  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Inhibition in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 889-906. <a href="https://doi.org/10.1002/cmdc.201900107" title="DOI URL">https://doi.org/10.1002/cmdc.201900107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900107%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DCovalent%252BInhibition%252Bin%252BDrug%252BDiscovery%26aulast%3DGhosh%26aufirst%3DAvick%2BKumar%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D889%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory B.  Craven</span>, <span class="hlFld-ContribAuthor ">Dominic P.  Affron</span>, <span class="hlFld-ContribAuthor ">Philip N.  Raymond</span>, <span class="hlFld-ContribAuthor ">David J.  Mann</span>, <span class="hlFld-ContribAuthor ">Alan  Armstrong</span>. </span><span class="cited-content_cbyCitation_article-title">Vinyl sulfonamide synthesis for irreversible tethering
              via
              a novel α-selenoether protection strategy. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 158-163. <a href="https://doi.org/10.1039/C8MD00566D" title="DOI URL">https://doi.org/10.1039/C8MD00566D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00566D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00566D%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DVinyl%252Bsulfonamide%252Bsynthesis%252Bfor%252Birreversible%252Btethering%252Bvia%252Ba%252Bnovel%252B%2525CE%2525B1-selenoether%252Bprotection%252Bstrategy%26aulast%3DCraven%26aufirst%3DGregory%2BB.%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D1%26spage%3D158%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.  Li</span>, <span class="hlFld-ContribAuthor ">Y.  Du</span>, <span class="hlFld-ContribAuthor ">J.  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2018,</strong> <em>29 </em>
                                    (11)
                                     , 847-873. <a href="https://doi.org/10.1080/1062936X.2018.1518927" title="DOI URL">https://doi.org/10.1080/1062936X.2018.1518927</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2018.1518927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2018.1518927%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DMolecular%252Bmodelling%252Bstudies%252Bon%252Bcinnoline-based%252BBTK%252Binhibitors%252Busing%252Bdocking%252Band%252Bstructure-based%252B3D-QSAR%26aulast%3DLi%26aufirst%3DR.%26date%3D2018%26date%3D2018%26volume%3D29%26issue%3D11%26spage%3D847%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Si  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Hua  Li</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (14)
                                     , 4179-4186. <a href="https://doi.org/10.1016/j.bmc.2018.07.007" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.07.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.07.007%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bamino%252Bacid-substituted%252Bdiphenylpyrimidine%252Bderivatives%252Bas%252Bpotent%252BBTK%252Binhibitors%252Bagainst%252BB%252Bcell%252Blymphoma%252Bcell%252Blines%26aulast%3DWang%26aufirst%3DChangyuan%26date%3D2018%26volume%3D26%26issue%3D14%26spage%3D4179%26epage%3D4186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Zhang</span>, <span class="hlFld-ContribAuthor ">Daoguang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yang  Liu</span>, <span class="hlFld-ContribAuthor ">Dezhi  Yang</span>, <span class="hlFld-ContribAuthor ">Fansheng  Ran</span>, <span class="hlFld-ContribAuthor ">Michael L.  Wang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2018,</strong> <em>351 </em>
                                    (7)
                                     , 1700369. <a href="https://doi.org/10.1002/ardp.201700369" title="DOI URL">https://doi.org/10.1002/ardp.201700369</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201700369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201700369%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DTargeting%252BBruton%252527s%252Btyrosine%252Bkinase%252Bfor%252Bthe%252Btreatment%252Bof%252BB%252Bcell%252Bassociated%252Bmalignancies%252Band%252Bautoimmune%252Bdiseases%25253A%252BPreclinical%252Band%252Bclinical%252Bdevelopments%252Bof%252Bsmall%252Bmolecule%252Binhibitors%26aulast%3DZhang%26aufirst%3DZhen%26date%3D2018%26date%3D2018%26volume%3D351%26issue%3D7%26spage%3D1700369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Li</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>, <span class="hlFld-ContribAuthor ">Zhipei  Gao</span>, <span class="hlFld-ContribAuthor ">Jingkang  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2018,</strong> <em>19 </em>
                                    (4)
                                     , 1244. <a href="https://doi.org/10.3390/ijms19041244" title="DOI URL">https://doi.org/10.3390/ijms19041244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms19041244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms19041244%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMolecular%252BModeling%252BStudies%252Bon%252BCarbazole%252BCarboxamide%252BBased%252BBTK%252BInhibitors%252BUsing%252BDocking%252Band%252BStructure-Based%252B3D-QSAR%26aulast%3DLi%26aufirst%3DRui%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D4%26spage%3D1244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">2-Aminopyrimidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 237-283. <a href="https://doi.org/10.1002/9781118686263.ch7" title="DOI URL">https://doi.org/10.1002/9781118686263.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch7%26sid%3Dliteratum%253Aachs%26atitle%3D2-Aminopyrimidines%26date%3D2018%26date%3D2018%26spage%3D237%26epage%3D283%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiao  Li</span>, <span class="hlFld-ContribAuthor ">Xiaogan  Wang</span>, <span class="hlFld-ContribAuthor ">Yan  Xie</span>, <span class="hlFld-ContribAuthor ">Zhitao  Ying</span>, <span class="hlFld-ContribAuthor ">Weiping  Liu</span>, <span class="hlFld-ContribAuthor ">Lingyan  Ping</span>, <span class="hlFld-ContribAuthor ">Chen  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>, <span class="hlFld-ContribAuthor ">Ning  Ding</span>, <span class="hlFld-ContribAuthor ">Yuqin  Song</span>, <span class="hlFld-ContribAuthor ">Jun  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Cancer</span><span> <strong>2018,</strong> <em>142 </em>
                                    (1)
                                     , 202-213. <a href="https://doi.org/10.1002/ijc.31044" title="DOI URL">https://doi.org/10.1002/ijc.31044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ijc.31044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fijc.31044%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Cancer%26atitle%3DThe%252BmTOR%252Bkinase%252Binhibitor%252Beverolimus%252Bsynergistically%252Benhances%252Bthe%252Banti-tumor%252Beffect%252Bof%252Bthe%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitor%252BPLS-123%252Bon%252BMantle%252Bcell%252Blymphoma%26aulast%3DLi%26aufirst%3DJiao%26date%3D2018%26date%3D2017%26volume%3D142%26issue%3D1%26spage%3D202%26epage%3D213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shijie  Song</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Huang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Yongming  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Jihong  Yao</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1847-1857. <a href="https://doi.org/10.1016/j.ejmech.2017.10.080" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.080%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bhighly%252Bpotent%252BBTK%252Band%252BJAK3%252Bdual%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Bfor%252Bthe%252Btreatment%252Bof%252BB-cell%252Blymphoma%26aulast%3DGe%26aufirst%3DYang%26date%3D2018%26volume%3D143%26spage%3D1847%26epage%3D1857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yao  Yao</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 493-505. <a href="https://doi.org/10.1016/j.ejmech.2017.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Bbinding%252Bdesign%252Bstrategy%25253A%252BA%252Bprospective%252Bmethod%252Bfor%252Bdiscovery%252Bof%252Bpotent%252Btargeted%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DLuhong%26date%3D2017%26volume%3D142%26spage%3D493%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Qiong  Huang</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Qianmao  Liang</span>, <span class="hlFld-ContribAuthor ">Jinghua  Wang</span>, <span class="hlFld-ContribAuthor ">Wensheng  Chen</span>, <span class="hlFld-ContribAuthor ">Jin  Dong</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Deng</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoxiang  Li</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-00482-4" title="DOI URL">https://doi.org/10.1038/s41598-017-00482-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-00482-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-00482-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DIrreversible%252Binhibition%252Bof%252BBTK%252Bkinase%252Bby%252Ba%252Bnovel%252Bhighly%252Bselective%252Binhibitor%252BCHMFL-BTK-11%252Bsuppresses%252Binflammatory%252Bresponse%252Bin%252Brheumatoid%252Barthritis%252Bmodel%26aulast%3DWu%26aufirst%3DHong%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Deng</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Qianmao  Liang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Weili  Miao</span>, <span class="hlFld-ContribAuthor ">Wooyoung  Hur</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Ellen L.  Weisberg</span>, <span class="hlFld-ContribAuthor ">Jinhua  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Yinsheng  Wang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>137 </em>, 545-557. <a href="https://doi.org/10.1016/j.ejmech.2017.06.016" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Binvestigation%252Bfor%252Bbenzonaphthyridinone%252Bderivatives%252Bas%252Bnovel%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Birreversible%252Binhibitors%26aulast%3DWang%26aufirst%3DBeilei%26date%3D2017%26volume%3D137%26spage%3D545%26epage%3D557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephane  De Cesco</span>, <span class="hlFld-ContribAuthor ">Jerry  Kurian</span>, <span class="hlFld-ContribAuthor ">Caroline  Dufresne</span>, <span class="hlFld-ContribAuthor ">Anthony K.  Mittermaier</span>, <span class="hlFld-ContribAuthor ">Nicolas  Moitessier</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent inhibitors design and discovery. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>138 </em>, 96-114. <a href="https://doi.org/10.1016/j.ejmech.2017.06.019" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Binhibitors%252Bdesign%252Band%252Bdiscovery%26aulast%3DDe%2BCesco%26aufirst%3DStephane%26date%3D2017%26volume%3D138%26spage%3D96%26epage%3D114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">He  Liu</span>, <span class="hlFld-ContribAuthor ">Menghua  Qu</span>, <span class="hlFld-ContribAuthor ">Lina  Xu</span>, <span class="hlFld-ContribAuthor ">Xu  Han</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Jihong  Yao</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>135 </em>, 60-69. <a href="https://doi.org/10.1016/j.ejmech.2017.04.037" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.037%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bsulfonamide-substituted%252Bdiphenylpyrimidines%252B%252528SFA-DPPYs%252529%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Btoward%252BB-cell%252Blymphoblastic%252Bleukemia%26aulast%3DLiu%26aufirst%3DHe%26date%3D2017%26volume%3D135%26spage%3D60%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingyan  Ping</span>, <span class="hlFld-ContribAuthor ">Ning  Ding</span>, <span class="hlFld-ContribAuthor ">Yunfei  Shi</span>, <span class="hlFld-ContribAuthor ">Lixia  Feng</span>, <span class="hlFld-ContribAuthor ">Jiao  Li</span>, <span class="hlFld-ContribAuthor ">Yalu  Liu</span>, <span class="hlFld-ContribAuthor ">Yufu  Lin</span>, <span class="hlFld-ContribAuthor ">Cunzhen  Shi</span>, <span class="hlFld-ContribAuthor ">Xing  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>, <span class="hlFld-ContribAuthor ">Yuqin  Song</span>, <span class="hlFld-ContribAuthor ">Jun  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (24)
                                     , 39218-39229. <a href="https://doi.org/10.18632/oncotarget.16836" title="DOI URL">https://doi.org/10.18632/oncotarget.16836</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.16836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.16836%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DThe%252BBruton%252527s%252Btyrosine%252Bkinase%252Binhibitor%252Bibrutinib%252Bexerts%252Bimmunomodulatory%252Beffects%252Bthrough%252Bregulation%252Bof%252Btumor-infiltrating%252Bmacrophages%26aulast%3DPing%26aufirst%3DLingyan%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D24%26spage%3D39218%26epage%3D39229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianmao  Liang</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Shouxiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaochuan  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N -(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-( tert -butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>131 </em>, 107-125. <a href="https://doi.org/10.1016/j.ejmech.2017.03.001" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.03.001%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN%252B-%2525283-%2525285-%252528%2525283-acrylamido-4-%252528morpholine-4-carbonyl%252529phenyl%252529amino%252529-1-methyl-6-oxo-1%25252C6-dihydropyridin-3-yl%252529-2-methylphenyl%252529-4-%252528%252Btert%252B-butyl%252529benzamide%252B%252528CHMFL-BTK-01%252529%252Bas%252Ba%252Bhighly%252Bselective%252Birreversible%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitor%26aulast%3DLiang%26aufirst%3DQianmao%26date%3D2017%26volume%3D131%26spage%3D107%26epage%3D125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Wu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Xixiang  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-E  Yan</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Wu</span>, <span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Ren</span>, <span class="hlFld-ContribAuthor ">Shanchun  Zhang</span>, <span class="hlFld-ContribAuthor ">Cai-Hong  Yun</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (11)
                                     , 18359-18372. <a href="https://doi.org/10.18632/oncotarget.15443" title="DOI URL">https://doi.org/10.18632/oncotarget.15443</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.15443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.15443%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DDiscovery%252Band%252Bcharacterization%252Bof%252Ba%252Bnovel%252Birreversible%252BEGFR%252Bmutants%252Bselective%252Band%252Bpotent%252Bkinase%252Binhibitor%252BCHMFL-EGFR-26%252Bwith%252Ba%252Bdistinct%252Bbinding%252Bmode%26aulast%3DHu%26aufirst%3DChen%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D11%26spage%3D18359%26epage%3D18372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavithra K.  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Anand  Balupuri</span>, <span class="hlFld-ContribAuthor ">Hee-Young  Kang</span>, <span class="hlFld-ContribAuthor ">Seung Joo  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">BMC Systems Biology</span><span> <strong>2017,</strong> <em>11 </em>
                                    (S2)
                                     <a href="https://doi.org/10.1186/s12918-017-0385-5" title="DOI URL">https://doi.org/10.1186/s12918-017-0385-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12918-017-0385-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12918-017-0385-5%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Systems%2520Biology%26atitle%3DReceptor-guided%252B3D-QSAR%252Bstudies%25252C%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculations%252Bof%252BBtk%252Bkinase%252Binhibitors%26aulast%3DBalasubramanian%26aufirst%3DPavithra%2BK.%26date%3D2017%26date%3D2017%26volume%3D11%26issue%3DS2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">D.  Qu</span>, <span class="hlFld-ContribAuthor ">A.  Yan</span>, <span class="hlFld-ContribAuthor ">J. S.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">SAR and QSAR study on the bioactivities of human epidermal growth factor receptor-2 (HER2) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2017,</strong> <em>28 </em>
                                    (2)
                                     , 111-132. <a href="https://doi.org/10.1080/1062936X.2017.1284898" title="DOI URL">https://doi.org/10.1080/1062936X.2017.1284898</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2017.1284898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2017.1284898%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DSAR%252Band%252BQSAR%252Bstudy%252Bon%252Bthe%252Bbioactivities%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor-2%252B%252528HER2%252529%252Binhibitors%26aulast%3DQu%26aufirst%3DD.%26date%3D2017%26date%3D2017%26volume%3D28%26issue%3D2%26spage%3D111%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Inhibitors of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 75-104. <a href="https://doi.org/10.1007/7355_2017_6" title="DOI URL">https://doi.org/10.1007/7355_2017_6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_6%26sid%3Dliteratum%253Aachs%26atitle%3DSmall-Molecule%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DZuo%26aufirst%3DYingying%26date%3D2017%26spage%3D75%26epage%3D104%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Tridente</span>. </span><span class="cited-content_cbyCitation_article-title">Ibrutinib. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 609-637. <a href="https://doi.org/10.1016/B978-0-12-809400-6.00027-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-809400-6.00027-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-809400-6.00027-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-809400-6.00027-5%26sid%3Dliteratum%253Aachs%26atitle%3DIbrutinib%26aulast%3DTridente%26aufirst%3DGiuseppe%26date%3D2017%26spage%3D609%26epage%3D637%26pub%3DElsevier%26atitle%3DAdverse%252BEvents%252Band%252BOncotargeted%252BKinase%252BInhibitors%26date%3D2017%26volume%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Haijun  Yang</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhen</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton’s tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (2)
                                     , 765-772. <a href="https://doi.org/10.1016/j.bmc.2016.11.054" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.11.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.11.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.11.054%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bphosphoryl-substituted%252Bdiphenylpyrimidines%252B%252528Pho-DPPYs%252529%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%25253A%252BTargeted%252Btreatment%252Bof%252BB%252Blymphoblastic%252Bleukemia%252Bcell%252Blines%26aulast%3DGe%26aufirst%3DYang%26date%3D2017%26volume%3D25%26issue%3D2%26spage%3D765%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Zhao</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Menghua  Qu</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Zhen  Li</span>, <span class="hlFld-ContribAuthor ">Jinyong  Peng</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 444-455. <a href="https://doi.org/10.1016/j.ejmech.2016.11.047" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.11.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.11.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.11.047%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Bof%252Bdiphenylpyrimidine%252Bderivatives%252B%252528DPPYs%252529%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bwith%252Bimproved%252Bactivity%252Btoward%252BB%252Bleukemia%252Bcell%252Blines%26aulast%3DZhao%26aufirst%3DDan%26date%3D2017%26volume%3D126%26spage%3D444%26epage%3D455" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ye  Ding</span>, <span class="hlFld-ContribAuthor ">Chunyong  Ding</span>, <span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Zhiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Eric A.  Wold</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Christopher  Wild</span>, <span class="hlFld-ContribAuthor ">Qiang  Shen</span>, <span class="hlFld-ContribAuthor ">Jia  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and development of natural product oridonin-inspired anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>122 </em>, 102-117. <a href="https://doi.org/10.1016/j.ejmech.2016.06.015" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Bdevelopment%252Bof%252Bnatural%252Bproduct%252Boridonin-inspired%252Banticancer%252Bagents%26aulast%3DDing%26aufirst%3DYe%26date%3D2016%26volume%3D122%26spage%3D102%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavithra K.  Balasubramanian</span>, <span class="hlFld-ContribAuthor ">Anand  Balupuri</span>, <span class="hlFld-ContribAuthor ">Seung Joo  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2016,</strong> <em>39 </em>
                                    (3)
                                     , 328-339. <a href="https://doi.org/10.1007/s12272-015-0698-0" title="DOI URL">https://doi.org/10.1007/s12272-015-0698-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-015-0698-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-015-0698-0%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DMolecular%252Bmodeling%252Bstudies%252Bon%252Bseries%252Bof%252BBtk%252Binhibitors%252Busing%252Bdocking%25252C%252Bstructure-based%252B3D-QSAR%252Band%252Bmolecular%252Bdynamics%252Bsimulation%25253A%252Ba%252Bcombined%252Bapproach%26aulast%3DBalasubramanian%26aufirst%3DPavithra%2BK.%26date%3D2016%26date%3D2015%26volume%3D39%26issue%3D3%26spage%3D328%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. V.  Koroleva</span>, <span class="hlFld-ContribAuthor ">Zh. I.  Ignatovich</span>, <span class="hlFld-ContribAuthor ">Yu. V.  Sinyutich</span>, <span class="hlFld-ContribAuthor ">K. N.  Gusak</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidine derivatives as protein kinases inhibitors. Molecular design, synthesis, and biologic activity. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>52 </em>
                                    (2)
                                     , 139-177. <a href="https://doi.org/10.1134/S1070428016020019" title="DOI URL">https://doi.org/10.1134/S1070428016020019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428016020019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428016020019%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAminopyrimidine%252Bderivatives%252Bas%252Bprotein%252Bkinases%252Binhibitors.%252BMolecular%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bbiologic%252Bactivity%26aulast%3DKoroleva%26aufirst%3DE.%2BV.%26date%3D2016%26date%3D2016%26volume%3D52%26issue%3D2%26spage%3D139%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingying  Zuo</span>, <span class="hlFld-ContribAuthor ">Yanxia  Shi</span>, <span class="hlFld-ContribAuthor ">Xitao  Li</span>, <span class="hlFld-ContribAuthor ">Yingqi  Teng</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">A novel 2,5-diaminopyrimidine-based affinity probe for Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep16136" title="DOI URL">https://doi.org/10.1038/srep16136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep16136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep16136%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252Bnovel%252B2%25252C5-diaminopyrimidine-based%252Baffinity%252Bprobe%252Bfor%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DZuo%26aufirst%3DYingying%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinge  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Yazhou  Wang</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Qiu  Jin</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Cai</span>, <span class="hlFld-ContribAuthor ">Feng  Tang</span>, <span class="hlFld-ContribAuthor ">Yong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xiang</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrrolo[2,3-b]pyridine derivatives as potent Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4344-4353. <a href="https://doi.org/10.1016/j.bmc.2015.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPyrrolo%25255B2%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DXinge%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4344%26epage%3D4353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ning  Ding</span>, <span class="hlFld-ContribAuthor ">Xitao  Li</span>, <span class="hlFld-ContribAuthor ">Yunfei  Shi</span>, <span class="hlFld-ContribAuthor ">Lingyan  Ping</span>, <span class="hlFld-ContribAuthor ">Lina  Wu</span>, <span class="hlFld-ContribAuthor ">Kai  Fu</span>, <span class="hlFld-ContribAuthor ">Lixia  Feng</span>, <span class="hlFld-ContribAuthor ">Xiaohui  Zheng</span>, <span class="hlFld-ContribAuthor ">Yuqin  Song</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>, <span class="hlFld-ContribAuthor ">Jun  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (17)
                                     , 15122-15136. <a href="https://doi.org/10.18632/oncotarget.3824" title="DOI URL">https://doi.org/10.18632/oncotarget.3824</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.3824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.3824%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DIrreversible%252Bdual%252Binhibitory%252Bmode%25253A%252Bthe%252Bnovel%252BBtk%252Binhibitor%252BPLS-123%252Bdemonstrates%252Bpromising%252Banti-tumor%252Bactivity%252Bin%252Bhuman%252BB-cell%252Blymphoma%26aulast%3DDing%26aufirst%3DNing%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D17%26spage%3D15122%26epage%3D15136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Xu</span>, <span class="hlFld-ContribAuthor ">Y.  Zhang</span>, <span class="hlFld-ContribAuthor ">T.  Ran</span>, <span class="hlFld-ContribAuthor ">H.  Liu</span>, <span class="hlFld-ContribAuthor ">S.  Lu</span>, <span class="hlFld-ContribAuthor ">J.  Xu</span>, <span class="hlFld-ContribAuthor ">X.  Xiong</span>, <span class="hlFld-ContribAuthor ">Y.  Jiang</span>, <span class="hlFld-ContribAuthor ">T.  Lu</span>, <span class="hlFld-ContribAuthor ">Y.  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Quantitative structure–activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2015,</strong> <em>26 </em>
                                    (4)
                                     , 279-300. <a href="https://doi.org/10.1080/1062936X.2015.1032346" title="DOI URL">https://doi.org/10.1080/1062936X.2015.1032346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2015.1032346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2015.1032346%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DQuantitative%252Bstructure%2525E2%252580%252593activity%252Brelationship%252Bstudy%252Bon%252BBTK%252Binhibitors%252Bby%252Bmodified%252Bmultivariate%252Badaptive%252Bregression%252Bspline%252Band%252BCoMSIA%252Bmethods%26aulast%3DXu%26aufirst%3DA.%26date%3D2015%26date%3D2015%26volume%3D26%26issue%3D4%26spage%3D279%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0020.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Examples of Btk inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Structure of compound <b>4</b> and the “head”, “center”, and “tail” regions in the structure–activity relationship (SAR) study. (b) Compound <b>4</b> (carbon atoms in yellow) was docked in a structure of Btk (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PJ3">3PJ3</a>). The red dots indicate potential hydrogen bonds between compound <b>4</b> and Btk. Cys481 (carbon atoms in cyan) is highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Selectivity of compound <b>31</b> against 18 kinases. The values are the mean of duplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mass spectra of the Btk kinase domain indicating that 1-to-1 adducts were formed between <b>31</b> or <b>38</b> and Btk. The molecular weight of apo Btk (387–659) is 32136. After incubation with <b>31</b> (exact mass, 560.5) or <b>38</b> (exact mass, 617.6) at 4 °C for 1 h, the peaks were fully shifted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Washout experiments with the reversible inhibitor <b>13</b> and irreversible inhibitors <b>31</b> and <b>38</b>. In Ramos cells, Btk Tyr551 phosphorylation was measured after the cells were treated with compound for 1 h in a normal experiment or after treatment for 1 h followed by washout with fresh media for 2 h in the washout experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Compound <b>31</b> is a potent inhibitor of proliferation in multiple malignant B cell lines. The values shown are the averages of triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Tumor cell proliferation assays. Representative dose–response curves of <b>31</b>, <b>38</b>, and ibrutinib treating DoHH2, Pfeiffer, SU-DHL-6, and WSU-NHL cells. Cells were seeded in 96-well plates, incubated for 24 h, then treated with compounds for 72 h, and measured with a luminescent cell viability assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Btk inhibitor <b>31</b> in vivo efficacy study. (a) Compound <b>31</b> significantly prevented tumor growth in a xenograft mouse model. DoHH2 cells were implanted subcutaneously in female CB17/SCID mice. When tumors reached ∼167 mm<sup>3</sup> on average, mice were randomized into four groups (<i>n</i> = 6/group). Compounds were administered via tail vein as a clear solution in polyoxyl 15 hydroxystearate/ethanol (1:1). Tumor size and weight were monitored periodically for 14 days. Statistical analysis was conducted by one-way ANOVA. The Dunnett test was used to analyze the statistical significance between each treatment group and the vehicle group. (∗) <i>P</i> < 0.05 and (∗∗) <i>P</i> < 0.01 indicate statistical significance of tumor growth inhibition. (b) The body weights of the mice changed over time, and the mice in every group slightly gained weight at the end of the study.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>4</b>–<b>10</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ammonium hydroxide, THF, rt, 1 h (96%); (b) R-NH<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O, rt, 3 h (81–96%); (c) 5% Pd/C, H<sub>2</sub>, methanol, rt, overnight (88–93%); (d) 2-methyl-5-(3-(trifluoromethyl)benzamido)benzoic acid, HATU, DIEA, DMF, rt, 8 h (71–98%).</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>12</b>–<b>18</b>, <b>31</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-(<i>tert</i>-butoxycarbonylamino)aniline or 4-(<i>tert</i>-butoxycarbonylamino)aniline, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, H<sub>2</sub>O, rt, 3 h (89%); (b) 5% Pd/C, H<sub>2</sub>, methanol, rt, overnight (88%); (c) various aromatic acids, HATU, DIEA, DMF, rt, 6 h (72–80%); (d) TFA, DCM, rt, 2 h (71–98%); (e) various acyl chlorides, THF–H<sub>2</sub>O, rt, 1 h (<b>13</b>, 91%; <b>31</b>, 90%; <b>35</b>, 87%); or various carboxylic acids, HATU, DIEA, DMF, rt, 5 h (<b>14</b>, 73%; <b>32</b>, 90%; <b>33</b>, 83%; <b>36</b>, 81%; <b>38</b>, 88%); or various acyl chlorides, THF, rt, 1 h (<b>15</b>, 91%; <b>37</b>, 93%); or 2-chloroethanesulfonyl chloride, DIEA, DMAP, THF, rt, 7 h (<b>34</b>, 84%).</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/medium/jm-2013-017762_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Alternative Route to 2,5-Diaminopyrimidines <b>21</b>–<b>30</b>, <b>39</b>–<b>41</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-12/jm4017762/production/images/large/jm-2013-017762_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4017762&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <b>44</b>, HATU, DIEA, DMF, 5 h (71%); (b) 5% Pd/C, H<sub>2</sub>, methanol, 60 °C, 10 h (53%); (c) R-COOH, HATU, DMF, rt, 5 h (82–93%); (d) TFA, DCM, rt, 3 h (88–91%); (e) acryloyl chloride, THF, H<sub>2</sub>O, rt, 1 h (84–98%).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i74">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 67 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Küppers, R.</span><span> </span><span class="NLM_article-title">Mechanisms of B-cell lymphoma pathogenesis</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnrc1589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=251-262&author=R.+K%C3%BCppers&title=Mechanisms+of+B-cell+lymphoma+pathogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of B-cell lymphoma pathogenesis</span></div><div class="casAuthors">Kueppers, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">251-262</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chromosomal translocations involving the Ig loci are a hallmark of many types of B-cell lymphoma.  Other factors, however, also have important roles in the pathogenesis of B-cell malignancies.  Most B-cell lymphomas depend on the expression of a B-cell receptor (BCR) for survival, and in several B-cell malignancies antigen activation of lymphoma cells through BCR signaling seems to be an important factor for lymphoma pathogenesis.  Recent insights into the lymphomagenic role of factors supplied by the microenvironment also offer new therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQJru-Lq2OdbVg90H21EOLACvtfcHk0lhXChUgBJHmXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXivVars7c%253D&md5=c8451de36e49f59432a4cee00419f97d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc1589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1589%26sid%3Dliteratum%253Aachs%26aulast%3DK%25C3%25BCppers%26aufirst%3DR.%26atitle%3DMechanisms%2520of%2520B-cell%2520lymphoma%2520pathogenesis%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D251%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Nakken, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munthe, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konttinen, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandberg, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekanecz, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alex, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szodoray, P.</span><span> </span><span class="NLM_article-title">B-cells and their targeting in rheumatoid arthritis—current concepts and future perspectives</span> <span class="citation_source-journal">Autoimmun. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">28</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2Fj.autrev.2011.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVSksbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=28-34&author=B.+Nakkenauthor=L.+A.+Muntheauthor=Y.+T.+Konttinenauthor=A.+K.+Sandbergauthor=Z.+Szekaneczauthor=P.+Alexauthor=P.+Szodoray&title=B-cells+and+their+targeting+in+rheumatoid+arthritis%E2%80%94current+concepts+and+future+perspectives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">B-cells and their targeting in rheumatoid arthritis - Current concepts and future perspectives</span></div><div class="casAuthors">Nakken, Britt; Munthe, Ludvig A.; Konttinen, Yrjoe T.; Sandberg, Anna Klokk; Szekanecz, Zoltan; Alex, Philip; Szodoray, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Autoimmunity Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-34</span>CODEN:
                <span class="NLM_cas:coden">ARUEBU</span>;
        ISSN:<span class="NLM_cas:issn">1568-9972</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Rheumatoid arthritis (RA) is a chronic, autoimmune disease that affects primarily the joints and without proper treatment results in their progressive destruction.  In addn. to T-cells, B-cells play a central role in the pathogenesis of this disease.  The synovial tissue is an active site of B-cell accumulation, plasma cell differentiation and in situ antibody-prodn. in RA.  As part of the complex role of B-cells in the joints and synovial membrane of RA patients, B cells secrete chemokines and cytokines and may function as antigen presenting cells.  The multifaceted pathogenic function of B-cells identifies them as excellent targets for immunosuppressive therapy.  B-cell targeting involves a wide spectrum of mols., for example the B-cell antigen CD20 that allows specific and effective B-cell depletion.  Another target, CD79, expressed by B-cell and plasma cell precursors is an obvious candidate that induces apoptosis as well as inhibition of B-cell receptor (BCR) activation and possibly depletion of ectopic germinal centers (GC).  Inhibition of B-cell co-stimulatory mols. such as CD40, CD80/86 and ICOS, can lead to diminished B-cell activation.  Moreover, anti-chemokine and anti-cytokine therapies can be efficacious in RA by the disruption of B-cell activation and autoantibody prodn., B-cell synovial migration and ectopic GC formation.  Finally, targeting the signal transduction pathways required for proximal BCR signaling has also been found efficacious in early clin. trials in RA.  Even so, some B cells inhibit immune responses, these regulatory B cells may play a part in immune regulation in patients and it is unclear what effects B cell depletion strategies have in terms of such B cell subsets.  This review discusses current strategies of targeting B-cells as therapeutic candidates in the management of RA.  Better insights into the pathogenic role of B-cells provide efficacious opportunities to improve both therapy and prognosis of patients with RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXuHEK_hHsLVg90H21EOLACvtfcHk0ljoPNBingVpeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVSksbvK&md5=a854c46ccb57e4b81179702a7028c66a</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.autrev.2011.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.autrev.2011.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DNakken%26aufirst%3DB.%26aulast%3DMunthe%26aufirst%3DL.%2BA.%26aulast%3DKonttinen%26aufirst%3DY.%2BT.%26aulast%3DSandberg%26aufirst%3DA.%2BK.%26aulast%3DSzekanecz%26aufirst%3DZ.%26aulast%3DAlex%26aufirst%3DP.%26aulast%3DSzodoray%26aufirst%3DP.%26atitle%3DB-cells%2520and%2520their%2520targeting%2520in%2520rheumatoid%2520arthritis%25E2%2580%2594current%2520concepts%2520and%2520future%2520perspectives%26jtitle%3DAutoimmun.%2520Rev.%26date%3D2011%26volume%3D11%26spage%3D28%26epage%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mohamed, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bäckesjö, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faryal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aints, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berglöf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vihinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">73</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fj.1600-065X.2008.00741.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=19290921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2009&pages=58-73&author=A.+J.+Mohamedauthor=L.+Yuauthor=C.+M.+B%C3%A4ckesj%C3%B6author=L.+Vargasauthor=R.+Faryalauthor=A.+Aintsauthor=B.+Christenssonauthor=A.+Bergl%C3%B6fauthor=M.+Vihinenauthor=B.+F.+Nore&title=Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29%3A+function%2C+regulation%2C+and+transformation+with+special+emphasis+on+the+PH+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain</span></div><div class="casAuthors">Mohamed, Abdalla J.; Yu, Liang; Backesjo, Carl-Magnus; Vargas, Leonardo; Faryal, Rani; Aints, Alar; Christensson, Birger; Berglof, Anna; Vihinen, Mauno; Nore, Beston F.; Smith, C. I. Edvard</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">228</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-73</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">1600-065X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase important in B-lymphocyte development, differentiation, and signaling.  Btk is a member of the Tec family of kinases.  Mutations in the Elk gene lead to X-linked agammaglobulinemia (XLA) in humans and X-linked immunodeficiency (Xid) in mice.  Activation of Btk triggers a cascade of signaling events that culminates in the generation of calcium mobilization and fluxes, cytoskeletal rearrangements, and transcriptional regulation involving nuclear factor-κB (NF-κB) and nuclear factor of activated T cells (NFAT).  In B cells, NF-κB was shown to bind to the Btk promoter and induce transcription, whereas the B-cell receptor-dependent NF-κB signaling pathway requires functional Btk.  Moreover, Btk activation is tightly regulated by a plethora of other signaling proteins including protein kinase C (PKC), Sab/SH3BP5, and caveolin-1.  For example, the prolyl isomerase Pin1 neg. regulates Btk by decreasing tyrosine phosphorylation and steady state levels of Btk.  It is intriguing that PKC and Pin1, both of which are neg. regulators, bind to the pleckstrin homol. domain of Btk.  To this end, we describe here novel mutations in the pleckstrin homol. domain investigated for their transforming capacity.  In particular, we show that the mutant D43R behaves similar to E41K, already known to possess such activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo1L-Ch4HjNLVg90H21EOLACvtfcHk0ljoPNBingVpeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGls7rO&md5=7a84f2b3604d67bcc1490fadcbfea234</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00741.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00741.x%26sid%3Dliteratum%253Aachs%26aulast%3DMohamed%26aufirst%3DA.%2BJ.%26aulast%3DYu%26aufirst%3DL.%26aulast%3DB%25C3%25A4ckesj%25C3%25B6%26aufirst%3DC.%2BM.%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DFaryal%26aufirst%3DR.%26aulast%3DAints%26aufirst%3DA.%26aulast%3DChristensson%26aufirst%3DB.%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DVihinen%26aufirst%3DM.%26aulast%3DNore%26aufirst%3DB.%2BF.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%253A%2520function%252C%2520regulation%252C%2520and%2520transformation%2520with%2520special%2520emphasis%2520on%2520the%2520PH%2520domain%26jtitle%3DImmunol.%2520Rev.%26date%3D2009%26volume%3D228%26spage%3D58%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Smith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Islam, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vořechovský, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olerup, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallin, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabbani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baskin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammarström, L.</span><span> </span><span class="NLM_article-title">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fj.1600-065X.1994.tb00851.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=8070814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1994&pages=159-183&author=C.+Smithauthor=K.+B.+Islamauthor=I.+Vo%C5%99echovsk%C3%BDauthor=O.+Olerupauthor=E.+Wallinauthor=H.+Rabbaniauthor=B.+Baskinauthor=L.+Hammarstr%C3%B6m&title=X-linked+agammaglobulinemia+and+other+immunoglobulin+deficiencies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Khalid B.; Vorechovsky, Igor; Olerup, Olle; Wallin, Erik; Rabbani, Hodjattallah; Baskin, Berivan; Hammarstroem, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-83</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    </div><div class="casAbstract">A review with 123 refs. discussing Ig deficiencies, isolation of the XLA gene, structure and expression of Btk, mutation anal. in patients with XLA, the naturally occurring mouse mutant CBA/N, deletions in the IgH locus, IgA deficiency and common variable immunodeficiency, genetics of IgAD and CVID, the B-lymphocyte abnormality in IgAD, and IgG3 deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqcdUsf_XJ8LVg90H21EOLACvtfcHk0ljoPNBingVpeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D&md5=90f59e592743c3baeb1531c8c0689946</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.1994.tb00851.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.1994.tb00851.x%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVo%25C5%2599echovsk%25C3%25BD%26aufirst%3DI.%26aulast%3DOlerup%26aufirst%3DO.%26aulast%3DWallin%26aufirst%3DE.%26aulast%3DRabbani%26aufirst%3DH.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHammarstr%25C3%25B6m%26aufirst%3DL.%26atitle%3DX-linked%2520agammaglobulinemia%2520and%2520other%2520immunoglobulin%2520deficiencies%26jtitle%3DImmunol.%2520Rev.%26date%3D1994%26volume%3D138%26spage%3D159%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sideras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I.</span><span> </span><span class="NLM_article-title">Molecular and cellular aspects of X-linked agammaglobulinemia</span> <span class="citation_source-journal">Adv. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">59</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=1995&pages=135-224&author=P.+Siderasauthor=C.+I.+Smith&title=Molecular+and+cellular+aspects+of+X-linked+agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DMolecular%2520and%2520cellular%2520aspects%2520of%2520X-linked%2520agammaglobulinemia%26jtitle%3DAdv.%2520Immunol.%26date%3D1995%26volume%3D59%26spage%3D135%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Rickert, R. C.</span><span> </span><span class="NLM_article-title">New insights into pre-BCR and BCR signalling with relevance to B cell malignancies</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">578</span><span class="NLM_x">–</span> <span class="NLM_lpage">591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnri3487" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFKnt7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=578-591&author=R.+C.+Rickert&title=New+insights+into+pre-BCR+and+BCR+signalling+with+relevance+to+B+cell+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into pre-BCR and BCR signalling with relevance to B cell malignancies</span></div><div class="casAuthors">Rickert, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">578-591</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The B cell receptor (BCR) and its precursor (pre-BCR) control B cell homeostasis, differentiation and function.  Moreover, aberrant pre-BCR and BCR signalling have a central role in B cell neoplasia; for example, enhanced pos. signalling or disrupted neg. signalling downstream of the pre-BCR promotes B cell acute lymphocytic leukemia.  The emerging distinctions between tonic and chronic active BCR signalling have contributed to the identification of oncogenic targets downstream of BCR signalling in mature B cell neoplasms.  Indeed, the encouraging results of several ongoing clin. trials that target the activity of phosphoinositide 3-kinase δ-isoform (PI3Kδ), Bruton tyrosine kinase (BTK) or spleen tyrosine kinase (SYK) downstream of the BCR highlight the therapeutic potential of inhibiting BCR signalling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEVfPnHXGyE7Vg90H21EOLACvtfcHk0liMVE6xWDdn2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFKnt7nK&md5=8ae8c95aff039852282e02f6353979ca</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnri3487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3487%26sid%3Dliteratum%253Aachs%26aulast%3DRickert%26aufirst%3DR.%2BC.%26atitle%3DNew%2520insights%2520into%2520pre-BCR%2520and%2520BCR%2520signalling%2520with%2520relevance%2520to%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D13%26spage%3D578%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Davis, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ngo, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romesser, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohlhammer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamy, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenwald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller-Hermelink, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gascoyne, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connors, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rimsza, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaffe, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delabie, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smeland, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braziel, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tubbs, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisenburger, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierce, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staudt, L. M.</span><span> </span><span class="NLM_article-title">Chronic active B cell receptor signalling in diffuse large B cell lymphoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=88-92&author=R.+E.+Davisauthor=V.+N.+Ngoauthor=G.+Lenzauthor=P.+Tolarauthor=R.+M.+Youngauthor=P.+B.+Romesserauthor=H.+Kohlhammerauthor=L.+Lamyauthor=H.+Zhaoauthor=Y.+Yangauthor=W.+Xuauthor=A.+L.+Shafferauthor=G.+Wrightauthor=W.+Xiaoauthor=J.+Powellauthor=J.+K.+Jiangauthor=C.+J.+Thomasauthor=A.+Rosenwaldauthor=G.+Ottauthor=H.+K.+Muller-Hermelinkauthor=R.+D.+Gascoyneauthor=J.+M.+Connorsauthor=N.+A.+Johnsonauthor=L.+M.+Rimszaauthor=E.+Campoauthor=E.+S.+Jaffeauthor=W.+H.+Wilsonauthor=J.+Delabieauthor=E.+B.+Smelandauthor=R.+I.+Fisherauthor=R.+M.+Brazielauthor=R.+R.+Tubbsauthor=J.+R.+Cookauthor=D.+D.+Weisenburgerauthor=W.+C.+Chanauthor=S.+K.+Pierceauthor=L.+M.+Staudt&title=Chronic+active+B+cell+receptor+signalling+in+diffuse+large+B+cell+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DR.%2BE.%26aulast%3DNgo%26aufirst%3DV.%2BN.%26aulast%3DLenz%26aufirst%3DG.%26aulast%3DTolar%26aufirst%3DP.%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DRomesser%26aufirst%3DP.%2BB.%26aulast%3DKohlhammer%26aufirst%3DH.%26aulast%3DLamy%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DShaffer%26aufirst%3DA.%2BL.%26aulast%3DWright%26aufirst%3DG.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DPowell%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DJ.%2BK.%26aulast%3DThomas%26aufirst%3DC.%2BJ.%26aulast%3DRosenwald%26aufirst%3DA.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DMuller-Hermelink%26aufirst%3DH.%2BK.%26aulast%3DGascoyne%26aufirst%3DR.%2BD.%26aulast%3DConnors%26aufirst%3DJ.%2BM.%26aulast%3DJohnson%26aufirst%3DN.%2BA.%26aulast%3DRimsza%26aufirst%3DL.%2BM.%26aulast%3DCampo%26aufirst%3DE.%26aulast%3DJaffe%26aufirst%3DE.%2BS.%26aulast%3DWilson%26aufirst%3DW.%2BH.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DSmeland%26aufirst%3DE.%2BB.%26aulast%3DFisher%26aufirst%3DR.%2BI.%26aulast%3DBraziel%26aufirst%3DR.%2BM.%26aulast%3DTubbs%26aufirst%3DR.%2BR.%26aulast%3DCook%26aufirst%3DJ.%2BR.%26aulast%3DWeisenburger%26aufirst%3DD.%2BD.%26aulast%3DChan%26aufirst%3DW.%2BC.%26aulast%3DPierce%26aufirst%3DS.%2BK.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DChronic%2520active%2520B%2520cell%2520receptor%2520signalling%2520in%2520diffuse%2520large%2520B%2520cell%2520lymphoma%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D88%26epage%3D92" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Pan, Z.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase as a drug discovery target</span> <span class="citation_source-journal">Drug News Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1358%2Fdnp.2008.21.7.1255308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=19259548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=357&author=Z.+Pan&title=Bruton%E2%80%99s+tyrosine+kinase+as+a+drug+discovery+target"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase as a drug discovery target</span></div><div class="casAuthors">Pan, Zhengying</div><div class="citationInfo"><span class="NLM_cas:title">Drug News & Perspectives</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">357-362</span>CODEN:
                <span class="NLM_cas:coden">DNPEED</span>;
        ISSN:<span class="NLM_cas:issn">0214-0934</span>.
    
            (<span class="NLM_cas:orgname">Prous Science</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (Btk) is an important mediator in multiple signal transduction pathways.  Fifteen years of research have revealed a complex role for Btk in hematopoietic cells.  These studies suggest that Btk may be a promising target for therapeutic intervention for several complicated diseases.  Inhibitors targeting the Btk kinase domain have been developed and show clear beneficial effects in animal models of rheumatoid arthritis, lymphoma and other diseases.  Here, an overview of these studies is presented with an emphasis on results stemming from medicinal chem. research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Pn8DtrLdQ7Vg90H21EOLACvtfcHk0liMVE6xWDdn2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOgurnP&md5=dbb3e077ce56474a93b83c3be3783334</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1358%2Fdnp.2008.21.7.1255308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1358%252Fdnp.2008.21.7.1255308%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520as%2520a%2520drug%2520discovery%2520target%26jtitle%3DDrug%2520News%2520Perspect.%26date%3D2008%26volume%3D21%26spage%3D357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondru, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">4539</span><span class="NLM_x">–</span> <span class="NLM_lpage">4350</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4350&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+tyrosine+kinase+inhibitors%3A+approaches+to+potent+and+selective+inhibition%2C+preclinical+and+clinical+evaluation+for+inflammatory+diseases+and+B+cell+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%253A%2520approaches%2520to%2520potent%2520and%2520selective%2520inhibition%252C%2520preclinical%2520and%2520clinical%2520evaluation%2520for%2520inflammatory%2520diseases%2520and%2520B%2520cell%2520malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4350" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Mahajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudbeck, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Downs, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hupke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uckun, F. M.</span><span> </span><span class="NLM_article-title">Rational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [α-cyano-β-hydroxy-β-methyl-<i>N</i>-(2,5-dibromophenyl)propenamide]</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">274</span><span class="NLM_x">, </span> <span class="NLM_fpage">9587</span><span class="NLM_x">–</span> <span class="NLM_lpage">9599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=274&publication_year=1999&pages=9587-9599&author=S.+Mahajanauthor=S.+Ghoshauthor=E.+A.+Sudbeckauthor=Y.+Zhengauthor=S.+Downsauthor=M.+Hupkeauthor=F.+M.+Uckun&title=Rational+design+and+synthesis+of+a+novel+anti-leukemic+agent+targeting+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29%2C+LFM-A13+%5B%CE%B1-cyano-%CE%B2-hydroxy-%CE%B2-methyl-N-%282%2C5-dibromophenyl%29propenamide%5D"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMahajan%26aufirst%3DS.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DSudbeck%26aufirst%3DE.%2BA.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDowns%26aufirst%3DS.%26aulast%3DHupke%26aufirst%3DM.%26aulast%3DUckun%26aufirst%3DF.%2BM.%26atitle%3DRational%2520design%2520and%2520synthesis%2520of%2520a%2520novel%2520anti-leukemic%2520agent%2520targeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%252C%2520LFM-A13%2520%255B%25CE%25B1-cyano-%25CE%25B2-hydroxy-%25CE%25B2-methyl-N-%25282%252C5-dibromophenyl%2529propenamide%255D%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1999%26volume%3D274%26spage%3D9587%26epage%3D9599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bürckstümmer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kneidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellmeier, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">13283</span><span class="NLM_x">–</span> <span class="NLM_lpage">13288</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13283-13288&author=O.+Hantschelauthor=U.+Rixauthor=U.+Schmidtauthor=T.+B%C3%BCrckst%C3%BCmmerauthor=M.+Kneidingerauthor=G.+Sch%C3%BCtzeauthor=J.+Colingeauthor=K.+L.+Bennettauthor=W.+Ellmeierauthor=P.+Valentauthor=G.+Superti-Furga&title=The+Btk+tyrosine+kinase+is+a+major+target+of+the+Bcr-Abl+inhibitor+dasatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DB%25C3%25BCrckst%25C3%25BCmmer%26aufirst%3DT.%26aulast%3DKneidinger%26aufirst%3DM.%26aulast%3DSch%25C3%25BCtze%26aufirst%3DG.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DThe%2520Btk%2520tyrosine%2520kinase%2520is%2520a%2520major%2520target%2520of%2520the%2520Bcr-Abl%2520inhibitor%2520dasatinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D13283%26epage%3D13288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Di Paolo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balazs, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barck, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bravo, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carano, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeForge, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrando, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallion, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannetti, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurez, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hymowitz, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kropf, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maciejewski, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staker, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di+Paoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lhhtiigovwMvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coraggio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgardner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gopaul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggs, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuebler, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. C.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, X. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubach, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowell, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khojasteh, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hop, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1840</span><span class="NLM_x">–</span> <span class="NLM_lpage">1849</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1840-1849&author=L.+Liuauthor=J.+S.+Halladayauthor=Y.+Shinauthor=S.+Wongauthor=M.+Coraggioauthor=H.+Laauthor=M.+Baumgardnerauthor=H.+Leauthor=S.+Gopaulauthor=J.+Boggsauthor=P.+Kueblerauthor=J.+C.+Davisauthor=X.+C.+Liaoauthor=J.+W.+Lubachauthor=A.+Deeseauthor=C.+G.+Sowellauthor=K.+S.+Currieauthor=W.+B.+Youngauthor=S.+C.+Khojastehauthor=C.+E.+Hopauthor=H.+Wong&title=Significant+species+difference+in+amide+hydrolysis+of+GDC-0834%2C+a+novel+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DHalladay%26aufirst%3DJ.%2BS.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DBaumgardner%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DH.%26aulast%3DGopaul%26aufirst%3DS.%26aulast%3DBoggs%26aufirst%3DJ.%26aulast%3DKuebler%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DJ.%2BC.%26aulast%3DLiao%26aufirst%3DX.%2BC.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DKhojasteh%26aufirst%3DS.%2BC.%26aulast%3DHop%26aufirst%3DC.%2BE.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DSignificant%2520species%2520difference%2520in%2520amide%2520hydrolysis%2520of%2520GDC-0834%252C%2520a%2520novel%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1840%26epage%3D1849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Xu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Postelnek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, D. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pashine, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Mahony, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owens, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narula, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeMartino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, J. S.</span><span> </span><span class="NLM_article-title">RN486, a selective Bruton’s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">341</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">103</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.+Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitor%2C+abrogates+immune+hypersensitivity+responses+and+arthritis+in+rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span></div><div class="casAuthors">Xu Daigen; Kim Yong; Postelnek Jennifer; Vu Minh Diem; Hu Dong-Qing; Liao Cheng; Bradshaw Mike; Hsu Jonathan; Zhang Jun; Pashine Achal; Srinivasan Dinesh; Woods John; Levin Anita; O'Mahony Alison; Owens Timothy D; Lou Yan; Hill Ronald J; Narula Satwant; Demartino Julie; Fine Jay S</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of pharmacology and experimental therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Genetic mutation and pharmacological inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor cross-linking-induced degranulation in mast cells (IC(50) = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α production in monocytes (IC(50) = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC(50) = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-molecule disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqSnPYc5dDCNj_Vg2vObihfW6udTcc2eZW9AI8Pi_RGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zhtFymtQ%253D%253D&md5=a04c33939073dc33beda20c4b5e833d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.%2BQ.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%252C%2520abrogates%2520immune%2520hypersensitivity%2520responses%2520and%2520arthritis%2520in%2520rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheerens, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burrill, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendonca, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grothaus, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeffery, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spoerke, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalrymple, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">58</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.+J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+selective+irreversible+inhibitors+for+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.%2BJ.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Evans, E.; Ponader, S.; Karp, R.; Tester, R.; Sheets, M.; Aslanian, S.; Zhu, Z.; Chaturvedi, P.; Mazdiyasni, H.; Nacht, M.; Burger, J.; Petter, R.; Westlin, W.; Singh, J.</span><span> </span><span class="NLM_article-title">AVL-292: a targeted therapy for Bruton’s tyrosine kinase in B cell malignancies</span>. Presented at the 16th Congress of the European Hematology Association, London, U.K., June 9–12,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=E.+Evans&author=S.+Ponader&author=R.+Karp&author=R.+Tester&author=M.+Sheets&author=S.+Aslanian&author=Z.+Zhu&author=P.+Chaturvedi&author=H.+Mazdiyasni&author=M.+Nacht&author=J.+Burger&author=R.+Petter&author=W.+Westlin&author=J.+Singh&title=AVL-292%3A+a+targeted+therapy+for+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%26atitle%3DAVL-292%253A%2520a%2520targeted%2520therapy%2520for%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Kim, K.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maderna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hegen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyashiro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lussier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrocklage, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nickerson-Nutter, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soutter, H. C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S. K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunussi-Joannopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Imidazo[1,5-<i>a</i>]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">6258</span><span class="NLM_x">–</span> <span class="NLM_lpage">6263</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6258-6263&author=K.-H.+Kimauthor=A.+Madernaauthor=M.+E.+Schnuteauthor=M.+Hegenauthor=S.+Mohanauthor=J.+Miyashiroauthor=L.+Linauthor=E.+Liauthor=S.+Keeganauthor=J.+Lussierauthor=C.+Wrocklageauthor=C.+L.+Nickerson-Nutterauthor=A.+J.+Wittwerauthor=H.+C.+N.+Soutterauthor=S.+K.+R.+Hanauthor=K.+Dunussi-Joannopoulosauthor=J.+Douhanauthor=A.+Wissner&title=Imidazo%5B1%2C5-a%5Dquinoxalines+as+irreversible+BTK+inhibitors+for+the+treatment+of+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.-H.%26aulast%3DMaderna%26aufirst%3DA.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DHegen%26aufirst%3DM.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DMiyashiro%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DE.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DWrocklage%26aufirst%3DC.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DSoutter%26aufirst%3DH.%2BC.%2BN.%26aulast%3DHan%26aufirst%3DS.%2BK.%2BR.%26aulast%3DDunussi-Joannopoulos%26aufirst%3DK.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DImidazo%255B1%252C5-a%255Dquinoxalines%2520as%2520irreversible%2520BTK%2520inhibitors%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D6258%26epage%3D6263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhwpY7ojkEy0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Honigberg, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sirisawad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verner, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loury, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thamm, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">13075</span><span class="NLM_x">–</span> <span class="NLM_lpage">13080</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B-cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B-cell+malignancy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lhwpY7ojkEy0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B-cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B-cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francesco, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sokolove, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magadala, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">R115</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=R115&author=B.+Y.+Changauthor=M.+M.+Huangauthor=M.+Francescoauthor=J.+Chenauthor=J.+Sokoloveauthor=P.+Magadalaauthor=W.+H.+Robinsonauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+ameliorates+autoimmune+arthritis+by+inhibition+of+multiple+effector+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DHuang%26aufirst%3DM.%2BM.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSokolove%26aufirst%3DJ.%26aulast%3DMagadala%26aufirst%3DP.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520ameliorates%2520autoimmune%2520arthritis%2520by%2520inhibition%2520of%2520multiple%2520effector%2520cells%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2011%26volume%3D13%26spage%3DR115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Aalipour, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Advani, R. H.</span><span> </span><span class="NLM_article-title">Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas</span> <span class="citation_source-journal">Br. J. Haematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">163</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fbjh.12573" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2013&pages=463-443&author=A.+Aalipourauthor=R.+H.+Advani&title=Bruton+tyrosine+kinase+inhibitors%3A+a+promising+novel+targeted+treatment+for+B+cell+lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12573%26sid%3Dliteratum%253Aachs%26aulast%3DAalipour%26aufirst%3DA.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DBruton%2520tyrosine%2520kinase%2520inhibitors%253A%2520a%2520promising%2520novel%2520targeted%2520treatment%2520for%2520B%2520cell%2520lymphomas%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D163%26spage%3D463%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Vargas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamasy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nore, B. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, C. I. E.</span><span> </span><span class="NLM_article-title">Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases</span> <span class="citation_source-journal">Scand. J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1111%2Fsji.12069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=23672610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOit77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2013&pages=130-139&author=L.+Vargasauthor=A.+Hamasyauthor=B.+F.+Noreauthor=C.+I.+E.+Smith&title=Inhibitors+of+BTK+and+ITK%3A+state+of+the+new+drugs+for+cancer%2C+autoimmunity+and+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory Diseases</span></div><div class="casAuthors">Vargas, L.; Hamasy, A.; Nore, B. F.; E. Smith, C. I.</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-139</span>CODEN:
                <span class="NLM_cas:coden">SJIMAX</span>;
        ISSN:<span class="NLM_cas:issn">0300-9475</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  BTK and ITK are cytoplasmic tyrosine kinases of crucial importance for B and T cell development, with loss-of-function mutations causing X-linked agammaglobulinemia and susceptibility to severe, frequently lethal, Epstein-Barr virus infection, resp.  Over the last few years, considerable efforts have been made in order to develop small-mol. inhibitors for these kinases to treat lymphocyte malignancies, autoimmunity or allergy/hypersensitivity.  The rationale is that even if complete lack of BTK or ITK during development causes severe immunodeficiency, inactivation after birth may result in a less severe phenotype.  Moreover, therapy can be transient or only partially block the activity of BTK or ITK.  Furthermore, a drug-induced B cell deficiency is treatable by gamma globulin substitution therapy.  The newly developed BTK inhibitor PCI-32765, recently renamed Ibrutinib, has already entered several clin. trials for various forms of non-Hodgkin lymphoma as well as for multiple myeloma.  Exptl. animal studies have demonstrated highly promising treatment effects also in autoimmunity.  ITK inhibitors are still under the early developmental phase, but it can be expected that such drugs will also become very useful.  In this study, we present BTK and ITK with their signalling pathways and review the development of the corresponding inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqP0_rsdqSDoLVg90H21EOLACvtfcHk0lhw1_8bDgxjGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOit77M&md5=f9ba77b041266d4746a7cef27604f11a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fsji.12069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fsji.12069%26sid%3Dliteratum%253Aachs%26aulast%3DVargas%26aufirst%3DL.%26aulast%3DHamasy%26aufirst%3DA.%26aulast%3DNore%26aufirst%3DB.%2BF.%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26atitle%3DInhibitors%2520of%2520BTK%2520and%2520ITK%253A%2520state%2520of%2520the%2520new%2520drugs%2520for%2520cancer%252C%2520autoimmunity%2520and%2520inflammatory%2520diseases%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D2013%26volume%3D78%26spage%3D130%26epage%3D139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Sanderson, K.</span><span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Potashman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duggan, M. E.</span><span> </span><span class="NLM_article-title">Covalent modifiers: an orthogonal approach to drug design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1231</span><span class="NLM_x">–</span> <span class="NLM_lpage">1246</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8008597" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1231-1246&author=M.+H.+Potashmanauthor=M.+E.+Duggan&title=Covalent+modifiers%3A+an+orthogonal+approach+to+drug+design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Modifiers: An Orthogonal Approach to Drug Design</span></div><div class="casAuthors">Potashman, Michele H.; Duggan, Mark E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1231-1246</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In this article we review a variety of examples in which therapeutic targets are covalently bound by small-mol. drugs or by compds. in advanced clin. development.  The covalent interactions can be either reversible or irreversible, depending on the reaction partners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6BO6g9_F717Vg90H21EOLACvtfcHk0lhw1_8bDgxjGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1Sltbw%253D&md5=f8380d5a1cdd8638ad2a1e0405d25267</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm8008597&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8008597%26sid%3Dliteratum%253Aachs%26aulast%3DPotashman%26aufirst%3DM.%2BH.%26aulast%3DDuggan%26aufirst%3DM.%2BE.%26atitle%3DCovalent%2520modifiers%253A%2520an%2520orthogonal%2520approach%2520to%2520drug%2520design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1231%26epage%3D1246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lhw1_8bDgxjGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhw1_8bDgxjGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">261</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2FS0163-7258%2802%2900194-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=12191617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2002&pages=253-261&author=W.+A.+Denny&title=Irreversible+inhibitors+of+the+erbB+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the erbB family of protein tyrosine kinases</span></div><div class="casAuthors">Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">253-261</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review.  The erbB family of transmembrane receptor tyrosine kinases initiates a large no. of cellular signaling pathways.  Their over-expression in human tumors correlates with poor prognosis, and they have become important targets for drug development.  The 4-anilinoquinazolines are potent and selective ATP site inhibitors of these enzymes, esp. erbB1 (epidermal growth factor receptor).  Structure-activity studies for binding at the ATP site are narrow, consistent with homol. and crystal structure-binding models.  Combinations of small lipophilic groups at the 3'-position of the aniline and electron-donating groups at the 6- or 7-positions of the quinazoline result in extremely potent (picomolar) reversible inhibitors, several of which are in clin. trial.  Observation that the erbB family of enzymes contains a unique Cys residue (Cys773) close to the ATP-binding site prompted the development of irreversible inhibitors, the most successful being 6-acrylamides and related butynamides, which show significantly improved in vivo antitumor activity compared with closely related reversibly binding compds.  Solubilizing side chains can be placed either at the terminus of the alkylating unit or at the quinazoline C-7, and examples of both types are in clin. trial.  Both reversible and irreversible inhibitors synergize with a variety of DNA-damaging anticancer drugs, and it is likely that the greatest impact of these agents will be in combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwN71GFZA09rVg90H21EOLACvtfcHk0lhvjikBZEXTew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVShurk%253D&md5=7937e2efbf606734ae781554e7c26d15</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2802%2900194-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252802%252900194-8%26sid%3Dliteratum%253Aachs%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DPharmacol.%2520Ther.%26date%3D2002%26volume%3D93%26spage%3D253%26epage%3D261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Liu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simon, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of a selective irreversible BMX inhibitor for prostate cancer</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1428</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb4000629" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1423-1428&author=F.+Liuauthor=X.+Zhangauthor=E.+Weisbergauthor=S.+Chenauthor=W.+Hurauthor=H.+Wuauthor=Z.+Zhaoauthor=W.+Wangauthor=M.+Maoauthor=C.+Caiauthor=N.+I.+Simonauthor=T.+Sandaauthor=J.+Wangauthor=A.+T.+Lookauthor=J.+D.+Griffinauthor=S.+P.+Balkauthor=Q.+Liuauthor=N.+S.+Gray&title=Discovery+of+a+selective+irreversible+BMX+inhibitor+for+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer</span></div><div class="casAuthors">Liu, Feiyang; Zhang, Xin; Weisberg, Ellen; Chen, Sen; Hur, Wooyoung; Wu, Hong; Zhao, Zheng; Wang, Wenchao; Mao, Mao; Cai, Changmeng; Simon, Nicholas I.; Sanda, Takaomi; Wang, Jinhua; Look, A. Thomas; Griffin, James D.; Balk, Steven P.; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1423-1428</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BMX is a member of the TEC family of nonreceptor tyrosine kinases.  We have used structure-based drug design in conjunction with kinome profiling to develop a potent, selective, and irreversible BMX kinase inhibitor, BMX-IN-1, which covalently modifies Cys496.  BMX-IN-1 inhibits the proliferation of Tel-BMX-transformed Ba/F3 cells at two digit nanomolar concns. but requires single digit micromolar concns. to inhibit the proliferation of prostate cancer cell lines.  Using a combinatorial kinase inhibitor screening strategy, we discovered that the allosteric Akt inhibitor, MK2206, is able to potentiate BMX inhibitor's antiproliferation efficacy against prostate cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2n6bH8dNlUrVg90H21EOLACvtfcHk0lhvjikBZEXTew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVWksb8%253D&md5=bf861dad7c1a1f227695e8049f82a4d9</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fcb4000629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb4000629%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DSimon%26aufirst%3DN.%2BI.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520selective%2520irreversible%2520BMX%2520inhibitor%2520for%2520prostate%2520cancer%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1423%26epage%3D1428" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutt, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xian, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">A structure-guided approach to creating covalent FGFR inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">285</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2Fj.chembiol.2010.02.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20338520" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=285-295&author=W.+Zhouauthor=W.+Hurauthor=U.+McDermottauthor=A.+Duttauthor=W.+Xianauthor=S.+B.+Ficarroauthor=J.+Zhangauthor=S.+V.+Sharmaauthor=J.+Bruggeauthor=M.+Meyersonauthor=J.+Settlemanauthor=N.+S.+Gray&title=A+structure-guided+approach+to+creating+covalent+FGFR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Guided Approach to Creating Covalent FGFR Inhibitors</span></div><div class="casAuthors">Zhou, Wenjun; Hur, Wooyoung; McDermott, Ultan; Dutt, Amit; Xian, Wa; Ficarro, Scott B.; Zhang, Jianming; Sharma, Sreenath V.; Brugge, Joan; Meyerson, Matthew; Settleman, Jeffrey; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">285-295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: The fibroblast growth factor receptor tyrosine kinases (FGFR1, 2, 3, and 4) represent promising therapeutic targets in a no. of cancers.  We have developed the first potent and selective irreversible inhibitor of FGFR1, 2, 3, and 4, which we named FIIN-1 that forms a covalent bond with cysteine 486 located in the P loop of the FGFR1 ATP binding site.  We demonstrated that the inhibitor potently inhibits Tel-FGFR1-transformed Ba/F3 cells (EC50 = 14 nM) as well as numerous FGFR-dependent cancer cell lines.  A biotin-derivatized version of the inhibitor, FIIN-1-biotin, was shown to covalently label FGFR1 at Cys486.  FIIN-1 is a useful probe of FGFR-dependent cellular phenomena and may provide a starting point of the development of therapeutically relevant irreversible inhibitors of wild-type and drug-resistant forms of FGFR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqxMZh8QQP47Vg90H21EOLACvtfcHk0lgG8nQDfK2JHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFKhu7s%253D&md5=0b7b084a073b1c6f30f38565a0e4db81</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.02.007%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DHur%26aufirst%3DW.%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DDutt%26aufirst%3DA.%26aulast%3DXian%26aufirst%3DW.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBrugge%26aufirst%3DJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DA%2520structure-guided%2520approach%2520to%2520creating%2520covalent%2520FGFR%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D285%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Perez, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palomo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dans, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luque, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conde, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, A.</span><span> </span><span class="NLM_article-title">Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4042</span><span class="NLM_x">–</span> <span class="NLM_lpage">4056</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1016279" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4042-4056&author=D.+I.+Perezauthor=V.+Palomoauthor=C.+Perezauthor=C.+Gilauthor=P.+D.+Dansauthor=F.+J.+Luqueauthor=S.+Condeauthor=A.+Martinez&title=Switching+reversibility+to+irreversibility+in+glycogen+synthase+kinase+3+inhibitors%3A+clues+for+specific+design+of+new+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm1016279&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1016279%26sid%3Dliteratum%253Aachs%26aulast%3DPerez%26aufirst%3DD.%2BI.%26aulast%3DPalomo%26aufirst%3DV.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DGil%26aufirst%3DC.%26aulast%3DDans%26aufirst%3DP.%2BD.%26aulast%3DLuque%26aufirst%3DF.%2BJ.%26aulast%3DConde%26aufirst%3DS.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DSwitching%2520reversibility%2520to%2520irreversibility%2520in%2520glycogen%2520synthase%2520kinase%25203%2520inhibitors%253A%2520clues%2520for%2520specific%2520design%2520of%2520new%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4042%26epage%3D4056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Zapf, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerstenberger, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Limburg, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurumbail, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Czerwinski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medley, Q. G.</span><span> </span><span class="NLM_article-title">Covalent inhibitors of interleukin-2 inducible T cell kinase (Itk) with nanomolar potency in a whole-blood assay</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10047</span><span class="NLM_x">–</span> <span class="NLM_lpage">10063</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301190s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10047-10063&author=C.+W.+Zapfauthor=B.+S.+Gerstenbergerauthor=L.+Xingauthor=D.+C.+Limburgauthor=D.+R.+Andersonauthor=N.+Caspersauthor=S.+Hanauthor=A.+Aulabaughauthor=R.+Kurumbailauthor=S.+Shakyaauthor=X.+Liauthor=V.+Spauldingauthor=R.+M.+Czerwinskiauthor=N.+Sethauthor=Q.+G.+Medley&title=Covalent+inhibitors+of+interleukin-2+inducible+T+cell+kinase+%28Itk%29+with+nanomolar+potency+in+a+whole-blood+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk) with Nanomolar Potency in a Whole-Blood Assay</span></div><div class="casAuthors">Zapf, Christoph W.; Gerstenberger, Brian S.; Xing, Li; Limburg, David C.; Anderson, David R.; Caspers, Nicole; Han, Seungil; Aulabaugh, Ann; Kurumbail, Ravi; Shakya, Subarna; Li, Xin; Spaulding, Vikki; Czerwinski, Robert M.; Seth, Nilufer; Medley, Quintus G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10047-10063</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We wish to report a strategy that targets interleukin-2 inducible T cell kinase (Itk) with covalent inhibitors.  Thus far, covalent inhibition of Itk has not been disclosed in the literature.  Structure-based drug design was utilized to achieve low nanomolar potency of the disclosed series even at high ATP concns.  Kinetic measurements confirmed an irreversible binding mode with off-rate half-lives exceeding 24 h and moderate on-rates.  The analogs are highly potent in a cellular IP1 assay as well as in a human whole-blood (hWB) assay.  Despite a half-life of approx. 2 h in resting primary T cells, the covalent inhibition of Itk resulted in functional silencing of the TCR pathway for more than 24 h.  This prolonged effect indicates that covalent inhibition is a viable strategy to target the inactivation of Itk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnh9j28SM8jbVg90H21EOLACvtfcHk0lgG8nQDfK2JHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOlsbnP&md5=7e39a17151dc9493d13439bc48fa83a3</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm301190s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301190s%26sid%3Dliteratum%253Aachs%26aulast%3DZapf%26aufirst%3DC.%2BW.%26aulast%3DGerstenberger%26aufirst%3DB.%2BS.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DLimburg%26aufirst%3DD.%2BC.%26aulast%3DAnderson%26aufirst%3DD.%2BR.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DKurumbail%26aufirst%3DR.%26aulast%3DShakya%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DSpaulding%26aufirst%3DV.%26aulast%3DCzerwinski%26aufirst%3DR.%2BM.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DMedley%26aufirst%3DQ.%2BG.%26atitle%3DCovalent%2520inhibitors%2520of%2520interleukin-2%2520inducible%2520T%2520cell%2520kinase%2520%2528Itk%2529%2520with%2520nanomolar%2520potency%2520in%2520a%2520whole-blood%2520assay%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10047%26epage%3D10063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inesta-Vaquera, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niepel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ficarro, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marto, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laughlin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoGrasso, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patricelli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomanbhoy, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sorger, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of potent and selective covalent inhibitors of JNK</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">140</span><span class="NLM_x">–</span> <span class="NLM_lpage">154</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2Fj.chembiol.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=22284361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=140-154&author=T.+Zhangauthor=F.+Inesta-Vaqueraauthor=M.+Niepelauthor=J.+Zhangauthor=S.+B.+Ficarroauthor=T.+Machleidtauthor=T.+Xieauthor=J.+A.+Martoauthor=N.+Kimauthor=T.+Simauthor=J.+D.+Laughlinauthor=H.+Parkauthor=P.+V.+LoGrassoauthor=M.+Patricelliauthor=T.+K.+Nomanbhoyauthor=P.+K.+Sorgerauthor=D.+R.+Alessiauthor=N.+S.+Gray&title=Discovery+of+potent+and+selective+covalent+inhibitors+of+JNK"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Covalent Inhibitors of JNK</span></div><div class="casAuthors">Zhang, Tinghu; Inesta-Vaquera, Francisco; Niepel, Mario; Zhang, Jianming; Ficarro, Scott B.; Machleidt, Thomas; Xie, Ting; Marto, Jarrod A.; Kim, Nam Doo; Sim, Taebo; Laughlin, John D.; Park, Hajeung; LoGrasso, Philip V.; Patricelli, Matt; Nomanbhoy, Tyzoon K.; Sorger, Peter K.; Alessi, Dario R.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">140-154</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The mitogen-activated kinases JNK1/2/3 are key enzymes in signaling modules that transduce and integrate extracellular stimuli into coordinated cellular response.  Here, we report the discovery of irreversible inhibitors of JNK1/2/3.  We describe two JNK3 cocrystal structures at 2.60 and 2.97 Å resoln. that show the compds. form covalent bonds with a conserved cysteine residue.  JNK-IN-8 is a selective JNK inhibitor that inhibits phosphorylation of c-Jun, a direct substrate of JNK, in cells exposed to submicromolar drug in a manner that depends on covalent modification of the conserved cysteine residue.  Extensive biochem., cellular, and pathway-based profiling establish the selectivity of JNK-IN-8 for JNK and suggests that the compd. will be broadly useful as a pharmacol. probe of JNK-dependent signal transduction.  Potential lead compds. have also been identified for kinases, including IRAK1, PIK3C3, PIP4K2C, and PIP5K3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXs0FY7FSmt7Vg90H21EOLACvtfcHk0lji5rOerChNAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Ghurw%253D&md5=f7d9647fb2be162c637b1d31a778ceb4</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DInesta-Vaquera%26aufirst%3DF.%26aulast%3DNiepel%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DLaughlin%26aufirst%3DJ.%2BD.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DLoGrasso%26aufirst%3DP.%2BV.%26aulast%3DPatricelli%26aufirst%3DM.%26aulast%3DNomanbhoy%26aufirst%3DT.%2BK.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520covalent%2520inhibitors%2520of%2520JNK%26jtitle%3DChem.%2520Biol.%26date%3D2012%26volume%3D19%26spage%3D140%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Leproult, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barluenga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moras, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wurtz, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winssinger, N.</span><span> </span><span class="NLM_article-title">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1355</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101396q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1347-1355&author=E.+Leproultauthor=S.+Barluengaauthor=D.+Morasauthor=J.+M.+Wurtzauthor=N.+Winssinger&title=Cysteine+mapping+in+conformationally+distinct+kinase+nucleotide+binding+sites%3A+application+to+the+design+of+selective+covalent+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors</span></div><div class="casAuthors">Leproult, Emeline; Barluenga, Sofia; Moras, Dino; Wurtz, Jean-Marie; Winssinger, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1347-1355</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Kinases have emerged as one of the most prolific therapeutic targets.  An important criterion in the therapeutic success of inhibitors targeting the nucleotide binding pocket of kinases is the inhibitor residence time.  Recently, covalent kinase inhibitors have attracted attention since they confer terminal inhibition and should thus be more effective than reversible inhibitors with transient inhibition.  The most robust approach to design irreversible inhibitors is to capitalize on the nucleophilicity of a cysteine thiol group present in the target protein.  Herein, the authors report a systematic anal. of cysteine residues present in the nucleotide binding site of kinases, which could be harnessed for irreversible inhibition, taking into consideration the different kinase conformations.  The authors demonstrate the predictive power of this anal. with the design and validation of an irreversible inhibitor of KIT/PDGFR kinases.  This is the first example of a covalent kinase inhibitor that combines a pharmacophore addressing the DFG-out conformation with a covalent trap.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkzqt0gMrz3rVg90H21EOLACvtfcHk0lji5rOerChNAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFeis70%253D&md5=329ae5eaa6102b6dd34a0d1274631247</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm101396q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101396q%26sid%3Dliteratum%253Aachs%26aulast%3DLeproult%26aufirst%3DE.%26aulast%3DBarluenga%26aufirst%3DS.%26aulast%3DMoras%26aufirst%3DD.%26aulast%3DWurtz%26aufirst%3DJ.%2BM.%26aulast%3DWinssinger%26aufirst%3DN.%26atitle%3DCysteine%2520mapping%2520in%2520conformationally%2520distinct%2520kinase%2520nucleotide%2520binding%2520sites%253A%2520application%2520to%2520the%2520design%2520of%2520selective%2520covalent%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1347%26epage%3D1355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Henise, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4133</span><span class="NLM_x">–</span> <span class="NLM_lpage">4146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lji5rOerChNAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazdiyasni, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhavsar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medikonda, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span> </span><span class="NLM_article-title">Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">712</span><span class="NLM_x">–</span> <span class="NLM_lpage">721</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3008745" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=712-721&author=M.+Nachtauthor=L.+Qiaoauthor=M.+P.+Sheetsauthor=T.+St+Martinauthor=M.+Labenskiauthor=H.+Mazdiyasniauthor=R.+Karpauthor=Z.+Zhuauthor=P.+Chaturvediauthor=D.+Bhavsarauthor=D.+Niuauthor=W.+Westlinauthor=R.+C.+Petterauthor=A.+P.+Medikondaauthor=J.+Singh&title=Discovery+of+a+potent+and+isoform-selective+targeted+covalent+inhibitor+of+the+lipid+kinase+PI3K%CE%B1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα</span></div><div class="casAuthors">Nacht, Mariana; Qiao, Lixin; Sheets, Michael P.; St. Martin, Thia; Labenski, Matthew; Mazdiyasni, Hormoz; Karp, Russell; Zhu, Zhendong; Chaturvedi, Prasoon; Bhavsar, Deepa; Niu, Deqiang; Westlin, William; Petter, Russell C.; Medikonda, Aravind Prasad; Singh, Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">712-721</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PI3Kα has been identified as an oncogene in human tumors.  By use of rational drug design, a targeted covalent inhibitor 3 (CNX-1351) was created that potently and specifically inhibits PI3Kα.  We demonstrate, using mass spectrometry and X-ray crystallog., that the selective inhibitor covalently modifies PI3Kα on cysteine 862 (C862), an amino acid unique to the α isoform, and that PI3Kβ, -γ, and -δ are not covalently modified. 3 is able to potently (EC50 < 100 nM) and specifically inhibit signaling in PI3Kα-dependent cancer cell lines, and this leads to a potent antiproliferative effect (GI50 < 100 nM).  A covalent probe, 8 (CNX-1220), which selectively bonds to PI3Kα, was used to investigate the duration of occupancy of 3 with PI3Kα in vivo.  This is the first report of a PI3Kα-selective inhibitor, and these data demonstrate the biol. impact of selectively targeting PI3Kα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGrGxtOJ4wQbVg90H21EOLACvtfcHk0ljHb39_8hlJjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWjsr4%253D&md5=42bf6d9221fdb9eafe010064807d22b9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm3008745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3008745%26sid%3Dliteratum%253Aachs%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DQiao%26aufirst%3DL.%26aulast%3DSheets%26aufirst%3DM.%2BP.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DBhavsar%26aufirst%3DD.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DMedikonda%26aufirst%3DA.%2BP.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520isoform-selective%2520targeted%2520covalent%2520inhibitor%2520of%2520the%2520lipid%2520kinase%2520PI3K%25CE%25B1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D712%26epage%3D721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shokat, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Structural bioinformatics-based design of selective, irreversible kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">1318</span><span class="NLM_x">–</span> <span class="NLM_lpage">1321</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1126%2Fscience1108367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=15919995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=1318-1321&author=M.+S.+Cohenauthor=C.+Zhangauthor=K.+M.+Shokatauthor=J.+Taunton&title=Structural+bioinformatics-based+design+of+selective%2C+irreversible+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors</span></div><div class="casAuthors">Cohen, Michael S.; Zhang, Chao; Shokat, Kevan M.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5726</span>),
    <span class="NLM_cas:pages">1318-1321</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The active sites of 491 human protein kinase domains are highly conserved, which makes the design of selective inhibitors a formidable challenge.  We used a structural bioinformatics approach to identify two selectivity filters, a threonine and a cysteine, at defined positions in the active site of p90 ribosomal protein S6 kinase (RSK).  A fluoromethylketone inhibitor, designed to exploit both selectivity filters, potently and selectively inactivated RSK1 and RSK2 in mammalian cells.  Kinases with only one selectivity filter were resistant to the inhibitor, yet they became sensitized after genetic introduction of the second selectivity filter.  Thus, two amino acids that distinguish RSK from other protein kinases are sufficient to confer inhibitor sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovfUrzVFth_bVg90H21EOLACvtfcHk0ljHb39_8hlJjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXks1Ciurs%253D&md5=1364444dada4d1d46510aa0212428952</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscience1108367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience1108367%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DStructural%2520bioinformatics-based%2520design%2520of%2520selective%252C%2520irreversible%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D1318%26epage%3D1321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Kwarcinski, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fox, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffey, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soellner, M. B.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1910</span><span class="NLM_x">–</span> <span class="NLM_lpage">1917</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300337u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Kms77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1910-1917&author=F.+E.+Kwarcinskiauthor=C.+C.+Foxauthor=M.+E.+Steffeyauthor=M.+B.+Soellner&title=Irreversible+inhibitors+of+c-Src+kinase+that+target+a+nonconserved+cysteine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Inhibitors of c-Src Kinase That Target a Nonconserved Cysteine</span></div><div class="casAuthors">Kwarcinski, Frank E.; Fox, Christel C.; Steffey, Michael E.; Soellner, Matthew B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1910-1917</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have developed the first irreversible inhibitors of wild-type c-Src kinase.  We demonstrate that our irreversible inhibitors display improved potency and selectivity relative to that of their reversible counterparts.  Our strategy involves modifying a promiscuous kinase inhibitor with an electrophile to generate covalent inhibitors of c-Src.  We applied this methodol. to two inhibitor scaffolds that exhibit increased cellular efficacy when rendered irreversible.  In addn., we have demonstrated the utility of irreversible inhibitors in studying the conformation of an important loop in kinases that can control inhibitor selectivity and cause drug resistance.  Together, we have developed a general and robust framework for generating selective irreversible inhibitors from reversible, promiscuous inhibitor scaffolds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcojrr4XAxmLVg90H21EOLACvtfcHk0ljHb39_8hlJjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Kms77J&md5=db928e772f1ed18be2ac37ec930d743c</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcb300337u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300337u%26sid%3Dliteratum%253Aachs%26aulast%3DKwarcinski%26aufirst%3DF.%2BE.%26aulast%3DFox%26aufirst%3DC.%2BC.%26aulast%3DSteffey%26aufirst%3DM.%2BE.%26aulast%3DSoellner%26aufirst%3DM.%2BB.%26atitle%3DIrreversible%2520inhibitors%2520of%2520c-Src%2520kinase%2520that%2520target%2520a%2520nonconserved%2520cysteine%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2012%26volume%3D7%26spage%3D1910%26epage%3D1917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Gushwa, N. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Selective targeting of distinct active site nucleophiles by irreversible Src-family kinase inhibitors</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">134</span><span class="NLM_x">, </span> <span class="NLM_fpage">20214</span><span class="NLM_x">–</span> <span class="NLM_lpage">20217</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja310659j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCgsLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=20214-20217&author=N.+N.+Gushwaauthor=S.+Kangauthor=J.+Chenauthor=J.+Taunton&title=Selective+targeting+of+distinct+active+site+nucleophiles+by+irreversible+Src-family+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Targeting of Distinct Active Site Nucleophiles by Irreversible Src-Family Kinase Inhibitors</span></div><div class="casAuthors">Gushwa, Nathan N.; Kang, Sumin; Chen, Jing; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">50</span>),
    <span class="NLM_cas:pages">20214-20217</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Src-family tyrosine kinases play pivotal roles in human physiol. and disease, and several drugs that target members of this family are in clin. use.  None of these drugs appear to discriminate among closely related kinases.  However, assessing their selectivity toward endogenous kinases in living cells remains a significant challenge.  Here, we report the design of two Src-directed chem. probes, each consisting of a nucleoside scaffold with a 5'-electrophile.  A 5'-fluorosulfonylbenzoate (1) reacts with the conserved catalytic lysine (Lys295) and shows little discrimination among related kinases.  By contrast, a 5'-vinylsulfonate (2) reacts with a poorly conserved, proximal cysteine (Cys277) found in three Src-family and six unrelated kinases.  Both 1 and 2 bear an alkyne tag and efficiently label their resp. endogenous kinase targets in intact cells.  Using 1 as a competitive probe, we detd. the extent to which ponatinib, a clin. Bcr-Abl inhibitor, targets Src-family kinases.  Remarkably, while ponatinib had little effect on endogenous Fyn or Src, it potently blocked the crit. T-cell kinase, Lck.  Probes 1 and 2 thus enable competitive profiling vs. distinct kinase subsets in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOvY8gbkN9P7Vg90H21EOLACvtfcHk0ljHb39_8hlJjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCgsLfN&md5=21e537d7111cb159caba17a1fec4ef59</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fja310659j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja310659j%26sid%3Dliteratum%253Aachs%26aulast%3DGushwa%26aufirst%3DN.%2BN.%26aulast%3DKang%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DSelective%2520targeting%2520of%2520distinct%2520active%2520site%2520nucleophiles%2520by%2520irreversible%2520Src-family%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2012%26volume%3D134%26spage%3D20214%26epage%3D20217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lj_jkG8kyPAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Garuti, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottegoni, G.</span><span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2981</span><span class="NLM_x">–</span> <span class="NLM_lpage">2994</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.2174%2F092986711796391705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21651479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2981-2994&author=L.+Garutiauthor=M.+Robertiauthor=G.+Bottegoni&title=Irreversible+protein+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible protein kinase inhibitors</span></div><div class="casAuthors">Garuti, L.; Roberti, M.; Bottegoni, G.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2981-2994</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Targeting cancer with small mol. irreversible inhibitors of kinases represents an emerging challenge in drug discovery.  Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket.  The most common mechanism is the Michael reaction, that refers to the addn. of a nucleophile, such as cysteine, to an α,β-unsatd. carbonyl.  The nucleophile reacts at the electrophilic β-position to form an adduct; as a result the inhibitor irreversibly blocks binding of ATP to the kinase, rendering the kinase inactive.  Different cysteine-reactive groups have been evaluated, an acrylamide or a substituted acrylamide moiety are the Michael acceptors of choice.  There are some advantages for the irreversible kinase inhibition.  These compds. are highly selective because they target a specific cysteine and only a limited no. of kinases has a cysteine at the corresponding position.  Another advantage is that covalent bond formation can overcome competition with the high endogenous concn. of ATP.  A further motivation for designing irreversible inhibitors is their longer duration of action respect to conventional inhibitors.  In fact, once bound to enzyme, these compds. do not readily dissoc. and the inhibition continues even after the inhibitor leaves the circulation.  Moreover, these inhibitors have the potential to overcome and prevent the emergence of acquired resistance conferred by mutations.  In this review examples of irreversible inhibitors are reported, focusing on chem. structures, SAR and biol. activities.  The great potential of these compds. could open new and promising perspectives for a broader application of this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkLFECsvPg2LVg90H21EOLACvtfcHk0lj_jkG8kyPAlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsl2ru70%253D&md5=8c732cb9de810f9fac6484c245e41867</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F092986711796391705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711796391705%26sid%3Dliteratum%253Aachs%26aulast%3DGaruti%26aufirst%3DL.%26aulast%3DRoberti%26aufirst%3DM.%26aulast%3DBottegoni%26aufirst%3DG.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2981%26epage%3D2994" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Dinh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grunberger, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinney, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span> </span><span class="NLM_article-title">Activation mechanism and steady state kinetics of Bruton’s tyrosine kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">8768</span><span class="NLM_x">–</span> <span class="NLM_lpage">8776</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=8768-8776&author=M.+Dinhauthor=D.+Grunbergerauthor=H.+Hoauthor=S.+Y.+Tsingauthor=D.+Shawauthor=S.+Leeauthor=J.+Barnettauthor=R.+J.+Hillauthor=D.+C.+Swinneyauthor=J.+M.+Bradshaw&title=Activation+mechanism+and+steady+state+kinetics+of+Bruton%E2%80%99s+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDinh%26aufirst%3DM.%26aulast%3DGrunberger%26aufirst%3DD.%26aulast%3DHo%26aufirst%3DH.%26aulast%3DTsing%26aufirst%3DS.%2BY.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DBarnett%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DSwinney%26aufirst%3DD.%2BC.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26atitle%3DActivation%2520mechanism%2520and%2520steady%2520state%2520kinetics%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D8768%26epage%3D8776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wahl, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fluckiger, A.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span> </span><span class="NLM_article-title">Phosphorylation of two regulatory tyrosine residues in the activation of Bruton’s tyrosine kinase via alternative receptors</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">11526</span><span class="NLM_x">–</span> <span class="NLM_lpage">11533</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=11526-11533&author=M.+I.+Wahlauthor=A.-C.+Fluckigerauthor=R.+M.+Katoauthor=H.+Parkauthor=O.+N.+Witteauthor=D.+J.+Rawlings&title=Phosphorylation+of+two+regulatory+tyrosine+residues+in+the+activation+of+Bruton%E2%80%99s+tyrosine+kinase+via+alternative+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWahl%26aufirst%3DM.%2BI.%26aulast%3DFluckiger%26aufirst%3DA.-C.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DPark%26aufirst%3DH.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DPhosphorylation%2520of%2520two%2520regulatory%2520tyrosine%2520residues%2520in%2520the%2520activation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520via%2520alternative%2520receptors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1997%26volume%3D94%26spage%3D11526%26epage%3D11533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Nisitani, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, M. I.</span><span> </span><span class="NLM_article-title">In situ detection of activated Bruton’s tyrosine kinase in the Ig signaling complex by phosphopeptide-specific monoclonal antibodies</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">2221</span><span class="NLM_x">–</span> <span class="NLM_lpage">2226</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=2221-2226&author=S.+Nisitaniauthor=R.+M.+Katoauthor=D.+J.+Rawlingsauthor=O.+N.+Witteauthor=M.+I.+Wahl&title=In+situ+detection+of+activated+Bruton%E2%80%99s+tyrosine+kinase+in+the+Ig+signaling+complex+by+phosphopeptide-specific+monoclonal+antibodies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNisitani%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DWahl%26aufirst%3DM.%2BI.%26atitle%3DIn%2520situ%2520detection%2520of%2520activated%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520the%2520Ig%2520signaling%2520complex%2520by%2520phosphopeptide-specific%2520monoclonal%2520antibodies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1999%26volume%3D96%26spage%3D2221%26epage%3D2226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paolo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reif, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, H.</span><span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">338</span><span class="NLM_x">, </span> <span class="NLM_fpage">154</span><span class="NLM_x">–</span> <span class="NLM_lpage">163</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0lgL8Vy-t43wMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kang, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wahl, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitaura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tabuchi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarakhovsky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakami, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turck, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witte, O. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlings, D. J.</span><span> </span><span class="NLM_article-title">PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5692</span><span class="NLM_x">–</span> <span class="NLM_lpage">5702</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2001&pages=5692-5702&author=S.+W.+Kangauthor=M.+I.+Wahlauthor=J.+Chuauthor=J.+Kitauraauthor=Y.+Kawakamiauthor=R.+M.+Katoauthor=R.+Tabuchiauthor=A.+Tarakhovskyauthor=T.+Kawakamiauthor=C.+W.+Turckauthor=O.+N.+Witteauthor=D.+J.+Rawlings&title=PKC%CE%B2+modulates+antigen+receptor+signaling+via+regulation+of+Btk+membrane+localization"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DS.%2BW.%26aulast%3DWahl%26aufirst%3DM.%2BI.%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DKitaura%26aufirst%3DJ.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DKato%26aufirst%3DR.%2BM.%26aulast%3DTabuchi%26aufirst%3DR.%26aulast%3DTarakhovsky%26aufirst%3DA.%26aulast%3DKawakami%26aufirst%3DT.%26aulast%3DTurck%26aufirst%3DC.%2BW.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26atitle%3DPKC%25CE%25B2%2520modulates%2520antigen%2520receptor%2520signaling%2520via%2520regulation%2520of%2520Btk%2520membrane%2520localization%26jtitle%3DEMBO%2520J.%26date%3D2001%26volume%3D20%26spage%3D5692%26epage%3D5702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">de Rooij, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuil, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geest, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eldering, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buggy, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pals, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaargaren, M.</span><span> </span><span class="NLM_article-title">The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">2590</span><span class="NLM_x">–</span> <span class="NLM_lpage">2594</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2590-2594&author=M.+F.+de+Rooijauthor=A.+Kuilauthor=C.+R.+Geestauthor=E.+Elderingauthor=B.+Y.+Changauthor=J.+J.+Buggyauthor=S.+T.+Palsauthor=M.+Spaargaren&title=The+clinically+active+BTK+inhibitor+PCI-32765+targets+B-cell+receptor-+and+chemokine-controlled+adhesion+and+migration+in+chronic+lymphocytic+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BRooij%26aufirst%3DM.%2BF.%26aulast%3DKuil%26aufirst%3DA.%26aulast%3DGeest%26aufirst%3DC.%2BR.%26aulast%3DEldering%26aufirst%3DE.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DPals%26aufirst%3DS.%2BT.%26aulast%3DSpaargaren%26aufirst%3DM.%26atitle%3DThe%2520clinically%2520active%2520BTK%2520inhibitor%2520PCI-32765%2520targets%2520B-cell%2520receptor-%2520and%2520chemokine-controlled%2520adhesion%2520and%2520migration%2520in%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2590%26epage%3D2594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabinovsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zander, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeger, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frommolt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mermel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazdar, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garraway, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashkar, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span> </span><span class="NLM_article-title"><i>PTEN</i> loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">3256</span><span class="NLM_x">–</span> <span class="NLM_lpage">3261</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=3256-3261&author=M.+L.+Sosauthor=M.+Kokerauthor=B.+A.+Weirauthor=S.+Heynckauthor=R.+Rabinovskyauthor=T.+Zanderauthor=J.+M.+Seegerauthor=J.+Weissauthor=F.+Fischerauthor=P.+Frommoltauthor=K.+Michelauthor=M.+Peiferauthor=C.+Mermelauthor=L.+Girardauthor=M.+Peytonauthor=A.+F.+Gazdarauthor=J.+D.+Minnaauthor=L.+A.+Garrawayauthor=H.+Kashkarauthor=W.+Paoauthor=M.+Meyersonauthor=R.+K.+Thomas&title=PTEN+loss+contributes+to+erlotinib+resistance+in+EGFR-mutant+lung+cancer+by+activation+of+Akt+and+EGFR"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DWeir%26aufirst%3DB.%2BA.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DRabinovsky%26aufirst%3DR.%26aulast%3DZander%26aufirst%3DT.%26aulast%3DSeeger%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DFrommolt%26aufirst%3DP.%26aulast%3DMichel%26aufirst%3DK.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DMermel%26aufirst%3DC.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DGarraway%26aufirst%3DL.%2BA.%26aulast%3DKashkar%26aufirst%3DH.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26atitle%3DPTEN%2520loss%2520contributes%2520to%2520erlotinib%2520resistance%2520in%2520EGFR-mutant%2520lung%2520cancer%2520by%2520activation%2520of%2520Akt%2520and%2520EGFR%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D3256%26epage%3D3261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Versele, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwanami, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuga, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldrini, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palaskas, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsueh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulholland, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolle, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajasekaran, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liau, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cloughesy, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dikic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mischel, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellinghoff, I. K.</span><span> </span><span class="NLM_article-title">The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">6459</span><span class="NLM_x">–</span> <span class="NLM_lpage">6464</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=6459-6464&author=I.+Vivancoauthor=D.+Rohleauthor=M.+Verseleauthor=A.+Iwanamiauthor=D.+Kugaauthor=B.+Oldriniauthor=K.+Tanakaauthor=J.+Dangauthor=S.+Kubekauthor=N.+Palaskasauthor=T.+Hsuehauthor=M.+Evansauthor=D.+Mulhollandauthor=D.+Wolleauthor=S.+Rajasekaranauthor=A.+Rajasekaranauthor=L.+M.+Liauauthor=T.+F.+Cloughesyauthor=I.+Dikicauthor=C.+Brennanauthor=H.+Wuauthor=P.+S.+Mischelauthor=T.+Pereraauthor=I.+K.+Mellinghoff&title=The+phosphatase+and+tensin+homolog+regulates+epidermal+growth+factor+receptor+%28EGFR%29+inhibitor+response+by+targeting+EGFR+for+degradation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DRohle%26aufirst%3DD.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DIwanami%26aufirst%3DA.%26aulast%3DKuga%26aufirst%3DD.%26aulast%3DOldrini%26aufirst%3DB.%26aulast%3DTanaka%26aufirst%3DK.%26aulast%3DDang%26aufirst%3DJ.%26aulast%3DKubek%26aufirst%3DS.%26aulast%3DPalaskas%26aufirst%3DN.%26aulast%3DHsueh%26aufirst%3DT.%26aulast%3DEvans%26aufirst%3DM.%26aulast%3DMulholland%26aufirst%3DD.%26aulast%3DWolle%26aufirst%3DD.%26aulast%3DRajasekaran%26aufirst%3DS.%26aulast%3DRajasekaran%26aufirst%3DA.%26aulast%3DLiau%26aufirst%3DL.%2BM.%26aulast%3DCloughesy%26aufirst%3DT.%2BF.%26aulast%3DDikic%26aufirst%3DI.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DMischel%26aufirst%3DP.%2BS.%26aulast%3DPerera%26aufirst%3DT.%26aulast%3DMellinghoff%26aufirst%3DI.%2BK.%26atitle%3DThe%2520phosphatase%2520and%2520tensin%2520homolog%2520regulates%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitor%2520response%2520by%2520targeting%2520EGFR%2520for%2520degradation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2010%26volume%3D107%26spage%3D6459%26epage%3D6464" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Sierra, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cepero, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, S.</span><span> </span><span class="NLM_article-title">Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1186%2F1476-4598-9-75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20385023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A280%3ADC%252BC3czhtVelsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=75&author=J.+R.+Sierraauthor=V.+Ceperoauthor=S.+Giordano&title=Molecular+mechanisms+of+acquired+resistance+to+tyrosine+kinase+targeted+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy</span></div><div class="casAuthors">Sierra J Rafael; Cepero Virna; Giordano Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">75</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In recent years, tyrosine kinases (TKs) have been recognized as central players and regulators of cancer cell proliferation, apoptosis, and angiogenesis, and are therefore considered suitable potential targets for anti-cancer therapies.  Several strategies for targeting TKs have been developed, the most successful being monoclonal antibodies and small molecule tyrosine kinase inhibitors.  However, increasing evidence of acquired resistance to these drugs has been documented, and extensive preclinical studies are ongoing to try to understand the molecular mechanisms by which cancer cells are able to bypass their inhibitory activity.This review intends to present the most recently identified molecular mechanisms that mediate acquired resistance to tyrosine kinase inhibitors, identified through the use of in vitro models or the analysis of patient samples.  The knowledge obtained from these studies will help to design better therapies that prevent and overcome resistance to treatment in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRmF8Wk15sVr2xpATR2EQURfW6udTcc2eaIlllVEUUefbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czhtVelsQ%253D%253D&md5=89d75465d845f4bc04159d114fe57488</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-75%26sid%3Dliteratum%253Aachs%26aulast%3DSierra%26aufirst%3DJ.%2BR.%26aulast%3DCepero%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DS.%26atitle%3DMolecular%2520mechanisms%2520of%2520acquired%2520resistance%2520to%2520tyrosine%2520kinase%2520targeted%2520therapy%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soth, M. J.</span><span> </span><span class="NLM_article-title">Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2345</span><span class="NLM_x">–</span> <span class="NLM_lpage">2353</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm9012906" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2345-2353&author=D.+M.+Goldsteinauthor=A.+Kuglstatterauthor=Y.+Louauthor=M.+J.+Soth&title=Selective+p38%CE%B1+inhibitors+clinically+evaluated+for+the+treatment+of+chronic+inflammatory+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm9012906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9012906%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DSoth%26aufirst%3DM.%2BJ.%26atitle%3DSelective%2520p38%25CE%25B1%2520inhibitors%2520clinically%2520evaluated%2520for%2520the%2520treatment%2520of%2520chronic%2520inflammatory%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2345%26epage%3D2353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6639</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100540x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6629-6639&author=C.+Liuauthor=J.+Linauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=J.+Hynesauthor=H.+Wuauthor=A.+J.+Dyckmanauthor=T.+Liauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=D.+J.+Shusterauthor=H.+Zhangauthor=P.+H.+Maratheauthor=A.+M.+Doweykoauthor=J.+S.+Sackauthor=S.+E.+Kieferauthor=K.+F.+Kishauthor=J.+A.+Newittauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Discovery+of+4-%285-%28cyclopropylcarbamoyl%29-2-methylphenylamino%29-5-methyl-N-propylpyrrolo%5B1%2C2-f%5D%5B1%2C2%2C4%5Dtriazine-6-carboxamide+%28BMS-582949%29%2C+a+clinical+p38%CE%B1+MAP+kinase+inhibitor+for+the+treatment+of+inflammatory+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm100540x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100540x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204-%25285-%2528cyclopropylcarbamoyl%2529-2-methylphenylamino%2529-5-methyl-N-propylpyrrolo%255B1%252C2-f%255D%255B1%252C2%252C4%255Dtriazine-6-carboxamide%2520%2528BMS-582949%2529%252C%2520a%2520clinical%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6629%26epage%3D6639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Schieven, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petra, R.-M.</span><span> </span><span class="NLM_article-title">BMS-582949 is a dual action p38 kinase inhibitor well suited to avoid resistance mechanisms that increase p38 activation in cells</span> <span class="citation_source-journal">Arthitis Rheum</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">S629</span><span class="NLM_x">–</span> <span class="NLM_lpage">S630</span><div class="note"><p class="first last">(presented at the 2010 Congress American College of Rheumatology)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=S629-S630&issue=Suppl.+10&author=G.+Schievenauthor=R.+Zhangauthor=S.+Pittauthor=D.-R.+Shenauthor=J.+Caoauthor=J.+Sackauthor=D.+Arthurauthor=R.-M.+Petra&title=BMS-582949+is+a+dual+action+p38+kinase+inhibitor+well+suited+to+avoid+resistance+mechanisms+that+increase+p38+activation+in+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchieven%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.-R.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DArthur%26aufirst%3DD.%26aulast%3DPetra%26aufirst%3DR.-M.%26atitle%3DBMS-582949%2520is%2520a%2520dual%2520action%2520p38%2520kinase%2520inhibitor%2520well%2520suited%2520to%2520avoid%2520resistance%2520mechanisms%2520that%2520increase%2520p38%2520activation%2520in%2520cells%26jtitle%3DArthitis%2520Rheum%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3DS629%26epage%3DS630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lgJ0ZcblOHLuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Goldberg, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardozo, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckner, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammach, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakes, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapadia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kashem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morwick, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Panzenbeck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peet, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokopowicz, A. S.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snow, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellati, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tschantz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">Optimization of 2-phenylaminoimidazo[4,5-<i>h</i>]isoquinolin-9-ones: orally active inhibitors of lck kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1337</span><span class="NLM_x">–</span> <span class="NLM_lpage">1349</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm020446l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1337-1349&author=D.+R.+Goldbergauthor=T.+Butzauthor=M.+G.+Cardozoauthor=R.+J.+Ecknerauthor=A.+Hammachauthor=J.+Huangauthor=S.+Jakesauthor=S.+Kapadiaauthor=M.+Kashemauthor=S.+Lukasauthor=T.+M.+Morwickauthor=M.+Panzenbeckauthor=U.+Patelauthor=S.+Pavauthor=G.+W.+Peetauthor=J.+D.+Petersonauthor=A.+S.+Prokopowiczauthor=R.+J.+Snowauthor=R.+Sellatiauthor=H.+Takahashiauthor=J.+Tanauthor=M.+A.+Tschantzauthor=X.+J.+Wangauthor=Y.+Wangauthor=J.+Wolakauthor=P.+Xiongauthor=N.+Moss&title=Optimization+of+2-phenylaminoimidazo%5B4%2C5-h%5Disoquinolin-9-ones%3A+orally+active+inhibitors+of+lck+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm020446l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020446l%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DD.%2BR.%26aulast%3DButz%26aufirst%3DT.%26aulast%3DCardozo%26aufirst%3DM.%2BG.%26aulast%3DEckner%26aufirst%3DR.%2BJ.%26aulast%3DHammach%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DJakes%26aufirst%3DS.%26aulast%3DKapadia%26aufirst%3DS.%26aulast%3DKashem%26aufirst%3DM.%26aulast%3DLukas%26aufirst%3DS.%26aulast%3DMorwick%26aufirst%3DT.%2BM.%26aulast%3DPanzenbeck%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DU.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DPeet%26aufirst%3DG.%2BW.%26aulast%3DPeterson%26aufirst%3DJ.%2BD.%26aulast%3DProkopowicz%26aufirst%3DA.%2BS.%26aulast%3DSnow%26aufirst%3DR.%2BJ.%26aulast%3DSellati%26aufirst%3DR.%26aulast%3DTakahashi%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DTschantz%26aufirst%3DM.%2BA.%26aulast%3DWang%26aufirst%3DX.%2BJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWolak%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DP.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DOptimization%2520of%25202-phenylaminoimidazo%255B4%252C5-h%255Disoquinolin-9-ones%253A%2520orally%2520active%2520inhibitors%2520of%2520lck%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1337%26epage%3D1349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">DiMauro, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newcomb, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bemis, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boucher, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaffee, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deak, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epstein, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faust, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henkle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGowan, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgenstern, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveira-dos-Santos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, V. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tudor, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turci, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welcher, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure–activity relationships, and inhibition of in vivo T cell activation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1681</span><span class="NLM_x">–</span> <span class="NLM_lpage">1694</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm7010996" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1681-1694&author=E.+F.+DiMauroauthor=J.+Newcombauthor=J.+J.+Nunesauthor=J.+E.+Bemisauthor=C.+Boucherauthor=L.+Chaiauthor=S.+C.+Chaffeeauthor=H.+L.+Deakauthor=L.+F.+Epsteinauthor=T.+Faustauthor=P.+Gallantauthor=A.+Goreauthor=Y.+Guauthor=B.+Henkleauthor=F.+Hsiehauthor=X.+Huangauthor=J.+L.+Kimauthor=J.+H.+Leeauthor=M.+W.+Martinauthor=D.+C.+McGowanauthor=D.+Metzauthor=D.+Mohnauthor=K.+A.+Morgensternauthor=A.+Oliveira-dos-Santosauthor=V.+F.+Patelauthor=D.+Powersauthor=P.+E.+Roseauthor=S.+Schneiderauthor=S.+A.+Tomlinsonauthor=Y.+Y.+Tudorauthor=S.+M.+Turciauthor=A.+A.+Welcherauthor=H.+Zhaoauthor=L.+Zhuauthor=X.+Zhu&title=Structure-guided+design+of+aminopyrimidine+amides+as+potent%2C+selective+inhibitors+of+lymphocyte+specific+kinase%3A+synthesis%2C+structure%E2%80%93activity+relationships%2C+and+inhibition+of+in+vivo+T+cell+activation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm7010996&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010996%26sid%3Dliteratum%253Aachs%26aulast%3DDiMauro%26aufirst%3DE.%2BF.%26aulast%3DNewcomb%26aufirst%3DJ.%26aulast%3DNunes%26aufirst%3DJ.%2BJ.%26aulast%3DBemis%26aufirst%3DJ.%2BE.%26aulast%3DBoucher%26aufirst%3DC.%26aulast%3DChai%26aufirst%3DL.%26aulast%3DChaffee%26aufirst%3DS.%2BC.%26aulast%3DDeak%26aufirst%3DH.%2BL.%26aulast%3DEpstein%26aufirst%3DL.%2BF.%26aulast%3DFaust%26aufirst%3DT.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DGore%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DHenkle%26aufirst%3DB.%26aulast%3DHsieh%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMartin%26aufirst%3DM.%2BW.%26aulast%3DMcGowan%26aufirst%3DD.%2BC.%26aulast%3DMetz%26aufirst%3DD.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DMorgenstern%26aufirst%3DK.%2BA.%26aulast%3DOliveira-dos-Santos%26aufirst%3DA.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DPowers%26aufirst%3DD.%26aulast%3DRose%26aufirst%3DP.%2BE.%26aulast%3DSchneider%26aufirst%3DS.%26aulast%3DTomlinson%26aufirst%3DS.%2BA.%26aulast%3DTudor%26aufirst%3DY.%2BY.%26aulast%3DTurci%26aufirst%3DS.%2BM.%26aulast%3DWelcher%26aufirst%3DA.%2BA.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DStructure-guided%2520design%2520of%2520aminopyrimidine%2520amides%2520as%2520potent%252C%2520selective%2520inhibitors%2520of%2520lymphocyte%2520specific%2520kinase%253A%2520synthesis%252C%2520structure%25E2%2580%2593activity%2520relationships%252C%2520and%2520inhibition%2520of%2520in%2520vivo%2520T%2520cell%2520activation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1681%26epage%3D1694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Kuglstatter, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villaseñor, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Browner, M. F.</span><span> </span><span class="NLM_article-title">Insights into the conformational flexibility of Bruton’s tyrosine kinase from multiple ligand complex structures</span> <span class="citation_source-journal">Protein Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">428</span><span class="NLM_x">–</span> <span class="NLM_lpage">436</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1002%2Fpro.575" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=21280133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2011&pages=428-436&author=A.+Kuglstatterauthor=A.+Wongauthor=S.+Tsingauthor=S.+W.+Leeauthor=Y.+Louauthor=A.+G.+Villase%C3%B1orauthor=J.+M.+Bradshawauthor=D.+Shawauthor=J.+W.+Barnettauthor=M.+F.+Browner&title=Insights+into+the+conformational+flexibility+of+Bruton%E2%80%99s+tyrosine+kinase+from+multiple+ligand+complex+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures</span></div><div class="casAuthors">Kuglstatter, Andreas; Wong, April; Tsing, Stan; Lee, Simon W.; Lou, Yan; Villasenor, Armando G.; Bradshaw, J. Michael; Shaw, David; Barnett, Jim W.; Browner, Michelle F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">428-436</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a key role in B cell receptor signaling and is considered a promising drug target for lymphoma and inflammatory diseases.  We have detd. the X-ray crystal structures of BTK kinase domain in complex with six inhibitors from distinct chem. classes.  Five different BTK protein conformations are stabilized by the bound inhibitors, providing insights into the structural flexibility of the Gly-rich loop, helix C, the DFG sequence, and activation loop.  The conformational changes occur independent of activation loop phosphorylation and do not correlate with the structurally unchanged WEI motif in the Src homol. 2-kinase domain linker.  Two novel activation loop conformations and an atypical DFG conformation are obsd. representing unique inactive states of BTK.  Two regions within the activation loop are shown to structurally transform between 310- and α-helixes, one of which collapses into the adenosine-5'-triphosphate binding pocket.  The first crystal structure of a Tec kinase family member in the pharmacol. important DFG-out conformation and bound to a type II kinase inhibitor is described.  The different protein conformations obsd. provide insights into the structural flexibility of BTK, the mol. basis of its regulation, and the structure-based design of specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbjgkMYHniALVg90H21EOLACvtfcHk0lhn34SqVO8r2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFWnuro%253D&md5=4e46f4d05ac3d7b90f1a3e89c0275516</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fpro.575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.575%26sid%3Dliteratum%253Aachs%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DTsing%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DBradshaw%26aufirst%3DJ.%2BM.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DBarnett%26aufirst%3DJ.%2BW.%26aulast%3DBrowner%26aufirst%3DM.%2BF.%26atitle%3DInsights%2520into%2520the%2520conformational%2520flexibility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520from%2520multiple%2520ligand%2520complex%2520structures%26jtitle%3DProtein%2520Sci.%26date%3D2011%26volume%3D20%26spage%3D428%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mett, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span> </span><span class="NLM_article-title">Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1016%2FS0960-894X%2896%2900601-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=187-192&author=J.+Zimmermannauthor=E.+Buchdungerauthor=H.+Mettauthor=T.+Meyerauthor=N.+B.+Lydon&title=Potent+and+selective+inhibitors+of+the+Abl-kinase%3A+phenylamino-pyrimidine+%28PAP%29+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective inhibitors of the ABL-kinase: phenylaminopyrimidine (PAP) derivatives</span></div><div class="casAuthors">Zimmermann, Jurg; Buchdunger, Elisabeth; Mett, Helmut; Meyer, Thomas; Lydon, Nicholas B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-192</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Due to its relatively clear etiol., chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase.  Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEGaTJgyxfUbVg90H21EOLACvtfcHk0lgwvSYS8CKyrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXht1egs7w%253D&md5=35962f1735e8d3a595fdb49d95cdc305</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2896%2900601-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252896%252900601-4%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DMett%26aufirst%3DH.%26aulast%3DMeyer%26aufirst%3DT.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26atitle%3DPotent%2520and%2520selective%2520inhibitors%2520of%2520the%2520Abl-kinase%253A%2520phenylamino-pyrimidine%2520%2528PAP%2529%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1997%26volume%3D7%26spage%3D187%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Regan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capolino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroe, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madwed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pargellis, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swinamer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torcellini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span> </span><span class="NLM_article-title">Structure–activity relationships of the p38α MAP kinase inhibitor 1-(5-<i>tert</i>-butyl-2-<i>p</i>-tolyl-2<i>H</i>-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naphthalen-1-yl]-urea (BIRB 796)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">4676</span><span class="NLM_x">–</span> <span class="NLM_lpage">4686</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm030121k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=4676-4686&author=J.+Reganauthor=A.+Capolinoauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=E.+Hickeyauthor=R.+R.+Kroeauthor=J.+Madwedauthor=M.+Moriakauthor=R.+Nelsonauthor=C.+A.+Pargellisauthor=A.+Swinamerauthor=C.+Torcelliniauthor=M.+Tsangauthor=N.+Moss&title=Structure%E2%80%93activity+relationships+of+the+p38%CE%B1+MAP+kinase+inhibitor+1-%285-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl%29-3-%5B4-%282-morpholin-4-yl-ethoxy%29naphthalen-1-yl%5D-urea+%28BIRB+796%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Fjm030121k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030121k%26sid%3Dliteratum%253Aachs%26aulast%3DRegan%26aufirst%3DJ.%26aulast%3DCapolino%26aufirst%3DA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DHickey%26aufirst%3DE.%26aulast%3DKroe%26aufirst%3DR.%2BR.%26aulast%3DMadwed%26aufirst%3DJ.%26aulast%3DMoriak%26aufirst%3DM.%26aulast%3DNelson%26aufirst%3DR.%26aulast%3DPargellis%26aufirst%3DC.%2BA.%26aulast%3DSwinamer%26aufirst%3DA.%26aulast%3DTorcellini%26aufirst%3DC.%26aulast%3DTsang%26aufirst%3DM.%26aulast%3DMoss%26aufirst%3DN.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520of%2520the%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitor%25201-%25285-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl%2529-3-%255B4-%25282-morpholin-4-yl-ethoxy%2529naphthalen-1-yl%255D-urea%2520%2528BIRB%2520796%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D4676%26epage%3D4686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">1765</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1038%2Fsj.bjc.6603170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=16721371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFequr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2006&pages=1765-1769&author=E.+Weisbergauthor=P.+Manleyauthor=J.+Mestanauthor=S.+Cowan-Jacobauthor=A.+Rayauthor=J.+D.+Griffin&title=AMN107+%28nilotinib%29%3A+a+novel+and+selective+inhibitor+of+BCR-ABL"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL</span></div><div class="casAuthors">Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1765-1769</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic myelogenous leukemia (CML) and Philadelphia chromosome pos. (Ph+) acute lymphoblastic leukemia (ALL) are caused by the BCR-ABL oncogene.  Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML.  However, accelerated or blast-crisis phase CML patients and Ph+ ALL patients often relapse due to drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain.  This has stimulated the development of new kinase inhibitors that are able to over-ride resistance to imatinib.  The novel, selective BCR-ABL inhibitor, AMN107, was designed to fit into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib.  In addn. to being more potent than imatinib (IC50<30 nM) against wild-type BCR-ABL, AMN107 is also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.  In preclin. studies, AMN107 demonstrated activity in vitro and in vivo against wild-type and imatinib-resistant BCR-ABL-expressing cells.  In phase I/II clin. trials, AMN107 has produced haematol. and cytogenetic responses in CML patients, who either did not initially respond to imatinib or developed imatinib resistance.  Dasatinib (BMS-354825), which inhibits Abl and Src family kinases, is another promising new clin. candidate for CML that has shown good efficacy in CML patients.  In this review, the early characterization and development of AMN107 is discussed, as is the current status of AMN107 in clin. trials for imatinib-resistant CML and Ph+ ALL.  Future trends investigating prediction of mechanisms of resistance to AMN107, and how and where AMN107 is expected to fit into the overall picture for treatment of early-phase CML and imatinib-refractory and late-stage disease are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp04St4tlQLI7Vg90H21EOLACvtfcHk0lgwvSYS8CKyrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFequr4%253D&md5=ed9c74a560ee222b98d8c465a5160a84</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603170%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DAMN107%2520%2528nilotinib%2529%253A%2520a%2520novel%2520and%2520selective%2520inhibitor%2520of%2520BCR-ABL%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D94%26spage%3D1765%26epage%3D1769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Huang, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.-S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.-S.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span> </span><span class="NLM_article-title">Development and strategies of VEGFR-2/KDR inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1839</span><span class="NLM_x">–</span> <span class="NLM_lpage">1852</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.4155%2Ffmc.12.121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=23043480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVOhsb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=1839-1852&author=L.+Huangauthor=Z.+Huangauthor=Z.+Baiauthor=R.+Xieauthor=L.+Sunauthor=K.+Lin&title=Development+and+strategies+of+VEGFR-2%2FKDR+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Development and strategies of VEGFR-2/KDR inhibitors</span></div><div class="casAuthors">Huang, Lingyi; Huang, Zhengui; Bai, Zhiqiang; Xie, Rui; Sun, Liping; Lin, Kejiang</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1839-1852</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  VEGF is an important signaling protein involved in both vasculogenesis and angiogenesis.  As an essential receptor protein tyrosine kinase propagating cellular signal transduction processes, VEGFR-2 is a central target for drug discovery against tumor-assocd. angiogenesis.  Since the autophosphorylation of VEGFR-2 represents a key step in this signal pathway that contributes to angiogenesis, the discovery of small mol. inhibitors that block this reaction has attracted great interest for novel drugs research and development.  Advances in the understanding of catalytic cleft and the conformational changes of DFG motif have resulted in the development of small mol. inhibitors known as type I and type II.  High-resoln. crystal structures of various inhibitors in complex with the receptor offer an insight into the relationship among binding modes, inhibition mechanisms, activity, selectivity and resistance.  To control selectivity, improve activity and introduce intellectual property novelty, the strategies for the further development are discussed through structural and conformational anal. in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMgCdblpbQc7Vg90H21EOLACvtfcHk0lhNPgXYbj8vfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVOhsb3O&md5=96cc54622cc92d45a8549eb88d551a7f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.121%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DBai%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DK.%26atitle%3DDevelopment%2520and%2520strategies%2520of%2520VEGFR-2%252FKDR%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D1839%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhNPgXYbj8vfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Fjm4017762&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Fjm4017762&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Fjm4017762&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact ≤ 2.1 × 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lhNPgXYbj8vfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D173%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Kostwicz, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauns, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dressman, J. B.</span><span> </span><span class="NLM_article-title">Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media</span> <span class="citation_source-journal">Pharm. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">–</span> <span class="NLM_lpage">349</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=345-349&author=E.+S.+Kostwiczauthor=U.+Braunsauthor=R.+Beckerauthor=J.+B.+Dressman&title=Forecasting+the+oral+absorption+behavior+of+poorly+soluble+weak+bases+using+solubility+and+dissolution+studies+in+biorelevant+media"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKostwicz%26aufirst%3DE.%2BS.%26aulast%3DBrauns%26aufirst%3DU.%26aulast%3DBecker%26aufirst%3DR.%26aulast%3DDressman%26aufirst%3DJ.%2BB.%26atitle%3DForecasting%2520the%2520oral%2520absorption%2520behavior%2520of%2520poorly%2520soluble%2520weak%2520bases%2520using%2520solubility%2520and%2520dissolution%2520studies%2520in%2520biorelevant%2520media%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26spage%3D345%26epage%3D349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Honigberg, L. A.; Smith, A. M.; Chen, J.; Thiemann, P.; Vernet, E.</span><span> </span><span class="NLM_article-title">Targeting Btk in lymphoma: PCI-32765 inhibits tumor growth in mouse lymphoma models and a fluorescent analog of PCI-32765 is an active-site probe that enables assessment of Btk inhibition in vivo</span>.  <span class="citation_source-book">Blood</span>, ASH Annual Meeting Abstracts, Nov 2007; <span class="NLM_publisher-name">American Society of Hematology</span>: <span class="NLM_publisher-loc">Washington, DC</span>, 2007; Vol.  <span class="NLM_volume">110</span>, p  <span class="NLM_fpage">1592</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Honigberg%2C+L.+A.%3B+Smith%2C+A.+M.%3B+Chen%2C+J.%3B+Thiemann%2C+P.%3B+Vernet%2C+E.+Targeting+Btk+in+lymphoma%3A+PCI-32765+inhibits+tumor+growth+in+mouse+lymphoma+models+and+a+fluorescent+analog+of+PCI-32765+is+an+active-site+probe+that+enables+assessment+of+Btk+inhibition+in+vivo.+Blood%2C+ASH+Annual+Meeting+Abstracts%2C+Nov+2007%3B+American+Society+of+Hematology%3A+Washington%2C+DC%2C+2007%3B+Vol.+110%2C+p+1592."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26atitle%3DTargeting%2520Btk%2520in%2520lymphoma%253A%2520PCI-32765%2520inhibits%2520tumor%2520growth%2520in%2520mouse%2520lymphoma%2520models%2520and%2520a%2520fluorescent%2520analog%2520of%2520PCI-32765%2520is%2520an%2520active-site%2520probe%2520that%2520enables%2520assessment%2520of%2520Btk%2520inhibition%2520in%2520vivo%26btitle%3DBlood%26pub%3DAmerican%2520Society%2520of%2520Hematology%26volume%3D110%26spage%3D1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PJ3" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PJ3','PDB','3PJ3'); return false;">PDB: 3PJ3</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BYU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3BYU','PDB','3BYU'); return false;">PDB: 3BYU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OCS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3OCS','PDB','3OCS'); return false;">PDB: 3OCS</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i70"><a href="/doi/suppl/10.1021/jm4017762">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23721"></div></div></div></div></div><hr /></hr><p class="last">Syntheses of compounds <b>11</b>, <b>19</b>, and <b>20</b>, modeling study, and detailed procedures and data for biological assays. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4017762/suppl_file/jm4017762_si_001.pdf">jm4017762_si_001.pdf (747.13 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4017762&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm4017762%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4017762" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b485f9eb3c34","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
